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 i 
Abstract 
 
Cystic fibrosis (CF) is the most common inherited life-limiting condition in the United 
Kingdom. Lung disease, involving retention of mucopurulent secretions, neutrophilic 
inflammation and endobronchial infection is the major cause of mortality. CF is caused 
by variants in the CF-transmembrane conductance regulator gene, however the exact 
pathogenesis of lung disease is not fully understood. Valid experimental models are 
therefore critical to advance research. 
 
I describe the establishment of a successful method to culture primary bronchial 
epithelial cells (PBECs) from explanted CF lungs removed at transplantation. This 
technique has yielded an important resource to further study the pathogenesis of CF 
lung disease.  
 
The cytokine interleukin-17 orchestrates the activity of neutrophils and increases mucin 
gene expression in BECs – two key features of CF lung disease. I demonstrate that 
interleukin-17 is increased in the airway of people with advanced CF lung disease. I 
also show evidence suggesting that neutrophils themselves may be a source of 
interleukin-17 potentially leading to an ever-increasing spiral of inflammation. 
 
In a CF mouse model ceramide accumulates in BECs and is associated with neutrophilic 
inflammation and susceptibility to Pseudomonas aeruginosa infection. Furthermore, 
amitriptyline treatment normalised ceramide, inflammation and susceptibility to 
infection. The role of ceramide is a complex area, however, with a divergence of 
opinion in the literature and paucity of human data. I demonstrate using 
immunohistochemistry that ceramide is increased in the lower airway epithelium in 
advanced CF lung disease compared to pulmonary hypertension and unused lung donors 
and is correlated with neutrophilic inflammation and increased in those colonised with 
Pseudomonas aeruginosa. Ceramide species C16:0, C18:0 and C20:0 but not C22:0 are 
increased in lung homogenates of CF lungs compared to pulmonary hypertension 
measured using the independent technique of high performance liquid chromatography-
mass spectrometry. 
 
Both interleukin-17 and ceramide represent important topics for further translational CF 
lung disease research. 
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1. Chapter 1. Introduction 
 
 
1.1. Background: cystic fibrosis from 1938 to 2010  
 
Cystic fibrosis (CF) is the most common life-limiting genetically acquired disease of 
white populations with an incidence of approximately 1 in 2500 newborns. (O'Sullivan 
and Freedman, 2009) Although less frequent, CF is also increasingly recognised in non-
white racial groups. (Kabra et al., 2007, Kabra et al., 2006, Spencer et al., 1994) There 
are over 7000 individuals who have CF in the United Kingdom (UK), spanning both 
paediatric and adult age groups. (Davies et al., 2007)  
 
The first clinical description of CF was published in 1938. (Andersen, 1938) A disease 
entity, separate from infants with coeliac disease, consisting of mucus plugging of the 
pancreas was described and termed ‘cystic fibrosis of the pancreas’. The early clinical 
descriptions of CF were characterised by fat and protein malabsorption, steatorrhoea, 
growth failure and respiratory infection. It was assumed that pancreatic damage and 
subsequent deficiency of pancreatic enzymes resulted in malabsorption and poor 
nutrition leading to a predisposition for respiratory infections that were frequently 
terminal. (Davis, 2006) In 1944 Farber described thick and tenacious mucus obstructing 
the ducts of mucus glands throughout the body leading to the alternative terms 
‘mucoviscidosis’ and ‘generalised exocrinopathy’. (Farber, 1944, Di Sant’Agnese, 
1956) 
 
During the heat wave of 1948 in New York di Sant’Agnese observed that several 
infants presenting with dehydration fitted a CF phenotype. He demonstrated that their 
sweat was abnormal, containing five-fold concentrations of sodium and chloride, and 
that this abnormality persisted once the high temperatures had subsided. (Di 
Sant’Agnese, 1953) 
 
The modern day term CF refers to a disease caused by variants in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene that codes for a protein that 
functions primarily as a chloride channel. (O'Sullivan and Freedman, 2009, Sheppard 
and Welsh, 1999) CFTR is expressed in many epithelial cells, including sweat duct, 
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airway, pancreatic duct, intestine, biliary tree and vas deferens. This may give rise to an 
elevated sweat chloride concentration, lung disease characterised by bacterial infection 
and bronchiectasis, pancreatic insufficiency, intestinal obstruction, biliary cirrhosis and 
congenital bilateral absence of the vas deferens, often found in combination. (Davis, 
2006) 
 
Over the past two decades the level of understanding of the disease has increased 
rapidly and this has impacted significantly on the clinical management of people with 
CF. This has yielded a significant increase in survival. (Dodge et al., 2007) Where CF 
used to represent a lung and gastrointestinal disease primarily of young children it is 
now a complex multi-system disorder that extends in to adulthood. Indeed there will 
soon be more adults than children with CF in the UK. Infants born today with CF have a 
predicted median survival of greater than 50 years. (Dodge et al., 2007) Figure 1 shows 
the steady improvement in length of survival for people with CF born in the UK over 
the last four decades. 
 
 
■ 1968-70, ○ 1971-73, ▲ 1974-76, □ 1977-79, ♦ 1980-82, ◊ 1983-85, ∆ 1986-88, ● 1989-91, ∇ 
1992-94 (Dodge et al., 2007) 
 
 
Figure 1. Proportion of a) males and b) females in the UK with CF, of each 3-
year cohort, surviving until 2003. 
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1.2. Clinical aspects of cystic fibrosis 
 
1.2.1. Introduction 
 
As outlined above, CF is a multisystem disorder that arises from variants in the CFTR 
gene. (O'Sullivan and Freedman, 2009) Defects in ion and water transport across 
epithelia lead to a progressive disease that affects a number of different organs, 
including the upper and lower airways, pancreas, liver, and gastrointestinal and 
reproductive tracts. (Davies et al., 2007)  
 
1.2.2. Newborn screening and diagnosis 
 
In 2007 screening for CF was introduced in the UK as part of the newborn bloodspot 
programme. (Downing and Pollitt, 2008) This programme involves initial screening of 
samples for the level of immunoreactive trypsinogen (IRT). Positive samples (around 
0.5%) are then analysed for the most common CFTR variants and appropriate infants 
then referred for diagnostic sweat chloride testing. Importantly, the UK screening 
programme is designed to identify infants with CF, which is subsequently diagnosed 
formally by sweat testing, rather than to highlight heterozygote carriers. (Downing and 
Pollitt, 2008) It is inevitable however that some carrriers will be found by this method 
and also that some families will undergo the stress associated with an initial ‘false 
positive’ IRT result. (Kai et al., 2009)  
 
There is evidence from a North American randomised trial of nutritional benefits in 
children with CF diagnosed by newborn screening. (Farrell et al., 1997) Pulmonary 
outcomes were influenced by confounding factors in this study, none the less there are 
genuine concerns regarding possible earlier acquisition of Pseudomonas aeruginosa in 
screened children. (Southern et al., 2009) Prior to the introduction of newborn screening 
children were typically diagnosed when a sweat test was performed because of a 
chronic history of recurrent lower respiratory tract infections and growth faltering. 
Delay in diagnosis was common along with the inevitable associated morbidity for the 
child and emotional stress for the family involved. (Jackson et al., 2010) 
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1.2.3. Clinical aspects of cystic fibrosis lung disease 
 
It is estimated that lung disease is responsible for over 95% of morbidity and mortality 
in people with CF. (Doring et al., 2007) Clinically CF lung disease is characterised by 
chronic endobronchial infection with specific microorganisms including Staphylococcus 
aureus, Haemophilus influenzae and P. aeruginosa, neutrophilic inflammation and 
retention of mucopurulent secretions. This results in progressive bronchiectasis, decline 
in lung function and ultimately respiratory failure in young adulthood (Figure 2). The 
mainstays of treatment include intensive physiotherapy and inhaled mucolytics to aid 
clearance of secretions and prophylactic or treatment antimicrobials to deal with 
infection. (Davies et al., 2007) Lung transplantation is the only life-preserving 
intervention for end-stage CF lung disease. (Meachery et al., 2008) 
 
1.2.4. Non-pulmonary manifestations of cystic fibrosis 
 
Brief details of the common non-pulmonary clinical manifestations of CF and 
appropriate interventions are summarised in Table 1.  
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Figure 2. Severe bronchiectasis in end stage cystic fibrosis shown in chest 
radiograph and computed tomogram. 
(Davies et al., 2007) 
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Organ Problem(s) Intervention 
Pancreas Exocrine insufficiency 
and malabsorption 
High-fat diet, supplementation of 
pancreatic enzymes and fat- soluble 
vitamins 
 Pancreatitis Largely symptomatic 
 Endocrine insufficiency: 
CF-related diabetes 
Insulin 
Oesophagus Gastro-oesophageal reflux Pro-kinetics, acid suppression, 
fundoplication 
Small intestine Meconium ileus Gastrograffin enemas, surgery 
 Distal Intestinal 
Obstruction Syndrome 
Gastrograffin, surgery 
Large bowel Rectal prolapse Pancreatic enzymes, surgery 
Liver CF-related liver disease Ursodeoxycholic acid, vitamin K 
supplements, transplantation 
Upper airway Nasal polyps Topical steroids, surgery 
 Sinusitis Topical steroids or antibiotics, surgery 
Bones Osteopaenia Exercise, calcium and vitamin D 
supplements 
Sweat glands Increased electrolyte loss Electrolyte supplements 
Reproductive 
tract 
Bilateral absence of vas 
deferens 
Assisted fertilisation techniques 
 
Table 1. Non-pulmonary manifestations of cystic fibrosis and interventions 
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1.3. The cystic fibrosis transmembrane conductance regulator (CFTR) 
 
The gene encoding CFTR was first cloned in 1989 and is situated on the long arm of 
chromosome 7. (Riordan et al., 1989, Kerem et al., 1989, Rommens et al., 1989) CFTR 
is a member of the ATP-binding cassette transporter superfamily. (Verkman and 
Galietta, 2009) The major function of CFTR is as a chloride channel that regulates ion 
and water balance across epithelia. (Sheppard and Welsh, 1999) CFTR is also involved 
in the regulation of a multitude of other physiological cellular processes including 
bicarbonate-chloride exchange, sodium transport via the epithelial sodium channel 
(ENaC), acidification of intracellular organelles and calcium-activated chloride channel 
(CaCC) function. (Quinton, 2008, Reisin et al., 1994, Schwiebert et al., 1995, Stutts et 
al., 1995, Mehta, 2005) The protein contains 1480 amino acids and includes two 
membrane-spanning domains, two nucleotide-binding domains and a unique regulatory 
domain. (Hwang and Sheppard, 2009)  
 
Activation of CFTR relies on phosphorylation, particularly through protein kinase A, 
but most probably also involves a complex system of other kinases and phosphatases as 
well. (Ostedgaard et al., 2001, Hwang and Sheppard, 2009) Channel activity is 
governed by the two nucleotide-binding domains, which regulate channel gating. The 
carboxyl terminal of CFTR is anchored through a PDZ-type-binding interaction with the 
cytoskeleton and is kept in close approximation with a number of associated proteins. 
(Borthwick et al., 2007) These proteins influence CFTR function, including 
conductance, regulation of other channels, signal transduction, and localization at the 
apical plasma membrane. (Rowe et al., 2005) The hypothesized structure of CFTR is 
shown in Figure 3. 
 
Over 1500 loss-of-function CFTR variants have been identified, although the number of 
true disease-causing variants is probably much lower. (Proesmans et al., 2008, Verkman 
and Galietta, 2009) CFTR variants are recessive and may be classified in to five classes 
depending on their effect on the CFTR protein. (Wilschanski et al., 1995) Table 2 
describes the classes of variants I to V and Figure 4 depicts each class 
diagrammatically. 
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By far the most frequent disease-causing variant is p.Phe508del. It is traditionally 
considered to be a class II variant resulting from deletion of phenylalanine at position 
508 and leading to aberrantly folded CFTR protein that is identified and degraded in the 
endoplasmic reticulum. (Cheung and Deber, 2008) This defective trafficking of the 
protein is thought to result in the absence of mature CFTR at the apical membrane, 
although this is still a subject of some debate. (LA Borthwick, personal communication 
August 2010) There is evidence from work in nasal brushings and mice that 
p.Phe508del should also be considered to be a class IV variant with some apically 
localised p.Phe508del CFTR present in homozygotes. (Penque et al., 2000) Importantly 
p.Phe508del CFTR exhibits a reduced open probabililty compared to wild type CFTR. 
(Pilewski and Frizzell, 1999)  p.Phe508del accounts for 70% of all variant alleles with 
10-20 less common variants accounting for another 15%. (Proesmans et al., 2008) 
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Figure 3. Hypothesised structure of the cystic fibrosis transmembrane conductance 
regulator (CFTR) 
(Rowe et al., 2005) 
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Class of 
variant 
Effect Example of 
common variant 
allele 
I No CFTR mRNA or protein formed, e.g. 
nonsense, frame shift or splice site mutation 
p.Gly542X 
II Trafficking defect. CFTR protein forms but 
fails to traffic to cell membrane 
p.Phe508del  
(also class IV) 
III Regulation defect. CFTR reaches the cell 
membrane but does not respond to cAMP 
stimulation 
p.Gly551Asp 
IV Channel defect. CFTR functions as a defective 
Cl- channel 
p.Arg117His 
V Synthesis defect. Reduced or defective 
processing of normal CFTR 
p.Ala455Glu 
 
Table 2. Description of different classes of cystic fibrosis  
transmembrane conductance regulator (CFTR) variants 
(Proesmans et al., 2008, Wilschanski et al., 1995) 
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Figure 4. Schematic representation of the different classes of cystic fibrosis 
transmembrane conductance regulator (CFTR) variants 
(Rowe et al., 2005) 
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1.4. The science of cystic fibrosis lung disease 
 
1.4.1. Pathogenesis 
 
The lung histology of newborns with CF is essentially structurally normal with the 
exception of mild dilatation and plugging of submucosal gland ducts. (Konstan and 
Berger, 1997, Elizur et al., 2008) As outlined later in this thesis, there is some evidence 
of a pro-inflammatory milieu in the lungs of foetuses with CF however. (Hubeau et al., 
2001b) The respiratory tract is constantly exposed to numerous airborne pathogens. A 
wide array of innate host defences and clearance mechanisms are therefore critical to 
prevent infection. (Martin and Frevert, 2005, Chilvers and O'Callaghan, 2000) In CF 
these defences fail and the airways of young children with CF become inflamed with a 
predominantly neutrophilic infiltrate and infected with bacteria such as S. aureus and H. 
influenzae quite rapidly. (O'Sullivan and Freedman, 2009, Stafler et al., 2009) Airway 
neutophilia has been detected in bronchoalveolar lavage (BAL) fluid from clinically 
well infants with CF (Khan et al., 1995) A longstanding debate has existed in CF 
research as to whether inflammation precedes infection, or vice versa, this is discussed 
in more detail later in the thesis. (Wine, 2010) 
 
P. aeruginosa subsequently becomes the most prominent airway pathogen in older 
children and adults with CF. (Rosenfeld et al., 2003) P. aeruginosa has a particular 
predilection for the CF airway and chronic infection appears to be frequently 
established with a number of potential explanations. These include the presence of 
hypoxic microenvironmental niches in adherent mucus plugs, increased bacterial 
binding to epithelial cells deficient in CFTR, reduced innate immune defences and 
complex adaptations in the bacteria themselves, including biofilm formation, quorum 
signalling and even immunomodulation. (Matsui et al., 2006, Worlitzsch et al., 2002, 
Imundo et al., 1995, Campodonico et al., 2008, Davies et al., 1998, Buchanan et al., 
2009) 
 
An ever-increasing vicious cycle then ensues of chronic endobronchial infection, 
neutrophilic inflammation and obstruction of airways and submucosal gland ducts by 
tenacious secretions consisting of mucus, inflammatory debris and bacteria. (Rubin, 
2009, Elizur et al., 2008) The natural history of CF lung disease is typified by a gradual 
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drop in lung function punctuated by more marked drops associated with acute infective 
exacerbations. Progressive, severe bilateral bronchiectasis and ultimately respiratory 
failure and premature death occur. (O'Sullivan and Freedman, 2009) The only life-
sustaining intervention for end-stage disease is lung transplantation. (Meachery et al., 
2008) 
 
The precise connection between CFTR dysfunction and the chronic inflammation and 
infection present in CF lung disease has not been fully elucidated and has been the 
subject of a huge amount of research and indeed debate in the scientific literature. 
(Wine, 2010) The low volume hypothesis proposed by Boucher and colleagues from the 
University of North Carolina, USA is currently the most widely accepted explanation. 
(Boucher, 2007a) This theory involves excessive isotonic absorption in the airway 
reducing the periciliary liquid volume and concentrating mucus resulting in grossly 
defective mucociliary transport. Retained mucus then serves as a nidus for chronic 
bacterial infection. In addition to the results of several elegant in vitro experiments 
performed by Matsui (Figure 5) and colleagues to support this theory, the most striking 
clinical correlate is the recent proof that nebulisation of hypertonic saline, resulting in 
increased airway surface liquid volume, in people with CF improves mucus clearance 
and lung function and reduces pulmonary exacerbations (Figure 6). (Elkins et al., 2006, 
Donaldson et al., 2006, Matsui et al., 1998, Tarran et al., 2007, Boucher, 2007b) 
 
At least four other hypotheses have been put forward to explain how the presence of 
defective CFTR leads to the clinical CF phenotype and it is possible that aspects of all 
the various hypotheses contribute to the pathogenesis of CF lung disease in vivo. 
(O'Sullivan and Freedman, 2009) The high-salt hypothesis argues that as a result of 
defective CFTR the concentration of sodium and chloride is raised in the airway surface 
liquid leading to dysfunction of innate antimicrobial peptides and subsequent chronic 
opportunistic pulmonary infection. (Goldman et al., 1997, Smith et al., 1996, Zabner et 
al., 1998)  
 
In addition to effects on airway surface liquid and mucociliary transport there is also 
evidence that CFTR dysfunction per se leads to a pro-inflammatory milieu that results 
in airway inflammation prior to infection and exaggerated inflammatory responses once 
infection is established. (Major and Elborn, 2009) CFTR dysfunction may also cause a 
primary predisposition to infection. It is known that P. aeruginosa binds to functional 
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CFTR and normally initiates an appropriate, rapid and self-limiting innate immune 
response. This effect is lost in the presence of defective CFTR and furthermore there is 
increased binding of S. aureus and P. aeruginosa via lipid rafts to the apical membrane 
of epithelial cells. (Campodonico et al., 2008, Imundo et al., 1995) Accumulation of 
ceramide in airway epithelial cells has also been recently implicated in the pathogenesis 
of CF lung disease as discussed comprehensively in section 1.7. Paul Quinton, 
University of California, has also postulated that defective bicarbonate secretion plays a 
significant role in the pathogenesis of CF and leads to poorly solubilised mucins with 
the subsequent accumulation of mucus that is found in the affected organs of people 
with CF. (Quinton, 2008) 
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Figure 5. Evidence from well-differentiated human airway cultures supporting 
airway surface liquid (ASL) volume depletion in the pathogenesis of cystic 
fibrosis lung disease 
(a) Measurement of ASL volume after addition of small volume of 'ASL' in normal 
airway epithelia devoid of mucus layer. ASL is absorbed until height is reached (∼7 µm) 
that maintains beating of extended cilia (see EM insert). Bar above depicts relative rates 
of Na+ absorption versus Cl− secretion with ASL height. (b) Measurement of ASL 
volume (height) after addition of ASL to CF culture. Note, added ASL is absorbed more 
rapidly than in normal cultures and all ASL is absorbed, as defined by the absence of 
sufficient liquid to maintain ciliary extension (see EM insert). Bar above illustrates that 
Na+ absorption persists, and there is a failure to secrete Cl−, despite inappropriately low 
ASL height/volume. (c, d) Similar experiments, but with mucus layer left intact on 
normal (c) and CF (d) cultures. Note concentration of mucus and apposition/adhesion of 
mucus to 'bent over' cilia in CF. e) Immunohistochemistry of mucus layer adherent to 
CF culture after ASL volume depletion. A mucus plaque has formed on the epithelial 
surface (containing nuclei labelled with DAPI) composed of MUC5AC (red) and 
MUC5B (green). (f) Light micrograph of airway excised from young adult CF patient. 
Within the airway lumen is mucopurulent material containing multiple round 
macrocolony-like biofilms of Pseudomonas aeruginosa. (Boucher, 2007b) 
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Figure 6. Mucociliary transport in the healthy lung and in cystic fibrosis and the 
therapeutic effect of osmotic agents. 
A fluid layer that is maintained through a balance of chloride secretion and sodium 
absorption covers the surface of airway epithelial cells. The airway surface fluid 
supports a thin mucus layer produced by mucosal secretory glands. The mucus layer is 
transported by respiratory cilia from the lower airways to the airway opening (Panel A). 
In cystic fibrosis, defective chloride secretion and sodium hyperabsorption lead to the 
depletion of the layer of airway surface fluid, with consecutive breakdown of 
mucociliary transport (Panel B). Osmotic agents increase the volume of airway surface 
fluid through an increase in water influx, thereby restoring mucociliary function (Panel 
C). (Ratjen, 2006) 
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1.4.2. The role of inflammation in cystic fibrosis lung disease 
 
As mentioned earlier in this thesis, lung histopathology from newborns with CF is 
essentially structurally normal with the exception of mild dilatation and plugging of 
submucosal gland ducts. (Konstan and Berger, 1997, Elizur et al., 2008) However, there 
is some evidence of an in vivo pro-inflammatory state in the lungs of foetuses with CF. 
This includes dysregulated activation of the nuclear factor-kappa B (NF-κB) pathway 
and infiltration of the airways by macrophages. (Verhaeghe et al., 2007, Hubeau et al., 
2001b)  
 
Direct sampling studies from young children with CF have identified raised baseline 
levels of inflammatory biomarkers and both increased and exaggerated inflammatory 
responses to bacterial infection. Khan and colleagues demonstrated raised neutrophil 
counts and levels of interleukin (IL)-8 and neutrophil elastase in BAL fluid from 
asymptomatic infants with CF diagnosed by newborn screening compared to controls. 
Moreover the BAL fluid from 7 of the 16 children with CF was negative on culture for 
bacteria and viruses but markers of inflammation were still raised. (Khan et al., 1995) 
Similarly Balough et al. (1995) and Rosenfeld et al. (2001) found raised neutrophil 
counts in sterile BAL fluid from young children with CF but minimal respiratory 
symptoms. (Balough et al., 1995, Rosenfeld et al., 2001) In a larger study, Muhlebach 
and colleagues obtained BAL fluid from children with CF and controls both with and 
without positive cultures for bacterial lower respiratory tract infection. They found that 
children with CF in both the infected and non-infected groups had raised neutrophil 
counts and that the ratio of IL-8 and neutrophils to number of bacteria in those infected 
were raised. (Muhlebach et al., 1999)  
 
An important deficiency of these studies however is that in order to warrant a 
bronchoscopy all of these children had a history of recent lower respiratory tract 
symptoms. Conversely Armstrong et al. found no significant difference in BAL fluid 
neutrophil counts and inflammatory markers in truly infection naïve children with CF 
compared to controls. (Armstrong et al., 2005, Armstrong et al., 1995) It is perhaps 
significant though that around a third of the control group had either a positive growth 
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from BAL fluid or symptoms of lower respiratory tract infection within 48 hours of the 
bronchoscopy. (Rao and Grigg, 2006)    
 
There is indirect evidence of a pro-inflammatory state in CF from work showing that 
cultured peripheral monocytes from adults with the disease produce increased amounts 
of tumour necrosis factor-alpha (TNF-α) compared to controls. (Pfeffer et al., 1993) 
Macrophages cultured from a CF mouse model contain four times the TNF-α 
messenger ribonucleic acid (mRNA) found in macrophages from wild-type mice. 
(Thomas et al., 2000) In addition, airways from infection naïve CF mice grafted on to 
animals with severe combined immunodeficiency produce raised amounts of IL-8 
relative to controls and ultimately display luminal inflammation. (Tirouvanziam et al., 
2000) 
 
In contrast however, recently published work performed using a new porcine model of 
CF suggests that there is no significant difference between CF and wild-type newborn 
piglets in baseline levels of BAL fluid IL-8 and inflammatory cell counts. (Stoltz et al., 
2010) The newborn CF piglets did have evidence of a defective capacity to eliminate 
bacteria however. (Stoltz et al., 2010)  
 
There is also evidence that in addition to a pro-inflammatory state that there may be 
defective down regulation of inflammation in CF lung disease. Work performed by 
Bonfield et al. has demonstrated that IL-10 production is decreased in bronchial 
epithelial cells from people with CF compared to controls. (Bonfield et al., 1995) 
 
In conclusion there is good evidence that an exaggerated inflammatory response occurs 
in the CF airway to infection. There is also inconclusive evidence that the airway may 
be primed in a pro-inflammatory state prior to infection.  
 
1.4.3. How is airway inflammation damaging in cystic fibrosis lung disease? 
 
Intense endobronchial and peribronchial neutrophilic inflammation are the hallmarks of 
the histopathology of established CF lung disease. (Hubeau et al., 2001a) The principal 
chemoattractant for neutrophils in the CF airway is IL-8. (Downey et al., 2009) 
Bronchial epithelial cells and immune cells such as macrophages and dendritic cells 
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produce IL-8 in the lungs. A wide range of other factors such as leukotriene B4, IL-1, 
IL-6, granulocyte-macrophage colony-stimulating factor (GMCSF), TNF-α and more 
recently IL-17 have also been identified as important in the modulation of the 
inflammatory response. (Downey et al., 2009, Brodlie et al., 2009c) This includes 
stimulating further production of IL-8 and recruitment of immune cells such as 
neutrophils and macrophages. (Elizur et al., 2008) Neutrophils then trigger the release 
of additional pro-inflammatory mediators and chemoattractants resulting in a sustained 
inflammatory response and positive feedback loop. (Downey et al., 2009) 
 
Neutrophils contain a number of proteolytic enzymes that are stored in specific 
cytoplasmic granules and are critical in intracellular pathogen destruction and hence 
response to infection. (Haslett et al., 1989) Large amounts of these proteases, such as 
the serine proteases neutrophil elastase, proteinase 3 and cathepsin G and matrix 
metalloproteases-8 and -9, are released in to the extracellular milieu on neutrophil 
degranulation or death and subsequently mediate tissue damage. (Linden et al., 2005, 
Korkmaz et al., 2008) Neutrophil elastase in particular digests a diverse range of 
substrates found in the lung including the structural proteins elastin and fibronectin and 
further activates pro-matrix metalloprotease-9. (Gaggar et al., 2007, Korkmaz et al., 
2008) In the CF lung this large protease burden overwhelms intrinsic anti-protease 
activity and results in epithelial injury, airway remodelling and irreversible damage to 
structure leading to severe bronchiectasis. (Balfour-Lynn, 1999, Griese et al., 2008, 
Hilliard et al., 2007) There is also evidence from ex vivo studies that neutrophil elastase 
stimulates airway gland mucus secretion. (Schuster et al., 1992, Cardell et al., 1999)  
 
On a clinical basis there is indirect evidence of the role of neutrophil elastase from work 
published by Sagel et al. (2002). They found that the concentration of neutrophil 
elastase in induced sputum from stable children with CF correlated negatively with their 
forced expiratory volume in one second (FEV1). (Sagel et al., 2002)    
 
Pathogens are also eliminated by neutrophils via cytotoxic reactive oxygen species that 
are generated through a membrane-associated nicotinamide adenine dinucleotide 
phosphate (NADP)-oxidase system. (Roos et al., 2003) Along with oxygen radicals 
from bacterial products and the environment this produces a cumulative oxidative stress 
in the CF lung that serves to further exacerbate airway injury. (Elizur et al., 2008) 
Kettle and colleagues found evidence of oxidative stress in the airways of young 
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children with CF in terms of raised concentrations of myeloperoxidase, 3-
chlorotyrosine, a biomarker for hypochlorous acid, and protein carbonyls in BAL fluid. 
(Kettle et al., 2004)  
 
Finally, on cell death neutrophils release large amounts of deoxyribonucleic acid (DNA) 
that constitutes a major polymeric component of the highly adhesive secretions 
characteristic of CF lung disease. (Rubin, 2007) The successful use of nebulised 
dornase alpha, which hydrolyses DNA in the airway, to improve mucociliary clearance 
in many people with CF provides practical evidence of the importance of increased 
concentrations of DNA in secretions in CF lung disease. (Jones and Wallis, 2003) 
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1.5. Interleukin-17 
 
1.5.1. Introduction 
 
IL-17 is the signature cytokine of the recently described TH-17 subset of CD4+ T cells. 
(Gaffen, 2009) The TH-17 cell lineage represents the first major revision to the 
landmark TH-1/TH-2 paradigm proposed by Mossman and Coffman over 20 years ago 
and addresses a number of discrepancies that had become apparent in the model. 
(Mosmann et al., 1986) IL-17 was first described and cloned in 1993. (Yao et al., 
1995b, Rouvier et al., 1993) A family of cytokines has now been described that 
comprises of six unique homodimeric domains, namely IL-17A, IL-17B, IL-17C, IL-
17D, IL-17E (IL-25) and IL-17F. The IL-17 family of cytokines are structurally very 
similar with homologous features such as disulphide linkage, C-terminal amino acid 
sequences and cysteine residues. (Linden et al., 2005) The most widely studied and 
prevalent members of the family in human biology are IL-17A and the related T cell 
isoform IL-17F. From this point onwards in this thesis unless specifically stated IL-17 
refers to the cytokine IL-17A. 
 
TH-17 cells are characterised in humans by the production of the cytokines IL-17A, IL-
17F, IL-22, IL-21 and IL-26. (Gaffen, 2009) In mice the differentiation of naïve T cells 
to a TH-17 phenotype is regulated by the transcription factors signal transducer and 
activator of transcription 3 (STAT3), retinoic acid receptor-related orphan receptor-γt 
(RORγt) and aryl hydrocarbon receptor. This process is driven by transforming growth 
factor-β (TGF-β), IL-1 and IL-6. (Gaffen, 2009, Ivanov et al., 2006)  
 
Our understanding of the immunobiology of IL-17 in humans is currently evolving 
rapidly and, interestingly there appear to be significant differences to the situation in 
mice. (Laurence and O'Shea, 2007, de Jong et al., 2010) Yang et al. (2008) found that 
TGF-β and IL-21 uniquely promote the differentiation of naïve human CD4+ T cells to 
TH-17 cells that is accompanied by expression of the transcription factor RORC2, the 
human orthologue of RORγt. (Yang et al., 2008, Unutmaz, 2009) IL-1β and IL-6 
induced IL-17A production from human central memory CD4+ T cells but not from 
naïve CD4+ T cells. IL-23 is required to expand and stabilise the TH-17 population but is 
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not involved in the differentiation of naïve T cells. (Bettelli et al., 2007, Aggarwal et al., 
2003) Figure 7 illustrates the differentiation of TH cell subsets. 
 
TH-17 cells are not the only source of IL-17 identified however. IL-17 is also known to 
be produced by γδ T cells and natural killer T cells. (Michel et al., 2007, Roark et al., 
2008) Apart from lymphocytes there is also an emerging literature showing that 
myeloid cells can also express IL-17. It has recently been shown that mast cells in 
rheumatoid arthritis synovium and alveolar macrophages in a mouse model of allergy 
express IL-17. (Hueber et al., 2010, Song et al., 2008) Moreover it has also been 
suggested in human alcoholic liver disease and mouse models of lipopolysaccharide-
induced airway inflammation and kidney ischaemia-reperfusion injury that neutrophils 
are a potential source of IL-17. (Lemmers et al., 2009, Ferretti et al., 2003, Li et al., 
2010) 
 
The current overall understanding of IL-17 receptor (IL-17R) biology is weak. The IL-
17R consists of five subunits, IL-17RA to IL-17RE. (Aggarwal and Gurney, 2002) IL-
17RA is by far the largest and most well studied receptor. (Gaffen, 2009) IL-17RA is 
expressed by a wide range of cells relevant to lung immunobiology, including airway 
epithelial cells, fibroblasts, B- and T-lymphocytes, endothelial cells and 
myelomonocytic cells. (Linden et al., 2005, Yao et al., 1995a, McAllister et al., 2005) 
The majority of these cells express the receptor constitutively suggesting that under 
physiological conditions they are primed for an immediate response on exposure to IL-
17. IL-17RA activation by IL-17A induces a highly pro-inflammatory programme of 
gene expression, including the NFκB and mitogen-activated protein kinase (MAPK) 
pathways, similar to that induced by receptors associated with innate immunity such as 
Toll-like and IL-1 receptors (Figure 8). (Gaffen, 2009) In the future an improved 
understanding of the receptor biology of IL-17 is likely to lead to novel therapeutic 
approaches with greater precision in terms of targeting the harmful aspects of 
inflammation while avoiding more general deleterious effects on the host immune 
system. (Gaffen, 2009) 
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Figure 7. Differentiation of TH cell subsets 
Following activation by antigen-presenting cells such as dendritic cells (DCs), naive 
CD4+ T cells can be polarized into different effector T cell subsets — T helper 1 (TH1), 
TH2, TH17 and regulatory T (TReg) cells — depending on the local cytokine 
environment. The differentiation of each of these effector T cell subsets is controlled by 
distinct sets of transcription factors. In the presence of interleukin-6 (IL-6) and 
transforming growth factor-β (TGFβ), naive T cells can differentiate into TH17 cells, 
which are characterized by expression of the transcription factors retinoic acid receptor-
related orphan receptor-γt (RORγt) and signal transducer and activator of transcription 3 
(STAT3). Furthermore, IL-1 and IL-23 can promote and/or stabilize TH17 cell 
differentiation and expansion. FOXP3, forkhead box P3; GATA3, GATA-binding 
protein 3; IFNγ, interferon-γ; TCR, T cell receptor. (Zou and Restifo, 2010) 
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Figure 8. Interleukin-17 induced signalling pathways 
Schematic depicting interleukin-17 receptor (IL-17R) signalling. The IL-17R complex 
is composed of IL-17RA and IL-17RC. IL-17RA engages the SEFIR domain-containing 
adaptor ACT1 to mediate various downstream events. Specifically, ACT1 is required 
for recruitment of TNFR-associated factor 6 (TRAF6) and possibly TRAF3, which are 
essential upstream activators of the canonical nuclear factor-B (NF-B) pathway. It is not 
clear whether TRAF6 is also required for the activation of the mitogen-activated protein 
kinase (MAPK) p38. ACT1, but not TRAF6, is required for IL-17A-induced 
stabilization of several target mRNAs, particularly those encoding chemokines and 
cytokines. A second functional domain on IL-17RA is located in the carboxy-terminal 
region and is not required for efficient activation of NF-B and MAPK pathways. 
(Gaffen, 2009) 
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1.5.2. Interleukin-17 and neutrophils 
 
A substantial body of evidence supports a central role for IL-17A in host defence in the 
lungs. Principally IL-17A exerts an orchestrating effect on the accumulation and 
associated activity of neutrophils in the bronchoalveolar space. (Linden et al., 2005) 
This effect is achieved indirectly via the local release of neutrophil-mobilising factors, 
including IL-8, IL-6, GM-CSF, IL-1β, TGF-β, TNF-α and prostaglandin E2, from cells 
resident in the lung such as bronchial epithelial cells, fibroblasts, macrophages and 
endothelial cells. (Aujla et al., 2007) There is clear evidence that airway challenge with 
IL-17 causes substantial neutrophil accumulation in rats and mice in vivo. (Hoshino et 
al., 2000, Prause et al., 2004) The activated neutrophil products neutrophil elastase and 
myeloperoxidase are also similarly increased. (Hoshino et al., 2000) Animal studies 
have also demonstrated that IL-17 signalling plays a central role in defence against 
Gram-negative bacterial infections in the lungs. Mice deficient for the IL-17 receptor 
have an increased mortality due to Klebsiella pneumoniae lower respiratory tract 
infection, decreased neutrophil mobilisation and poorer clearance of bacteria. (Ye et al., 
2001a)  
 
As described earlier in this thesis, TH-17 cells are thought to be an important source of 
IL-17. (Bettelli et al., 2007) IL-17 therefore represents a strategic link between acquired 
and innate immunity and there is growing evidence that T lymphocytes play a role in 
the sustained mobilisation and activation of neutrophils through this mechanism. 
(Linden et al., 2005, Glader et al., 2010)  
 
1.5.3. Interleukin-17 and disease 
 
The IL-17 family of cytokines has been the focus of a great deal of research over recent 
years and has been implicated in the pathogenesis of a diverse range of inflammatory 
conditions. These include the neutrophilic lung diseases asthma, chronic bronchitis, 
chronic obstructive pulmonary disease and chronic lung allograft rejection along with 
non-respiratory conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory 
bowel disease and autoimmune encephalomyelitis. (Bullens et al., 2006, Laan et al., 
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2002, Curtis et al., 2007, Murphy et al., 2008b, Asquith and McInnes, 2007, McFarland 
and Martin, 2007, Bamias and Cominelli, 2007, McGeachy and Anderton, 2005) 
 
1.5.4. Interleukin-17 and cystic fibrosis 
 
As outlined above, IL-17 is linked to both neutrophilic inflammation and mucus excess, 
which are two cardinal features of CF lung disease, in addition to dysregulation of 
acquired immunity.(Chen et al., 2003, Bettelli et al., 2007, Aujla et al., 2007) It has 
been shown that people with CF who exhibit robust T cell responses to P. aeruginosa 
manifest more severe lung disease. (Winnie and Cowan, 1991) Other findings in the 
published literature pertinent to a role for IL-17 in CF lung disease include the reports 
that immortalised airway epithelial cells that do not express functional CFTR upregulate 
their innate immune responses following stimulation with IL-17. In particular 
nucleotide-binding oligomerisation domain 1 is increased. (Roussel and Rousseau, 
2009) IL-17 also modulates bicarbonate secretion in normal airway epithelial cells 
suggesting that it may affect airway surface liquid physiology. (Kreindler et al., 2009) 
In addition treatment with IL-17 increases expression of the mucin genes MUC5AC and 
MUC5B in bronchial epithelial cells in vitro. (Chen et al., 2003) 
 
Dendritic cells (DCs) are an important source of IL-23 in the lung. DCs form an 
immune sensing mesh that surrounds the airway and rapidly processes antigens. This is 
achieved by a process known as “snorkelling” where by DCs extend processes through 
intercellular spaces in the epithelium and sample the airway milieu. (Vermaelen et al., 
2001, Holt, 2005) Dubin et al. (2007) hypothesise that the resultant high antigen load 
generates marked induction of IL-23 production by DCs in the airways of people with 
CF. (Dubin et al., 2007) It follows that a cytokine milieu rich in IL-23 would favour 
expansion of TH-17 cells and hence IL-17 production.  
    
Published human studies of IL-17 in CF are rare but some support the importance of 
this axis. McAllister et al. (2005) analysed sputum from 8 young adults with CF, known 
to be colonised with P. aeruginosa, during hospitalisation for intravenous antibiotic 
therapy to treat an infective exacerbation. Sputum was collected pre-treatment and on 
days 10 and 20 of antibiotics. Levels of IL-17A, IL-17F and IL-23 along with a panel of 
IL-17-induced cytokines including IL-8 and GM-CSF were measured in the sputum 
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samples by enzyme-linked immunosorbent assay (ELISA). They found that IL-17A, IL-
17F and IL-23 were raised in sputum during the exacerbation and were significantly 
reduced by day 20 of antibiotic treatment. A similar pattern was observed in the panel 
of IL-17-induced cytokines, most notably IL-8. (McAllister et al., 2005) Raised levels 
of IL-17 have also been reported in BAL fluid from children with CF during infective 
exacerbations by the same research group. (Dubin et al., 2007, Aujla et al., 2008) IL-17 
has also been found to be raised in the serum of clinically stable adults with CF. 
(Dufresne et al., 2009) 
  
In summary, there is strong evidence from animal and cellular studies that IL-17 is 
linked to neutrophilic airway inflammation and IL-17 has also been demonstrated in 
vitro to increase mucin gene expression. Neutrophilic inflammation and mucus excess 
are two of the cardinal features of the CF airway making IL-17 a highly plausible 
mediator in the pathogenesis of CF lung disease. To date actual evidence of the 
probable role of IL-17 in CF lung disease is limited to a sputum study involving a small 
number of patients. It follows that further research in this area is likely to yield 
important results in terms of enhancing our understanding of the pathogenesis of CF 
lung disease and elucidating potential therapeutic targets in the cascade of neutrophilic 
inflammation that is responsible for progressive bronchiectasis. 
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1.6. Experimental models of cystic fibrosis lung disease 
 
1.6.1. Introduction 
 
As outlined earlier in this chapter, over 95% of morbidity and mortality in CF is 
associated with lung disease. (Doring et al., 2007) Developments in clinical care have 
yielded ever-increasing survival for people with CF over recent decades. (Dodge et al., 
2007) However, 20 years after the identification of the CFTR gene, the exact 
pathogenesis of CF lung disease remains poorly understood. (Rogers et al., 2008a, 
Riordan et al., 1989) Valid experimental models are therefore required to further 
determine the pathogenesis of CF lung disease. (Wine, 2010)   
 
A number of exciting novel, small-molecular compounds targeted at specific CFTR 
mutations have been described in recent years. For example, VX-770 is a CFTR 
potentiator that has shown promising early results in a phase IIa clinical trial in people 
with at least one p.Gly551Asp class III variant. (O'Sullivan and Freedman, 2009, Van 
Goor et al., 2009) PTC124 was initially identified using a cell-based assay and induces 
ribosomes to read through premature stop codons. (Welch et al., 2007) This compound 
has potential benefit in approximately 10% of people with CF who have in-frame 
nonsense variants, such as p.Trp1282X or p.Gly542X, and PTC124 has been shown to 
restore CFTR protein and function in a mouse model with the p.Gly542X mutation. (Du 
et al., 2008, O'Sullivan and Freedman, 2009) A subsequent phase II clinical trial in 
people with nonsense variants showed an increase in nasal potential difference in some 
but not all. (Kerem et al., 2008) These findings highlight the huge importance of 
accurate experimental models to enable the development and evaluation of novel 
potentially therapeutic strategies. (Auld et al., 2009) 
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1.6.2. Animal models 
 
Since the cloning of the CFTR gene it has been possible to develop animal models of 
CF. (Riordan et al., 1989) A large amount of work has been performed in this area, 
principally focussed on mice, that has generated over 2500 publications to date. 
(Scholte et al., 2004) There has also been exciting progress recently in the development 
of CF pig and ferret models. (Rogers et al., 2008b, Sun et al., 2008, Stoltz et al., 2010) 
The obvious strength of animal models is that they allow in vivo study designs of 
disease pathogenesis or the evaluation of novel therapeutic strategies, which are not 
technically or ethically possible in humans. Once the appropriate genetic manipulation 
has been achieved, however, the utility of an animal model is dependent on how closely 
the phenotype of the animal matches that observed in human disease. This is further 
complicated by the relatively weak correlation between CFTR genotype and phenotype 
of lung disease seen clinically in people with CF. (Rowntree and Harris, 2003, 
Bronsveld et al., 2001) When considering this area, it is important to be aware of the 
timely establishment of organisations such as the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research in the United Kingdom to facilitate 
the careful use of animals in medical research. (NC3Rs, 2010) 
 
1.6.3. Mouse models 
 
The first murine models were produced by interruption of the CFTR gene and produced 
a knockout effect resulting in no detectable mouse CFTR mRNA production. 
(Snouwaert et al., 1992, Ratcliff et al., 1993, Hasty et al., 1995, Rozmahel et al., 1996) 
Mice with residual function that produce low levels of mouse CFTR mRNA were 
subsequently produced by an insertional strategy. (Dorin et al., 1992, O'Neal et al., 
1993) Although fundamental to subsequent research it became apparent that the 
mutations in these early models did not accurately simulate the effects of relevant 
clinical mutations such as the dysfunctional CFTR produced with the p.Phe508del 
mutation. (Grubb and Boucher, 1999)  
 
In view of this recombinant mice were therefore generated with specific clinically 
relevant mutations. The first example of which were p.Phe508del CFTR mice 
 30 
developed to replicate the most frequent human CF mutation. (Colledge et al., 1995, 
Zeiher et al., 1995, van Doorninck et al., 1995) In addition mice carrying the human CF 
mutations p.Gly480Cys, p.Gly551Asp and p.Gly542X have been produced. (Delaney et 
al., 1996, Dickinson et al., 2002, Du et al., 2002)  
 
Once the appropriate genetic manipulation has been achieved clearly a vital 
consideration are the phenotypic properties of the various strains of CFTR mutant mice. 
In general the mice exhibit a characteristic CF bioelectric phenotype. (Grubb and 
Boucher, 1999) Intestinal disease, typified by intestinal obstruction, dilated crypts filled 
with mucus and goblet cell hyperplasia, is the most prominent feature in CF mice. This 
intestinal phenotype closely mimics that seen in humans and is widely accepted as a 
valid model. (Guilbault et al., 2007) Pancreatic insufficiency is a problematic feature of 
classical CF in humans but is not convincingly replicated in most mouse models. 
Pancreatic disease appears to be less severe in CF mice due to lower levels of CFTR 
expression in the murine pancreas and the presence of an alternative secretory pathway. 
(Gray et al., 1995) In male mice CFTR dysfunction leads to mucoid obstruction of the 
vas deferens rather than complete absence as is seen in human CF. The net effect 
however is similarly severely reduced fertility. (Scholte et al., 2004)     
 
CF lung disease in humans is characterised by chronic infection with bacteria such as S. 
aureus, H. influenzae and P. aeruginosa, neutrophilic inflammation and retention of 
mucopurulent secretions. (Davidson et al., 1995, Downey et al., 2009) Unfortunately 
there are significant differences between the human CF lung phenotype and that seen in 
CF mice. Despite promising bioelectric features of the airway in some CF mice, 
establishing chronic infection with P. aeruginosa and subsequent inflammation and 
fibrotic lung damage has proved difficult. Scholte et al. in a review of animal models 
for CF concluded that: “the development of an ideal mouse model of CF lung disease, 
to enable the dissection of pathogenesis, or testing of novel therapeutics, is yet to be 
achieved.” (Scholte et al., 2004) Possible explanations for this observation include 
inter-species differences in lung physiology, innate immunity, airway epithelial cell 
composition, alternative chloride channels and less widespread submucosal glands. 
(Pack et al., 1980, Grubb et al., 1994, Borthwick et al., 1999, Maxwell et al., 2003) 
 
In an alternative approach, Mall and colleagues, developed a mouse with airway-
specific overexpression of the β epithelial sodium channel subunit. (Mall et al., 2004) 
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Interestingly the resultant increase in sodium absorption in vivo generated a spontaneous 
CF-like lung disease in the mice including reduced airway surface liquid, increased 
mucus concentration, defective mucus transport, neutrophilic inflammation and poor 
bacterial clearance. This model provides an important mechanistic link between altered 
ion transport, dysregulation of airway surface liquid and CF-like lung disease. However, 
unlike human CF lung disease CFTR function is preserved and the mice also develop 
pulmonary emphysema. (Mall et al., 2008) The model is therefore currently of limited 
value in translation to human CF.  
 
1.6.4. Other animal models 
 
The limitations outlined above of murine models have led to attempts in recent years to 
develop other animal models. Larger animals such as pigs, sheep or ferrets have the 
advantage that their lungs resemble human lungs more closely in terms of anatomy and 
in particular submucosal glands are extensively distributed throughout the respiratory 
tract. (Rogers et al., 2008a)  
 
The preliminary results of a major programme of work based at the University of Iowa 
to develop pigs and ferrets with CFTR mutations have recently been published and 
presented at international meetings. (Rogers et al., 2008b, Sun et al., 2008, Rogers et al., 
2008c) Piglets with disrupted CFTR have been observed to develop an extreme 
gastrointestinal phenotype including meconium ileus, necessitating ileostomy, exocrine 
pancreatic destruction and focal biliary cirrhosis. (Rogers et al., 2008c, Meyerholz et al., 
2010) Gastrointestinal morbidity has also included gastric ulceration and abdominal 
pathology has been responsible for a significant early mortality rate.  
 
The initial results with regard to the recapitulation of CF lung disease have recently 
been published. (Stoltz et al., 2010) As mentioned earlier, newborn CF piglets did not 
show increased evidence of inflammation (BAL fluid IL-8 and neutrophil counts) but 
were less often sterile and eliminated bacteria less effectively. This suggests an intrinsic 
host defense defect against bacteria is the initial pathogenic event in the lungs of CF 
piglets. Within only months of birth the piglets developed spontaneously several 
features of human CF lung disease including mucus accumulation, neutrophilic 
inflammation and endobronchial infection. (Stoltz et al., 2010) Figure 9 illustrates some 
of the pathological features found in the CF pigs. (Stoltz et al., 2010) The pig model 
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remains at an experimental stage and certainly does not represent a mainstream research 
tool that is available to other researchers currently. A major challenge for this model to 
realise its full potential will be to increase the length of survival of the pigs. This has 
been limited to 6 months due to severe morbidity, requiring euthanasia, associated with 
meconium ileus, gastric ulceration and respiratory infections. (Wine, 2010)     
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Figure 9. Lung disease in cystic fibrosis pigs 
(A) Infiltration of the airway wall by lymphocytes and plasma cells (arrows). PAS stain. 
Scale bar, 80 µm. (B) Obstruction (arrows) of bronchi and small bronchioles was a 
striking feature in otherwise unaffected lung (asterisks). H&E stain. Scale bars, 0.75 
mm. (C) Airways from non-CF and CF pigs were scored for the most severe degree of 
leukocytic infiltration de- tected, *P < 0.05, Mann-Whitney test. Horizontal line 
indicates the median. (D) Airways (left panels) (scale bar, 0.7 mm) ranged from 
relatively unaffected (top) to severe disease (bottom; note that the luminal mucocellular 
plug was removed at necropsy) with airway wall thickening. Surface epithelium (right 
panels) (scale bar, 70 µm) ranged from near normal (top) to mucinous and hyperplastic 
change (asterisks) in moderate to severe disease (middle and bottom panels). Note that 
hypertrophy or hyperplasia of submucosal glands (arrows, bottom right) was uncommon 
and generally restricted to the most severe and chronically affected airways. (Stoltz et 
al., 2010) 
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1.6.5. Cellular models 
 
In addition to structural and barrier functions airway epithelial cells are increasingly 
recognised to operate as ‘effector’ cells. Airway epithelial cells produce a wide range of 
inflammatory and immunomodulatory cytokines and growth factors that contribute to 
the pathogenesis of respiratory disease. (Ward et al., 2009, Smyth, 2009, Crystal et al., 
2008, Wang et al., 2009, Brodlie et al., 2009a) 
 
For a number of decades it has been possible to culture human airway epithelial cells in 
vitro. (Gruenert et al., 1995, Lechner et al., 1981) Cells may be cultured most simply 
under submerged conditions on plastic in petri dishes or flasks, however, primary cells 
revert to a poorly differentiated phenotype within a limited number of passages. 
(Gruenert et al., 1995, Araya et al., 2007) More advanced culture techniques, such as 
within collagen gels, as three-dimensional spheroids or most commonly on semi-
permeable membranes at an air-liquid interface, allow more accurate reproduction of the 
native airway epithelium. (de Jong et al., 1993, Ulrich and Doring, 2004, Bals et al., 
2004, Choe et al., 2006)  
 
Air-liquid interface cultures have been pivotal in several major advances in our current 
understanding of the pathogenesis of CF lung disease, including depletion of the 
periciliary liquid layer. (Matsui et al., 1998) Semi-permeable membranes may also be 
used to co-culture different cell types and investigate their interactions, for instance 
airway epithelial cells and fibroblasts. (Zhang et al., 1999) Airway epithelial cells may 
also be used in electrophysiology experiments in whole-cell patch clamping or cultured 
monolayers in assays of iodide efflux or Ussing chambers. (Rakonczay et al., 2008, 
Jurkuvenaite et al., 2009, Brodlie et al., 2010f)  
	  
1.6.6. Immortalised cell lines 
 
Immortalised airway epithelial cell lines, originating from human neoplasms or 
produced in vitro by physical or chemical mutagenesis or introduction of viral 
oncogenes, are used extensively in CF research and have contributed significantly. 
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(Gruenert et al., 1995, Lundberg et al., 2002, Fulcher et al., 2009, Pedemonte et al., 
2005) Immortalised cell lines have been particularly useful for the investigation of 
relationships between CFTR genotypes, metabolic and biochemical characteristics and 
disease phenotypes. (Gruenert et al., 2004) Immortalised cells are also essential in the 
early stages of high-throughput screening strategies to identify novel therapeutic 
compounds. (Pedemonte et al., 2005) Advantages of immortalised cell lines include 
their widespread availability, especially when compared to the scarcity of primary CF 
tissue and cells, homogeneity in terms of biochemical, electrophysiological and growth 
characteristics and the presence of matched isogenic control lines. (Gruenert et al., 
2004) Cell lines that are commonly used in CF research have been comprehensively 
reviewed. (Gruenert et al., 2004)   
 
However, the process of immortalisation may generate karyotypic instability and have 
major effects on cellular differentiation, morphology or function compared to the 
situation in vivo. (Gruenert et al., 2004, Fulcher et al., 2009, Karp et al., 2002) The 
condition of the primary culture prior to immortalisation is crucial in determining the 
validity and utility of the cell line.  Careful selection must be made of the most 
appropriate immortalised cell line guided by the biological end points that are to be 
evaluated. Although the dependence of these end points on the cellular context cannot 
always be regulated. (Gruenert et al., 2004) Karyotypic instability may also lead to the 
emergence of subpopulations that do not retain the phenotypic characteristics of 
interest. (Gruenert et al., 2004)   
	  
1.6.7. Primary tissue or cellular ex vivo models 
 
CF is a uniquely human disease and therefore primary tissue or cells cultured directly 
from people with CF represent a highly valuable experimental resource. The ex vivo 
culture of primary airway epithelial cells from people with CF, that have not been 
immortalised, is likely to reproduce the behaviour of cells in vivo more accurately than 
immortalised cell lines. Furthermore, primary airway epithelial cell cultures have been 
instrumental in several important developments in our understanding of the 
pathophysiology of CF lung disease. (Fulcher M. L., 2005, Matsui et al., 1998, Blouquit 
et al., 2006, Joseph et al., 2005, Widdicombe, 1990)  
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Primary airway epithelial cells are particularly important in the new era of targeted 
therapies for the molecular defects associated with specific CFTR variants. (O'Sullivan 
and Freedman, 2009) The problems outlined earlier with the murine models of CF lung 
disease clearly limit their utility in drug discovery. (Scholte et al., 2004) Although 
immortalised cell lines are extremely valuable in the early stages of high-throughput 
screening, primary cells are vital to confirm and validate any initial findings in a 
immortalised cell line prior to more advanced stages of analysis. (Pedemonte et al., 
2005, Van Goor et al., 2006, Ma et al., 2002, O'Sullivan and Freedman, 2009) 
 
In CF there is a diverse spectrum of disease and often a weak correlation between CFTR 
genotype and clinical lung phenotype. (Rowntree and Harris, 2003) Primary airway 
epithelial cells from individual donors are likely to reflect this inherent biological 
heterogeneity in terms of their function. (Becker et al., 2004) Indeed, for some 
experiments the homogeneity of an immortalised cell line along with isogenic controls 
may be preferable. Primary cells possess a finite reproductive capacity before they 
senesce and this has provided impetus to establish novel immortalised cell lines derived 
from primary cells. (Fulcher et al., 2009, Ben-Porath and Weinberg, 2005)  
 
Several potential sources of primary airway epithelial cells from people with CF are 
described below, including explanted lungs, bronchial and nasal brushings. Appropriate 
ethical approval and strict adherence with human tissue legislation are clearly essential 
along with the informed consent of the participants and any research sampling must not 
compromise the care or health of patients. (Trouet, 2004, Anon, 2006, Trouet et al., 
2004, Dodge, 2004, Mallory, 2006, Bush and Davies, 2006) 
	  
1.6.8. Explanted lungs 
 
The only life-sustaining intervention for end-stage CF lung disease is transplantation. 
(Meachery et al., 2008) Explanted lungs removed at the time of transplantation from 
people with CF represent a potential source of large numbers of primary bronchial 
epithelial cells. The procurement of appropriate lung tissue is logistically demanding 
however, lung transplantation is unpredictable in nature, informed consent is required in 
advance from patients and the cooperation of the multidisciplinary transplant team is 
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essential. (Brodlie et al., 2010f) It is also important to note that cells and tissue obtained 
from explanted lungs maybe only representative of advanced disease. 
 
It is imperative that the multidrug-resistant microorganisms, which frequently colonise 
the airways of people with end-stage CF lung disease, are eradicated from cultures at an 
early stage to achieve success. (Gruenert et al., 2004, Randell et al., 2001) Chapter 5 of 
this thesis reports the establishment of a successful technique and programme to culture 
primary bronchial epithelial cells from explanted lungs in Newcastle upon Tyne. 
 
Intact sheets of bronchial epithelium may also be resected from lungs shortly after 
explantation and placed in perfused mini-Ussing chambers. This allows the 
investigation of electrophysiological responses, for example with small molecule CFTR 
correctors or potentiators, in the context of an intact epithelium complete with 
submucosal glands. (Derichs, 2009, Jaffar et al., 1999)  
	  
1.6.9. Bronchial brushings 
 
Bronchial epithelial cells maybe cultured in smaller numbers from brushings of the 
lower airway. Once the appropriate ethical approval is in place an opportunistic 
approach is likely to be required on behalf of the clinical researcher to obtain informed 
consent and bronchial brushings from people with CF when they undergo elective 
procedures such as gastrostomy or totally implantable vascular access device insertion. 
Eradication of infection remains essential for the successful ex vivo culture of cells.          
 
Bronchial brushings may be obtained blindly from patients who have been intubated by 
passing a cytology brush down the endotracheal tube. (Doherty et al., 2003) 
Alternatively, brushings may be performed under direct vision via a flexible 
bronchoscope in patients, including children, who are intubated or with a laryngeal 
mask airway in situ, or in those who are undergoing bronchoscopy for a clinical 
indication. (McNamara et al., 2008, Forrest et al., 2005, Lane et al., 2005)  
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1.6.10. Nasal brushings 
 
The nose is an alternative source of airway epithelial cells that is easily accessible. 
Nasal brushings may be performed in a relatively non-invasive manner in a clinic 
setting. In adults and older children the technique does not require any sedation or 
anaesthesia and therefore allows repeated isolations from the same individual, for 
instance with a particular CFTR genotype of interest. This also provides the potential 
for longitudinal studies of aetiology and treatment strategies, the evaluation of the 
effects of primary CFTR defects and subsequent host-pathogen interactions on 
phenotype.  Nasal brushings may also be performed on groups such as children who are 
less likely to undergo bronchoscopy due to practical or ethical reasons. (Mosler et al., 
2008, McDougall et al., 2008) There are several published methods for the culture of 
nasal epithelial cells from people with CF and feasibility of the technique has even been 
demonstrated in infants. (Bridges et al., 1991, Mosler et al., 2008)  
 
McDougall et al. compared the release of proinflammatory mediators and surface 
expression of receptors by undifferentiated monolayers of nasal and bronchial epithelial 
cells from the same individuals under resting conditions and in response to cytokine 
stimulation. (McDougall et al., 2008) They found differences in absolute mediator 
levels but similar responses to stimulation and comparable cell surface receptor 
expression suggesting that nasal epithelial cells may represent an accessible surrogate 
for lower airway epithelial cells to study inflammation. (McDougall et al., 2008) 
 
1.6.11. Experimental model summary 
 
Experimental models are critically important for use in research to advance both our 
knowledge of the pathogenesis of CF lung disease and to discover and evaluate novel 
therapeutic compounds and strategies. This is especially relevant in light of the recent 
exciting advances in the development of small-molecule compounds directed at specific 
CFTR mutations. A large amount of work over the last two decades has unfortunately 
failed to yield a good CFTR-deficient murine model of CF lung disease. The 
development of larger animal models, for example, the porcine model shows promise 
but remains in its infancy and is yet to be fully validated. Immortalised airway epithelial 
cell lines have contributed significantly to CF research but have inherent limitations, 
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including karyotypic instability and poor replication of behaviour in vivo. Primary lung 
tissue and airway epithelial cells harvested from nasal or bronchial brushings or 
explanted lungs from people with CF represent a valuable resource for the ex vivo study 
of CF lung disease. A schematic diagram of approaches to the use of different 
experimental models in drug discovery for CF lung disease is shown in Figure 10. 
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Figure 10. Schematic diagram illustrating the use of different experimental models 
in drug discovery for CF lung disease 
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1.7. Ceramide and cystic fibrosis lung disease 
 
1.7.1. Introduction and biochemistry 
 
Ceramide is a ubiquitous sphingolipid that is found in the membrane of cells. The 
original ‘fluid mosaic model’ of cell membrane structure has subsequently been revised 
to include the concept of membrane microdomains including ceramide-enriched lipid 
rafts. (Singer and Nicolson, 1972, Simons and Ikonen, 1997, Gulbins et al., 2004) Lipid 
rafts act as anchoring points in cell membranes for the cytoskeleton and as receptors for 
the start of signalling cascades and the uptake of microorganisms. (Grassme et al., 2003, 
Uhlig and Gulbins, 2008, Manes et al., 2003) In addition to their function in cell 
membranes, sphingolipids are also recognised to regulate a number of key physiological 
intracellular processes via roles as pleiotropic second-messengers. (Hannun and Obeid, 
2002) This includes apoptosis, senescence, innate and acquired immunity, vascular 
permeability and smooth muscle tone. (Uhlig and Gulbins, 2008, Novgorodov and 
Gudz, 2009) 
  
Sphingolipids are amphiphatic and comprise of a hydrophobic ceramide moiety and a 
hydrophilic headgroup. (Becker et al., 2010c) Sphingolipds are principally derived from 
sphingosine. Sphingosine-1-phosphate (S1P) is formed by phosphorylation of 
sphingosine and its acylation results in ceramide. Ceramide is coupled with 
phosphocholine to produce sphingomyelin. The reverse of this processs, the production 
of ceramide from sphingomyelin by sphingomyelinase, is of greater significance in 
disease. Ceramide itself may be degraded by acid ceramidase to sphingosine and fatty 
acid. (Uhlig and Gulbins, 2008) Figure 11 provides a summary of sphingolipid 
metabolism. Figure 12 illustrates the de novo synthesis pathway and the salvage 
pathway that ceramide is principally generated by. (Novgorodov and Gudz, 2009)   
 
Sphingolipids exert profound effects on cell fate. S1P mediates survival and 
proliferation where as ceramide promotes differentiation, apoptosis and cell-cycle 
arrest. (Uhlig and Gulbins, 2008) Hence the term ‘the sphingolipid rheostat’ has been 
coined to describe the critical role of sphingolipids in cell fate, particularly in response 
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to different stressors. (Pyne and Pyne, 2000) Accordingly sphingolipid levels are tightly 
regulated in cells. (Novgorodov and Gudz, 2009)  
 
There is wide-ranging evidence that ceramide in particular is a key sphingolipid 
messenger in the regulation of cellular responses to stress, including apoptosis and 
senescence. (Pettus et al., 2002) Ceramide consists of a family of approximately 50 
distinct species that are defined by molecular structure including acylation, desaturation 
and hydroxylation. (Novgorodov and Gudz, 2009)      
 
The study of sphingolipids in biological systems is highly complex and techinically 
demanding. Ceramide is hydrophobic and therefore the identification of specific 
intracellular binding partners has proved difficult. (Uhlig and Gulbins, 2008) Another 
major challenge is difficulties with the lack of an efficient method to quantify levels of 
sphingolipids in biological samples. Two ceramide antibodies are now commercially 
available, a mouse IgM monoclonal antibody (Sigma-Aldrich) and an antiserum 
enriched for IgM polyclonal antibody (Glycobiotech). Cowart et al. compared the 
specificity of these two antibodies and found the polyclonal antibody to be more 
specific for ceramide than the monoclonal antibody, which also detects 
dihydroceramide, phosphatidylcholine and sphingomyelin. (Cowart et al., 2002)  
 
As mentioned above, ceramide truly consists of a large family of distinct molecular 
species. Importantly, there is evidence that individual ceramide species have specific 
biological functions and vary in their relative concentrations, for example C16 and C24 
ceramide in apoptosis. (Kroesen et al., 2003) In order to identify and accurately 
quantify individual ceramide species analytical chemistry techniques are required. For 
example high performance liquid chromatography-mass spectrometry (HPLC-MS) may 
be used to analyse homogenates of tissues. (Pettus et al., 2003) Clearly such an 
approach does not allow architectural localisation of ceramide species in tissues 
however. (Brodlie et al., 2010d) 
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Figure 11. Overview of sphingolipid metabolism.  
Blue colours indicate chemical moieties transferred by the enzymatic reactions. Red 
arrows indicate heavily regulated enzymes that are thought to play a major role 
in pulmonary disease (Uhlig and Gulbins, 2008) 
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Figure 12. Biosynthesis of ceramide including the de novo and salvage pathways  
(Novgorodov and Gudz, 2009) 
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1.7.2. Sphingolipids and pulmonary disease 
 
Sphingolipids are increasingly recognised to play a role in the pathogenesis of several 
lung conditions. The metabolic conditions Niemann-Pick disease (NPD) type A and B 
result from deficiency of sphingomyelinase and subsequent lysosomal accumulation of 
sphingomyelin. NPD is associated with pulmonary infection and interstitial lung 
disease. (Schuchman, 2007) In the context of acute lung injury and pulmonary oedema 
acid sphingomyelinase activity has been shown to be increased and may represent a 
potentially useful therapeutic target. (Niessen et al., 2008, Claus et al., 2005, Lindner et 
al., 2005) Asthma is characterised by chronic inflammation involving eosinophils, mast 
cells, neutrophils and lymphocytes, airway smooth muscle contraction and 
hyperresponsiveness. (Brodlie and McKean, 2009, Holgate, 2008) Sphingolipids are 
involved in the regulation of all of the aforementioned processes. (Ammit et al., 2001) 
Ceramide has also been identified as an important mediator in the development of 
emphysema. In this context ceramide is thought to act by inducing oxidative stress and 
apoptosis of alveolar endothelial and epithelial cells. (Petrache et al., 2005, Petrache et 
al., 2008) 
 
Ceramide-enriched lipid rafts are intimately involved in airway epithelial cells defences 
against infection by microorganisms. This includes hosting key signalling events in the 
immune-surveillance of pathogens. (Manes et al., 2003) In addition a number of 
pathogens have evolved strategies to enter airway epithelial cells via lipid rafts. (Manes 
et al., 2003)  The invasion of epithelial cells by rhinovirus involves ceramide-enriched 
lipid rafts. (Grassme et al., 2005) The infection of epithelial cells with P. aeruginosa 
also critically involves ceramide-enriched membrane domains. (Grassme et al., 2003) 
Furthermore it has been shown that CFTR acts as a receptor for the internalization of P. 
aeruginosa. (Pier et al., 1996, Pier et al., 1997) 
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1.7.3. Ceramide and cystic fibrosis lung disease 
 
Chronic infection with P. aeruginosa and intense neutrophilic inflammation are two 
hallmarks of CF lung disease. (Davidson et al., 1995, Downey et al., 2009) In lung 
endothelial cells CFTR function is also required for stress-induced apoptosis by 
maintaining ceramide activation. (Noe et al., 2009) Ceramide is therefore a plausible 
mediator in the pathogenesis of CF lung disease.  
 
Two specific strains of CFTR-deficient mice have recently been demonstrated to 
accumulate ceramide in airway epithelial cells. (Teichgraber et al., 2008) The 
accumulation of ceramide triggered chronic neutrophilic pulmonary inflammation, 
death of airway epithelial cells and extracellular deposition of DNA in the airways, 
thereby increasing susceptibility to infection with P. aeruginosa. (Teichgraber et al., 
2008) Importantly, treatment with the tricyclic antidepressant amitriptyline, which is an 
acid sphingomyelinase inhibitor, normalised pulmonary ceramide, inflammation and 
susceptibility to P. aeruginosa infection. (Becker et al., 2010b, Teichgraber et al., 2008) 
Ceramide accumulation was also shown in nasal epithelial cells and demonstrated at a 
qualitative level in three sections of lower airway from people with CF. (Teichgraber et 
al., 2008)  
 
The precise role of epithelial ceramide accumulation in the pathogenesis of CF lung 
disease is yet to be fully elucidated. The work performed by Teichgräber et al. (2008) 
suggests that ceramide accumulation occured in a constitutive, age-dependent fashion in 
the airway epithelial cells of CFTR-deficient animals and promoted pro-inflammatory 
cytokine release, apoptosis and DNA deposition in the airway. (Teichgraber et al., 
2008) A proposed mechanism for ceramide accumulation is that defective CFTR leads 
to inappropriate alkalinisation of intracellular vesicles, in particular pre-lysosomes and 
lysosomes, resulting in an increase in acid sphingomyelase and reduction in acid 
ceramidase activity and subsequent ceramide accumulation (Figure 13). (Teichgraber et 
al., 2008) However, the role of CFTR in the acidification of lysosomes has been hotly 
debated recently with apparently contradictory results published by different 
investigators. (Haggie and Verkman, 2009a, Haggie and Verkman, 2009b, Di et al., 
2006, Teichgraber et al., 2008, Poschet et al., 2002, Noe et al., 2009) 
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Figure 13. Schematic diagram of proposed mechanism of ceramide accumulation 
in the pathogenesis of cystic fibrosis lung disease 
Synthesis of ceramide from sphingomyelin by acid sphingomyelinase (ASM) and 
degradation by acid ceramidase (AC) is optimal at an acidic pH, such as that of normal 
intracellular vesicles (pH 4.5). Lack of functional CFTR increases vesicle pH to 5.9, 
partially inhibiting ASM and highly inhibiting AC, resulting in ceramide accumulation 
in the vesicle and age-dependent pulmonary inflammation. Other properties of the 
cystic fibrosis–affected lung, including lack of the CFTR receptor needed for clearing 
Pseudomonas aeruginosa, enhanced mucin secretion, a dehydrated airway surface 
liquid, viscous mucus and DNA deposits released from ceramide-engorged apoptotic 
cells, also contribute to P. aeruginosa airway colonization. Eventually, this microbe 
establishes a chronic infection wherein bacterial cells reside in low-oxygen mucus plugs 
and become highly resistant to clearance or killing by host defenses. (Pier, 2008) 
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The findings of current research into ceramide and CF pathophysiology are divergent 
however, and possibly specific to the model systems studied. Furthermore, there is a 
lack of human data in the literature, particularly in relation to the lower airways, which 
are the site of the vast majority of morbidity and mortality in people with CF. (Guilbault 
et al., 2008b, Guilbault et al., 2008a, Teichgraber et al., 2008)  
 
Low plasma levels of ceramide have been reported by Guilbault et al. (2008a and 
2008b) in people with CF compared to healthy volunteers. The same researchers also 
found reduced levels of ceramide in the plasma, lungs, pancreas and ileum of CFTR-
deficient mice that could be corrected by treatment with fenretinide. (Guilbault et al., 
2008b, Guilbault et al., 2008a) Yu et al. found no significant difference in basal 
ceramide levels in IB3-1 immortalised CF bronchial epithelial cells and lung 
homogenate from CFTR knock out mice compared to wild type cells and mice. (Yu et 
al., 2009) Physiological levels of ceramide appear to be essential for the homeostasis of 
cells and inflammatory responses and therefore it is plausible that too little ceramide 
may be equally as deleterious to epithelial physiology as a situation where ceramide 
accumulation occurs. (Guilbault et al., 2008a) 
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1.8. Airway remodelling in cystic fibrosis lung disease 
 
CF lung disease is characterised by airflow obstruction, neutrophilic inflammation and 
chronic endobronchial infection. (Davies et al., 2007) Children with CF are born with 
airways of essentially normal structure however. (Konstan and Berger, 1997) Airway 
remodelling, in the form of architectural changes in the airway wall, is well recognised 
in people with asthma and chronic obstructive pulmonary disease (COPD). (Jeffery, 
2001, Davies, 2009)  
 
One specific feature of airway remodelling seen in adults and children with asthma is 
apparent thickening of the sub-epithelial reticular basement membrane (RBM) due to 
collagen matrix deposition (Figure 14). (Ward et al., 2002, Payne et al., 2003) It has 
also been postulated that airway remodelling may be implicated in the pathogenesis of 
CF lung disease and RBM thickening has been reported in endobronchial biopsies from 
children with CF. (Hilliard et al., 2007) Clinical evidence of structural airway 
remodelling at an early stage in CF lung disease includes the observation that airway 
function is demonstrably abnormal in infants newly diagnosed clinically with CF. 
(Ranganathan et al., 2001) Furthermore, their lung function does not improve despite 
intensive treatment, and the airway obstruction would appear to be ‘fixed’. 
(Ranganathan et al., 2004) 
 
However, in an earlier study Durieu et al. examined RBM thickness in a mixture of 
endobronchial and lobectomy specimens from a total of 9 children and adults with a 
spectrum of severity of CF lung disease. (Durieu et al., 1998) They assessed the basal 
lamina thickness of the basement membrane qualitatively using immunostaining for 
murine laminin in fresh frozen sections and transmission electron microscopy. In 
contrast to the findings of Hilliard et al., they found the RBM to be thinned in the CF 
specimens compared to 3 healthy, non-smoking volunteers. (Hilliard et al., 2007, 
Durieu et al., 1998) A dense, fibrous, acellular sub-epithelial deposit was observed 
however. (Durieu et al., 1998)  
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Figure 14. Example of airway remodelling in an endobronchial biopsy from a 
person with asthma 
(1) subepithelial reticular basement membrane thickening as denoted by collagen 
subtype I staining and (2) diffuse staining in the lamina propria. (Ward et al., 2001) 
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Wojnarowski et al. found the RBM to be thickened in association with a metaplastic 
epithelium in endobronchial biopsies taken from children during an acute exacerbation 
of CF. (Wojnarowski et al., 1999) In this study the biopsies were fixed in 
paraformaldehyde and embedded in paraffin prior to haematoxylin and eosin staining of 
2µm sections. Biopsies from clinically stable children with CF were found to contain an 
intact respiratory epithelium with normal RBM appearances. (Wojnarowski et al., 1999) 
Changes in airway dimension have been described in explanted CF lungs but RBM 
thickness has not been specifically investigated in end-stage disease to the best of my 
knowledge. (Tiddens et al., 2000) 
 
Eosinophilic inflammation has been implicated in the pathogenesis of airway 
remodelling in asthma via the maintenance and progression of aberrant airway tissue 
injury and repair. (Holgate and Polosa, 2008) The biological activity of eosinophils is 
largely mediated by the release of stored granules containing potent cytotoxic proteins 
such as eosinophilic cationic protein, eosinophil peroxidase and major basic protein. 
(Stone et al., 2010) In addition, eosinophils produce oxygen radicals, lipid mediators 
and a wide range of pro-inflmmatory cytokines and chemokines. (Hamid and Tulic, 
2009) A number of cytokines produced by eosinophils are associated with remodelling 
and fibrosis, most notably TGF-β but also IL-6, IL-11, IL-13, IL-17 and IL-25. (Hamid 
and Tulic, 2009, Minshall et al., 1997)  Interestingly, Hilliard et al. found a positive 
correlation between RBM thickness and total TGF-β1 concentration in bronchoalveolar 
lavage fluid in chidren with CF. (Hilliard et al., 2007) 
 
In summary, there are contradictory reports in the literature regarding RBM thickness in 
CF lung disease and no descriptions of RBM thickness in end-stage disease. 
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Figure 15. Schematic diagram of eosinophilic inflammation and airway 
remodelling in asthma 
Eosinophils in the asthmatic lung release latent TGF-β1. Latent TGF-β1 (latTGF-β1) is 
activated by αvβ6 expressed on airway epithelial cells. TGF-β1 mediates airway 
remodeling by inducing the formation of myofibroblasts that secrete extracellular 
matrix proteins, and the growth factor also stimulates airway smooth muscle 
hyperplasia. (Williams, 2004) 
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2. Chapter 2. Hypotheses 
 
 
The work described in this thesis investigated the following hypotheses 
 
1. It is technically possible to culture PBECs from explanted CF lungs and to 
establish a programme to do this at the Freeman Hospital, Newcastle upon Tyne. 
2. Expression of interleukin-17 is raised in the lower airway of people with 
advanced CF lung disease. 
3. Interleukin-17 may be localised to cells other than lymphocytes in the lower 
airway of people with CF 
4. Stimulation with interleukin-17 would increase the production of pro-
neutrophilic mediators by ex vivo cultures of PBECs from people with advanced 
CF lung disease. 
5. Ceramide is raised in the lower airway epithelium of people with advanced CF 
lung disease and is correlated with markers of neutrophilic inflammation and P. 
aeruginosa infection. 
6. RBM thickness is increased in advanced CF lung disease and that this is linked 
to mucosal eosinophils. 
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3. Chapter 3. Aims 
 
 
In accordance with the hypotheses outlined in Chapter 2 the aims of the work described 
in this thesis were to: 
 
1. Develop and optimise a method to culture PBECs from explanted CF lungs 
2. Establish a programme to culture PBECs from lungs removed at the time of 
transplantation from people with CF at the Freeman Hospital in Newcastle upon 
Tyne 
3. Investigate the protein expression of interleukin-17 in the lower airway of 
people with advanced CF lung disease and compare to the non-suppurative 
condition pulmonary hypertension. 
4. Describe the cellular localisation of interleukin-17 in the lower airway of people 
with advanced CF lung disease. 
5. Investigate the effects of stimulation with interleukin-17 on the production of the 
pro-neutrophilic mediators interleukin-8, interleukin-6 and granulocyte 
monocyte colony-stimulating factor by ex vivo primary bronchial epithelial cell 
cultures from people with advanced CF lung disease.  
6. Investigate levels of ceramide in the lower airway of people with advanced CF 
lung disease. More specifically to: 
a. Quantify immunoreactive ceramide localised to the lower airway 
epithelium in advanced CF lung disease compared to pulmonary 
hypertension, emphysema and, previously healthy, unused lung donors. 
b. Quantify the specific ceramide species C16:0, C18:0, C20:0 and C22:0 
in whole lung tissue from people with advanced CF lung disease 
compared to pulmonary hypertension by the independent technique of 
high performance liquid chromatography-mass spectrometry. 
7. Correlate the amount of immunoreactive ceramide in the lower airway 
epithelium in advanced CF lung disease, pulmonary hypertension, emphysema 
and unused lung donors with levels of neutrophilic inflammaion in the lower 
airway mucosa, as measured by the number of cells staining positive for 
neutrophil elastase and myeloperoxidase per mm of basement membrane. 
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8. Investigate the relationship between the amount of immunoreactive ceramide in 
the lower airway epithelium in advanced CF lung disease, pulmonary 
hypertension and emphysema, and colonisation with P. aeruginosa. 
9. Quantify RBM thickness in the lower airways of people with advanced CF lung 
disease requiring transplantation 
10. Investigate any relationship between RBM thickness and number of mucosal 
eosinophils 
11. Investigate any relationship between RBM thickness and age at time of lung 
transplantation 
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4. Chapter 4. Materials and methods 
 
 
4.1. Ethics and consent 
 
Approval was obtained for this study from the Newcastle and North Tyneside 2 
Research Ethics Committee, reference number 07/Q0906/47, on an application by Drs 
Malcolm Brodlie, Christopher Ward, Michael McKean and James Lordan. The study 
was also approved by the Research and Development Department of the Newcastle 
upon Tyne Hospitals Foundation NHS Trust, reference number 3910. 
 
I obtained informed consent from all participants at the time of acceptance on to the 
active lung transplantation list at the Freeman Hospital, Newcastle upon Tyne. 
	  
	  
4.2. Culture of primary bronchial epithelial cells from the lungs of people with 
cystic fibrosis removed at the time of transplantation 
 
4.2.1. Procurement of explanted lungs 
 
As a matter of routine lungs removed at the time of transplantation are examined 
macroscopically and histologically by a Consultant Pathologist in order to confirm the 
nature of the underlying disease and to identify any additional pathology present that 
may have been unidentified prior to transplantation, for example a malignancy. 
(Abrahams et al., 2004) I am grateful to Dr Fiona Black, Consultant Pathologist, 
Newcastle upon Tyne Hospitals NHS Foundation Trust, for permission to remove the 
tissue samples for this study prior to processing of the lungs for routine pathology. 
 
Explanted lungs were stored at 4°C once samples of frank airway secretions had been 
obtained for microbiology testing. Tissue was processed as soon as possible following 
explantation, typically in under 60 minutes. This work has therefore necessitated a 
permanent on-call commitment on my part in the event of a lung transplant occurring. 
The support of Dr Laura MacKay, MRC Clinical Research Training Fellow, Newcastle 
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University, the cardiopulmonary transplant coordinators, cardiothoracic surgeons and 
theatre staff at the Freeman Hospital has also been invaluable. 
 
4.2.2. Airway lavage of explanted lungs 
 
A small-volume airway lavage of 15mL of phosphate-buffered saline (PBS) was 
performed on each CF lung (total volume of 30mL/patient). This was achieved by 
installation of saline in to the main or first generation bronchus via a 20mL syringe with 
a 5cm quill attached that was then aspirated back in to the syringe. The median lavage 
return was 22mL/patient (73%) using this technique. The resulting lavage fluid was then 
promptly centrifuged at 2000 revolutions per minute (rpm) and the supernatant 
aliquoted and frozen at -20°C prior to analysis. The lower phase, containing cellular and 
mucoid material was also frozen and stored.    
  
4.2.3. Resection of main bronchus and initial processing 
 
All culture work was performed using strict aseptic technique in a class II laminar flow 
hood. Pieces of main bronchus, around 0.5cm by 2cm in dimension, were resected and 
cut free from surrounding connective, lymphoid, alveolar and vascular tissue. Around 
four pieces of bronchus were removed from each lung. The pieces of bronchus were 
then rinsed twice in 25mL volumes of sterile phosphate buffered saline (Sigma-Aldrich, 
Dorset, UK) at 4°C. The rinsed tissue was then submerged in 20mls of washing solution 
A at 4°C (Table 3). After 30 minutes the solution was agitated and the pieces of 
bronchus were rinsed twice in 25mL volumes of Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Invitrogen, Paisley, UK) at 4°C before being submerged in 20mls of washing 
solution B (Table 4). The tissue was then maintained at 4°C whilst being agitated on a 
rocker-shaker set at 50Hz for 48 to 72 hours. 
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Component Concentration Supplier 
DMEM Neat Invitrogen 
Dnase 10µg/mL Sigma-Aldrich 
Dithiothreitol 500µg/mL Sigma-Aldrich 
Designated antimicrobials See Table 5 
 
Table 3. Constituents of washing solution A 
 
 
Component Concentration Supplier 
DMEM Neat Invitrogen 
Dnase 1µg/mL Sigma-Aldrich 
Protease 0.1% Sigma-Aldrich 
Designated antimicrobials See Table 5 
 
Table 4. Constituents of washing solution B 
 
 
Initially a fixed, ‘best-guess’, combination of antimicrobials (amphotericin B, 
ceftazidime, vancomycin and tobramycin) was used based on discussions with Professor 
John Perry, Microbiology Department, Freeman Hospital.  This approach was 
subsequently changed however to a tailored, ‘patient-specific’, approach that was based 
on expert microbiology advice from Professor John Perry and Audrey Nicholson taking 
in to account where possible the sensitivity results for organisms recently isolated from 
the sputum of specific patients. The antimicrobial strategy is discussed fully in section 
5.6 and this was the principal difference from the method previously published by Dr 
Scott Randell, University of North Carolina at Chapel Hill, USA. (Randell et al., 2001) 
 
The various antimicrobials used along with the working concentrations are detailed in 
Table 9. The concentration of each antimicrobial used was decided based on data 
published by Randell et al. (2001) regarding the relative cytotoxicity of different agents 
in primary bronchial epithelial cell (PBEC) cultures and discussion with Professor Perry 
concerning the concentration required for the desired antimicrobial effect. (Randell et 
al., 2001)    
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Antimicrobial Concentration 
Ceftazidime 128µg/mL 
Tobramycin 16µg/mL 
Vancomycin 10µg/mL 
Colistin 5µg/mL 
Meropenem 100µg/mL 
Co-trimoxazole 12µg/mL 
Ticarcillin and clavulanate 16µg/mL 
Amphotericin B 4µg/mL 
Voriconazole 10µg/mL 
 
Table 5. Working concentrations of antimicrobials used in media 
 
 
4.2.4. Harvesting of primary bronchial epithelial cells 
 
Following 48 to 72 hours in washing solution B the PBECs were harvested. This was 
achieved by firstly adding 5mls of Roswell Park Memorial Institute-1640 (RPMI) 
(Invitrogen) containing 10% fetal calf serum (FCS) (Invitrogen) to the solution in order 
to neutralise any remaining protease activity. The pieces of bronchus were then 
transferred to a sterile petri dish. A scalpel blade was used to lightly scrape the lumenal 
side of the bronchi and thus remove the epithelial cells. The scraped cells were then 
suspended in 10mls of RPMI containing 10% FCS and centrifuged at 1000 rpm for 5 
minutes.  
 
The supernatant was discarded and the cells were resuspended in 5mls of Bronchial 
Epithelial Growth Medium (BEGM) (Lonza, Basel, Switzerland) warmed to 37°C and 
supplemented with the single quots detailed in Table 6, 1% streptomycin (Sigma-
Aldrich), 1% penicillin (Sigma-Aldrich) and designated antimicrobials as described in 
Table 5. The resulting cell suspension was then seeded in to a 25cm2 tissue culture flask 
(Corning, New York, USA) pre-coated with type I collagen (Purecol, Nutacon, 
Leimuiden, Netherlands) and placed in a carbon dioxide (5%) enriched incubator at 
37°C. 
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Component Volume added to 
500mL* 
Bovine pituitary extract 2mL 
Insulin 500µL 
Hydrocortisone 500µL 
Retinoic acid 500µL 
Transferrin 500µL 
Epinephrine 500µL 
Human epidermal growth factor 500µL 
Tri-iodothyronine 500µL 
Gentamicin/amphotericin 500µL 
 
*concentrations not published by the manufacturer  
(available as product number CC-4175 from Lonza) 
 
Table 6. Components (single quots) added to bronchial epithelial basal medium to 
create bronchial epithelial growth medium 
 
 
The PBEC cultures were then carefully observed to ensure that the cells were growing 
satisfactorily and for any evidence of infection. In the latter event the flask was 
immediately removed from the incubator and the contents sent for routine bacterial and 
fungal cultures to identify the infecting organism and relevant antimicrobial sensitivities 
(performed by Professor John Perry and Audrey Nicholson). The BEGM was replaced 
every 48 hours. The designated antimicrobials were normally removed from the BEGM 
after around 96 hours of successful cell culture free of overt infection.     
 
Once flasks were around 80% confluent the PBECs were passaged using 
trypsin/ethylene diamine tetraacetic acid (EDTA) (Sigma-Aldrich) by the following 
method. The culture medium was removed from the flask and replaced with 2mls of 
trypsin/EDTA pre-warmed to 37°C. Adherent PBECs were then gently removed by a 
shaking action. The level of trypsinisation was assessed dynamically by light 
microscopy. Once it was gauged that a sufficient number of cells had been lifted from 
the base of the flask the trypsin was neutralised by the addition of an equal volume of 
RPMI containing 10% FCS. The resultant suspension was then removed and 
centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and the cell pellet 
was either resuspended in BEGM and seeded in to flasks or 24-well plates (Corning) for 
 61 
further submerged culture, on to Transwell® inserts (Corning) for air-liquid interface 
(ALI) culture or cryopreserved. 
 
4.2.5. Cryopreservation 
 
Cell pellets were generated using the trypsinisation method described above. The pellets 
were resuspended in 1ml of 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich) in FCS 
and transferred to sterile cryotubes (Fisher Scientific, Loughborough, UK). Tubes were 
placed in an isopropranolol cell freezer (Fisher Scientific) at room temperature that was 
then stored at -80°C for 24 hours. At this point the tubes were transferred to a liquid 
nitrogen cell freezer for long-term storage. It is important to note that no cryopreserved 
cells were used for the experiements described in this thesis. All experiments were 
performed using cells freshly isolated from expanted cystic fibrosis lungs.  
 
4.2.6. Fixation of submerged cultures for tinctorial staining and 
immunohistochemistry 
 
First-passage PBECs were grown on 8-chamber slides (Fisher Scientific) coated with 
type I collagen as outlined above. Once confluent the cells were fixed with 4% 
paraformaldehyde (Mallinckrodt Baker, Deventer, Netherlands) for 20 minutes. 
 
4.2.7. Reconstitution of cryopreserved cells 
 
Cryotubes containing 1ml cell suspensions in 10% DMSO in FCS were removed from a 
liquid nitrogen cell freezer and rapidly rewarmed in a 37°C water bath. Once defrosted 
the suspension was centrifuged at 1000rpm for 5 minutes. The supernatant was 
discarded and the cells were immediately resuspended in 2mls of BEGM pre-warmed to 
37°C and seeded in a 25cm2 tissue culture flask and grown as described previously. 
 
4.2.8. Electrophysiology studies 
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First passage PBECs from patient 9, (see Table 9), were grown on type I collagen 
(Nutacon) coated glass coverslips. The PBECs were transferred to a tissue chamber and 
mounted on the stage of an inverted microscope. Whole-cell currents were recorded 
with an EPC-7 patch clamp amplifier (List Electronic, Darmstadt, Germany). Currents 
were elicited using a step voltage protocol over the range ± 100 mV and analysed as 
described previously. (Winpenny et al., 1995) 
 
The pipette solution for experiments involving ionomycin contained (mM): 120.0 CsC1, 
2.0 MgCl2, 0.2 EGTA, 1.0 ATP and 10.0 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), (pH 7.2 with CsOH). Pipette solution for 
experiments using forskolin had EGTA adjusted to 5 mM and the addition of 2.12 mM 
CaCl2 (calculated free Ca2+ concentration 100 nM).  The standard bath solution 
contained (mM): 145 NaCl, 4.5 KCl, 2.0 CaCl2, 1.0 MgCl2, 10.0 HEPES, and 5.0 
glucose (pH 7.4). Cl- selectivity of whole cell current was confirmed by measuring the 
change in reversal potential (Erev) following the replacement of 100mM NaCl in the 
standard bath solution with 100mM sodium aspartate. Stock solutions of 100mM 
forskolin (Tocris, Bristol, UK) and 10mM ionomycin (Calbiochem, San Diego, USA) 
were prepared in DMSO. 
 
4.2.9. Air-liquid interface culture of primary bronchial epithelial cells 
 
A solution containing 1*105 cells/mL suspended in BEGM was generated by the 
trypsinisation method described above from PBECs grown in submerged culture at 
either passage level 0 or 1. Transwell inserts were pre-coated with type IV collagen 
(Nutacon) and seeded with 0.5mL of this suspension and placed in a carbon dioxide 
(5%) enriched incubator at 37°C. The lower basolateral chamber was filled with 1ml of 
pre-warmed BEGM. Once at 80-90% confluency, typically after 48 to 72 hours, the 
apical medium was removed and the PBECs were exposed to air at the apical 
membrane. At this stage the medium in the basolateral chamber was changed to ALI 
medium (Table 7) and was replaced every 48 to 72 hours.  
 
Once mucus was visible by light microscopy at the apical surface it was washed every 
72 hours in order to remove excess mucus and to harvest it for analysis. This was 
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achieved by gently applying 500µL of PBS warmed to 37°C. The PBS was left in situ 
for 5 minutes after which time it was carefully removed by pipette and stored at   
-20°C immediately prior to analysis. 
 
Constituent Volume or concentration 
Bronchial epithelial basal medium (Lonza) 250mL 
DMEM high glucose (Invitrogen) 250mL 
1% Penicillin/streptomycin (Sigma-Aldrich) 5mL 
Human epidermal growth factor 0.5ng/mL 
Bovine pituitary extract 2mL* 
Insulin 500µL* 
Hydrocortisone 500µL* 
Retinoic acid 500µL* 
Transferrin 500µL* 
Epinephrine 500µL* 
Tri-iodothyronine 500µL* 
Calcium chloride 1mM 
 
*concentrations not published by the manufacturer  
(available as product number CC-4175 from Lonza) 
 
Table 7. Air-liquid interface medium 
 
 
4.2.10. Fixation of air-liquid interface cultures for tinctorial staining 
 
ALI cultures were fixed by addition of 4% paraformaldehyde (Mallinckrodt Baker) for 
20 minutes. 
 
4.2.11. Scanning electron microscopy of air-liquid interface cultures 
 
Scanning electron microscopy (SEM) of ALI cultures was performed by Electron 
Microscopy Research Services, Newcastle University. In brief, cultures were fixed by 
treatment with gluteraldehyde followed by osmium tetroxide. This was followed by 
dehydration through graded alcohols and embedding in resin. SEM was performed by 
Electron Microscopy Research Services staff using a Cambridge Stereoscan 240 
electron microscope with digital image capture. 
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4.2.12. Slot blot enzyme-linked immunosorbent assay for MUC5B 
 
A slot blot technique was used to detect the airway gel-forming mucin MUC5B in 
apical washings from ALI cultures. (Taylor et al., 2004, Smirnova et al., 2003) 
Nitrocellulose membrane sheets (Whatman, Kent, UK) of 0.2µm pore size were 
mounted on the Minifold II 72-well slot blot apparatus (Schleicher and Schuell, Dassel, 
Germany) and supported on blotting paper wetted with deionised water. Standards of 
MUC5B, purified from human saliva (Professor JP Pearson, Newcastle University), and 
100µL aliquots of ALI washings were added to individual wells in triplicate and the 
block attached to a vacuum source. Once the samples were absorbed on to the 
membrane it was removed and blocked overnight at 4°C, to minimise non-specific 
binding in PBS containing 2% bovine serum albumin (BSA). After blocking the 
membrane was incubated with the primary antibody, MUC5B thick effusion polyclonal 
anti-serum (Queen’s Medical Centre, Nottingham, UK), at 1:1000 dilution in PBS 
containing 1% BSA for 2 hours at room temperature. The membrane was then washed 
twice in 0.5% Tween20 in PBS followed by 3 changes of PBS. The secondary antibody, 
anti-rabbit IgG horseradish peroxidase conjugated (Sigma-Aldrich) diluted at 1:10000 
in 1% BSA in PBS, was then added for 1.5 hours at room temperature. The membrane 
was then washed as described above and developed using 0.05% 3, 3’diaminobenzidine 
tetrahydrochloride (DAB) (Sigma-Aldrich) with 0.3% H2O2 in PBS for 5 minutes. Once 
sufficiently developed the membrane was washed in tap water and left to dry overnight. 
The membrane was then read at 595nm using a Shimadzu scanning densitometer 
(Columbia, USA). Negative controls were performed to determine non-specific binding 
of the primary antibody by incubating it with 1% BSA in PBS alone.     
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4.2.13. Measurement of trans-epithelial resistance of air-liquid interface cultures of 
primary bronchial epithelial cells 
 
Trans-epithelial resistance (TER) measurements were performed using an epithelial 
volt-ohmmeter (World Precision Instruments, Stevenage, UK) as per the manufacturer’s 
instructions. In order to measure the TER 0.5mL of pre-warmed BEGM was applied to 
the apical surface and allowed to equilibriate for 20 minutes prior to performance of the 
measurements. The resistance of a ‘blank’ membrane included in each plate that was 
treated identically, but not seeded with cells, was subtracted from each measurement. 
 
4.2.14. Stimulation of primary bronchial epithelial cells with interleukin-17 
 
First or second passage PBECs were grown to 70-80% confluence in 24-well plates 
coated with type I collagen using BEGM. Cells were rested for 24 hours with serum-
free resting medium (Table 8) prior to stimulation with 500µL of resting medium 
containing 1, 10 or 100ng/mL of recombinant human IL-17 (R&D Systems). 
 
 
Constituent Volume added to 500mL 
of bronchial epithelial 
basal medium (Lonza) 
ITS liquid media supplement: 1mg/mL insulin from 
bovine pancreas, 0.55mg/mL human transferrin and 
0.5µg/mL sodium selenite (Sigma-Aldrich) 
5mL 
1% Penicillin/streptomycin (Sigma-Aldrich) 5mL 
Gentamicin/amphotericin single quot (Lonza) 500µL* 
 
*concentrations not published by the manufacturer  
(available as product number CC-4175 from Lonza) 
 
Table 8. Constituents of resting medium 
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4.2.15. Stimulation of primary bronchial epithelial cells with flagellin 
 
First or second passage PBECs were grown to 70-80% confluence in 24-well plates 
coated with type I collagen using BEGM. Cells were rested for 24 hours with serum-
free resting medium (Table 8) prior to stimulation with 500µL of resting medium 
containing 1, 10 or 100 ng/mL of flagellin (Alexis biochemicals, Exeter, UK). 
 
4.2.16. Measurement of interleukin-17 in airway lavage fluid from explanted cystic 
fibrosis lungs 
 
Airway lavage fluid supernatants were defrosted on ice and then promptly assayed for 
IL-17 concentration using an ultrasensitive ELISA kit (MesoScale Discovery, 
Maryland, USA) with a lower limit of detection of 0.2pg/mL as per manufacturer’s 
instructions. The plates were read using the MSD Discovery Workbench analyser and 
software package. (MesoScale Discovery). 
 
4.2.17. Measurement of interleukin-23 in airway lavage fluid from explanted cystic 
fibrosis lungs 
 
Airway lavage fluid supernatants were defrosted on ice and then promptly assayed for 
IL-23 concentration using a Quantikine® ELISA kit (R&D Systems) with a lower limit 
of detection of 6.8pg/mL as per manufacturer’s instructions. Each sample and standard 
was assayed in triplicate and a mean taken. A standard curve was then constructed and 
the IL-23 concentration was quantified for each sample.  
 
4.2.18. Measurement of interleukin-8, interleukin-6 and granulocyte macrophage 
colony-stimulating factor in culture supernatants 
 
The contents of each well was removed by pipette after 24 hours, centrifuged at 
1000rpm for 2 minutes and the supernatant immediately frozen at -80°C prior to 
analysis. A multiplex enzyme-linked immunosorbent assay (ELISA) was then 
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performed as per manufacturer’s instructions (Meso Scale Discovery). The plates were 
read using the MSD Discovery Workbench analyser and software package. (MesoScale 
Discovery). 
 
 
4.3. Histology 
 
4.3.1. Preparation of paraffin embedded blocks of airway 
 
A 2cm by 0.5cm piece of lung parenchyma was resected using tweezers and a fresh 
scalpel. The intention being to produce sections of intermediate-large sized airways, in 
the region of 1-5mm diameter and lined by columnar ciliated respiratory epithelium. 
The tissue was then fixed in 10% buffered formalin (Genta Medical, York, UK) for 12 
hours. 
 
Fixed tissue was then placed in cassettes (Simport, Beloeil, Canada) and dehydrated 
through graded alcohols. This was performed by immersion for 20 minutes in: 70% 
industrial methylated spirit (IMS), 70% IMS, 80% IMS, 80% IMS, 95% IMS, 95% 
IMS, 74OP IMS, 74OP IMS and 74OP IMS respectively. Finally the tissue was 
submerged in xylene (VWR) twice for 20 minutes and then embedded in paraffin wax 
for 1 hour at 60ºC. 
 
4.3.2. Preparation of paraffin sections 
 
Sections of 5µm thickness were cut using a microtome from paraffin blocks of distal 
airway. The sections were dewaxed by soaking in xylene for 5 minutes and then 
rehydrated through graded alcohols, 1 minute each in 95% IMS, 99% IMS and 99% 
IMS again.
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4.4. Tinctorial stains 
 
4.4.1. Haematoxylin and eosin staining 
 
Haematoxylin and eosin staining was used to examine the basic histology of the 
sections. (Kiernan, 2008) Sections were cut, dewaxed and rehydrated as described 
above. In the case of 8-chamber slides the rehydration steps were unnecessary. The 
sections were then washed in water and stained in freshly filtered Harris Haematoxylin 
(Fisher Scientfic) for 1 minute. The staining process was assessed dynamically under a 
light microscope. Next the sections were washed in running tap water for 2-3 minutes 
before being differentiated in 0.1% acid alcohol and washed in running tap water until 
the nuclei were appropriately blue. The sections were then counterstained with Eosin Y 
(Fisher Scientific) for 2 minutes. Finally the sections were washed well in tap water and 
dehydrated back through graded alcohols and xylene. The sections were then mounted 
with DPX (VWR, Lutterworth, UK). 
 
4.4.2. Periodic acid-Schiff staining 
 
Periodic acid-Schiff (PAS) staining was used to stain for the mucin glycoproteins in 
mucus. (Kiernan, 2008) Sections were cut, dewaxed and rehydrated as described above. 
In the case of 8-chamber slides the rehydration steps were unnecessary.  Firstly the 
sections were soaked in 1% periodic acid for 5 minutes and then washed under running 
tap water for 2 minutes. Next they were soaked in Schiff’s solution (Sigma-Aldrich), 
diluted 1 in 4 with distilled water, for 6 minutes and then washed under running tap 
water for 5 minutes. The sections were then counter-stained with Harris Haematoxylin 
for 30 seconds and washed until blue. Finally the sections were dehydrated and 
mounted with DPX as described previously. 
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4.4.3. Alcian blue/periodic acid-Schiff staining 
 
The combination of alcian blue and PAS staining was used to stain acidic and neutral 
mucins in airway sections. (Kiernan, 2008) Sections were cut, dewaxed and rehydrated 
as described above. Firstly sections were incubated with 0.1% diastase (VWR) for 30 
minutes at 37°C followed by alcian blue pH 2.5 (Sigma-Aldrich) for 20 minutes and 
then washed thoroughly with tap water. Periodic acid-Schiff staining was then 
performed as outlined above. 
 
4.4.4. Sirius red staining 
 
Sirius red was used to stain for eosinophils. (Meyerholz et al., 2009) Sections were cut, 
dewaxed and rehydrated as described above. Nuclei were firstly stained with Harris 
Haematoxylin as outlined above. Sections were then stained with Sirius red (Sigma-
Aldrich) for 1 hour and then thoroughly washed in tap water for 10 minutes. Finally the 
sections were dehydrated and mounted with DPX as described previously. 
 
 
4.5. Immunohistochemistry 
 
4.5.1. Immunohistochemistry for pan-cytokeratin panel 
 
Confluent monolayers of PBECs were fixed on 8-chamber slides as described in section 
4.2.6 and stained for an epithelial panel of pan-cytokeratin markers as previously 
described. (Forrest et al., 2005) The cells were initially treated with 5% normal lamb 
serum (Dako, Ely, UK) in PBS for 1 hour to minimise non-specific antibody binding. 
The primary mouse monoclonal anti-human cytokeratin clone LP34 (Dako) was then 
applied at a dilution of 1:50 in normal lamb serum for 2 hours at room temperature. The 
slides were washed with PBS and then treated with an appropriate secondary system as 
per manufacturers instructions (EnVision/HRP, Dako). Matched istotype negative 
controls were used. 
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4.5.2. Immunohistochemistry for interleukin-17 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. Endogenous 
peroxidase activity was blocked by soaking sections in methanolic hydrogen peroxide. 
The sections were then washed for 10 minutes in running tap water. Antigen retrieval 
was performed in citrate buffer at pH 6 for 5 minutes in a microwave set at 30% power. 
The sections were then washed 3 times in tris-buffered saline (TBS) and blocked with 
20% normal horse serum (Vector Laboratories, Peterborough, UK) for 30 minutes. The 
primary antibody (goat polyclonal affinity purified anti-human IL-17, R&D Systems, 
Abingdon, UK) was diluted 1 in 40 in 3% bovine serum albumin (BSA) and applied for 
1 hour at room temperature. The sections were then washed twice with TBS and treated 
with biotinylated horse anti-goat secondary antibody (Vector Laboratories) for 30 
minutes. The sections were washed twice with TBS and treated with the ABC 
Vectastain Elite kit and DAB (Vector Laboratories) as per the manufacturer’s 
instructions.  The sections were finally counter-stained with Carazzi’s stain for 1 minute 
and then mounted. Isotype negative controls were performed using normal goat 
immunoglobulins (R&D Systems). 
 
4.5.3. Immunohistochemistry for retinoic acid receptor-related orphan receptor 
gamma 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. Endogenous 
peroxidase activity was blocked by soaking sections in methanolic hydrogen peroxide. 
The sections were then washed for 10 minutes in running tap water. The sections were 
steamed in citrate buffer pH 6 at 100°C for 20 minutes and then left to cool in the buffer 
at room temperature for a further 20 minutes. The sections were then washed 3 times in 
tris-buffered saline (TBS) and blocked with 20% normal horse serum (Vector 
Laboratories, Peterborough, UK) for 30 minutes. The primary antibody (retinoic acid 
receptor-related orphan receptor gamma rabbit polyclonal, AbCam, Cambridge, UK) 
was diluted 1 in 40 in 3% bovine serum albumin (BSA) and applied for 1 hour at room 
temperature. The sections were then washed twice with TBS and treated with 
biotinylated horse anti-rabbit secondary antibody (Vector Laboratories) for 30 minutes. 
The sections were washed twice with TBS and treated with the ABC Vectastain Elite kit 
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and DAB (Vector Laboratories) as per the manufacturer’s instructions.  The sections 
were finally counter-stained with Carazzi’s stain for 1 minute and then mounted. 
Isotype negative controls were performed using normal rabbit immunoglobulins (R&D 
Systems). 
 
4.5.4. Immunohistochemistry for ceramide (Glycobiotech antibody) 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. The antiserum 
enriched for IgM anti-ceramide polyclonal antibody (Glycobiotech, Kükels, Germany) 
is commercially available and has been utilised by other researchers and demonstrated 
by lipid overlay assays to be specific for ceramide.  (Cowart et al., 2002, Teichgraber et 
al., 2008, Vielhaber et al., 2001) Antigen retrieval was performed in citrate buffer at pH 
6.0 in a microwave on high power for 3 minutes. The primary antibody was used at 
1/150 dilution in 3% BSA. Sections were incubated for 48 hours at 4ºC with the primary 
antibody before treatment with the EnVision peroxidase-based secondary system 
(Dako). Appropriate negative controls; no primary antibody added and mouse IgM 
(Dako) istotype negative control were performed. 
 
4.5.5. Immunohistochemistry for ceramide (Sigma antibody) 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. The 
monoclonal anti-ceramide mouse IgM antibody (Sigma-Aldrich) was used at 1/50 
dilution in 3% BSA. Antigen retrieval was performed in citrate buffer at pH 6.0 in a 
microwave on high power for 3 minutes. Sections were incubated for 48 hours at 4ºC 
with the primary antibody before treatment with the EnVision peroxidase-based 
secondary system (Dako). Appropriate negative controls; no primary antibody added 
and mouse IgM (Dako) istotype negative control were performed. It is important to note 
that this antibody has been shown in lipid overlay assays to be less specific for ceramide 
than the polyclonal antibody in that it also detects dihydroceramide, phophatidylcholine 
and sphingomyelin. (Cowart et al., 2002) 
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4.5.6. Immunohistochemistry for neutrophil elastase 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. Sections were 
then incubated at room temperature for 45 minutes with mouse anti-neutrophil elastase 
monoclonal antibody (Dako) diluted 1/300 in 3% bovine serum albumin. No antigen 
retrieval was required. The EnVision secondary system (Dako) was used. Mouse 
immunoglobulin G1 (R&D Systems) isotype negative controls were performed. 
 
4.5.7. Immunohistochemistry for myeloperoxidase 
 
Paraffin sections were cut, dewaxed and rehydrated as described above. Antigen 
retrieval was performed for 10 minutes in citrate buffer at pH 6.0 in a microwave on 
high power. Sections were incubated overnight at 4°C with rabbit anti-myeloperoxidase 
polyclonal antibody (Novocastra, Newcastle upon Tyne, United Kingdom) diluted 
1/1000 in 3% bovine serum albumin. The Immpress peroxidase-based secondary system 
was used (Vector Labs, Peterborough, United Kingdom). Appropriate rabbit 
immunoglobulin (Dako) negative controls were performed. 
 
 
4.6. Quantification and analysis of staining 
 
4.6.1. Quantification and analysis of interleukin-17 staining 
 
Positive staining was measured in the airway epithelium in 5 randomly selected, non-
overlapping x40 objective high power fields for each patient. I was blinded to the 
diagnosis of each patient. Image analysis software was used (Image Pro Plus 4.0, 
MediaCybernetics, Bethesda, USA) to quantify the staining in terms of mean percentage 
area of epithelium staining positive and number of positive inflammatory cells per mm 
of basement membrane in the lamina propria and epithelial compartments as previously 
described. (Ward et al., 2005) Neutrophils were identified by appropriate dimensions 
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and characteristic morphological features such as multilobular nuclei and granular 
cytoplasm. (Bain, 2002) 
 
4.6.2. Quantification of ceramide staining 
 
Positive staining was measured in the airway epithelium in 5 randomly selected, non-
overlapping x40 objective high power fields for each patient. Image analysis software 
was used (Image Pro Plus 4.0) to quantify the staining in terms of percentage area of 
epithelium positive for ceramide as previously described. (Ward et al., 2005) I was 
blinded to the diagnosis of each patient. A further analysis using a Bland-Altman plot 
was performed to assess the intra-observer repeatability of these measurements that is 
presented in section 7.5.5. (Bland and Altman, 1986) 
 
4.6.3. Quantification of neutrophil elastase and myeloperoxidase staining 
 
The number of cells staining positive in the epithelium and lamina propria were counted 
in 5 randomly selected, non-overlapping x20 objective high power fields for each 
patient using image analysis software (Image Pro Plus 4.0). The length of basement 
membrane in each field was measured to calculate the number of positive 
cells/millimetre basement membrane. I was blinded to the diagnosis of each patient. 
 
4.6.4. Measurement of reticular basement membrane thickness 
 
Measurements were performed on 5µm sections stained with haematoxylin and eosin 
taken from formalin-fixed, paraffin-embeeded blocks of intermediate-large airway as 
described in sections 4.3.1 and 4.3.2. RBM thickness was quantified by measuring the 
distance between two demarcating lines in each high-power section using Image 
ProPlus software (MediaCybernetics) as shown in Figure 87. 
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4.7. High performance liquid chromatography-mass spectrometry for ceramide 
 
4.7.1. Clinical sample preparation and lipid extraction 
 
Biopsies were resected from freshly explanted lungs and immediately snap frozen in an 
isopentane slurry cooled with liquid nitrogen prior to storage at -80°C. At the time of 
analysis around 100mg of tissue was defrosted to room temperature, weighed and 
immediately homogenised. Lipids were then extracted from the homogenate using a 
previously described chloroform/methanol protocol. (Folch et al., 1957, Guilbault et al., 
2008b)  
 
4.7.2. High performance liquid chromatography-mass spectrometry 
 
A Waters (Milford, MA, USA) nanoACQUITY HPLC pump, with autosampler and a 
LTQ-FT hybrid linear ion trap-FTMS (Thermo Electron, Bremen, Germany) mass 
spectrometer were interfaced using an ADVANCE (Michrom Bioresources, Auburn, 
CA, USA) MS ion source. The calibration standards used were C16:0 (N-Palmitoyl-D-
Sphingosine, N-Hexadecanoyl-D-sphingosine, Palmitoyl ceramide, catalogue number 
C2777-8), C18:0 (N-Stearoyl-D-sphingosine, Stearoyl ceramide, catalogue number 
C2777-83), C20:0 (N-Eicosanoylsphingosine, catalogue number C2777-85) and C22:0 
(N-[(3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-docosanamide, catalogue 
number C2777-87) ceramides (US Biological, Swampscott, Ma, USA). Each standard 
was reconstituted using an appropriate volume of chloroform:methanol (2:1) to generate 
20mM stock solutions for HPLC-MS analysis. Further dilutions were made using 
acetonitrile.   
 
The lower (chloroform) phase of each patient sample was carefully transferred to a 
clean tube and then evaporated to dryness in a centrifugal evaporator. Samples were re-
suspended in 1mL of chloroform:methanol (2:1) and then diluted 1:10 with acetonitrile 
prior to HPLC-MS analysis.  
 
All samples and standards were analyzed in triplicate on a Waters (Milford, MA, USA) 
C18 symmetry column (0.3 by 100mm) maintained at 45°C and a flow rate of 
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10µL/min. A non-aqueous reversed phase HPLC (NARP) gradient was used. Buffer A 
comprised acetonitrile:formic acid (99.8:0.2) while buffer B was 20% isopropanol in 
acetonitrile. Samples were eluted using a gradient of 0 to 15% buffer B over 20 minutes. 
 
The mass spectrometer method consisted of two scan events, a FTMS scan at 12,500 
resolution in the range 475 – 675m/z (to minimize sample matrix noise), followed by 
one data-dependant ion trap MS/MS. The ADVANCE spray source was used without 
sheath gas and the spraying voltage was 1.5kV. 
 
Calibration curves were constructed from triplicate readings of a four ceramide mixture 
at 5, 0.5, 0.05 and 0.005pmoles injected on-column, (Table 15 and Figure 69 to Figure 
72 respectively). The initial plan was to monitor the MS/MS product ion at 264.3m/z as 
a means for selective quantitation. However it soon became apparent that the ceramide 
spectra were dominated by [M+Na]+ adducts as the major ion species precluding 
observation of the desired product ion at a sufficiently high sensitivity.  To circumvent 
this problem the mass accuracy of the FTMS was used for ion selection and 
quantitation.   
 
Qualbrowser software (Thermo Electron, Bremen, Germany) was used to sum the ion 
currents for both observed [M+H] + and [M+Na] + singly –charged ion species of each 
ceramide. For selectivity the mass tolerance for each ion was set to within 0.02m/z.  The 
peak areas of the detected ion signals were recorded and calibration plots constructed 
using this data for each of the four ceramide species. The calibration plots were then 
used to obtain quantitative results for C16:0, C18:0, C20:0 and C22:0 ceramides from 
triplicate measurements on the 10 patient samples. 
 
4.7.3. Protein assay 
 
The Bio-Rad Protein Micro Assay (Bio-Rad, Hemel Hempstead, UK), based on the 
Bradford protein assay technqiue, was used to measure protein levels spectroscopically 
in the upper phase of the HPLC-MS analysates. (Bradford, 1976) Standards ranging 
from 0.8 to 20µg/mL were prepared from a stock of 400µg/mL made by dissolving 
BSA in deionised water. Samples were diluted 1:2 with deionised water prior to 
analysis. In a clean dry test tube 800µL of standard or diluted sample was mixed with 
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200µL of reagent and incubated for 30 minutes at room temperature. The optical density 
at 595nm was then read in fresh cuvettes using a spectrometer (Unicam 8625 UV/VIS 
spectrometer, Cambridge, UK). The optical density of a ‘blank’ cuvette filled with 1mL 
of deionised water was subtracted from each reading. Each sample and standard was 
assayed in triplicate and a mean taken. A standard curve was then constructed and the 
protein concentration was quantified for each sample. 
 
4.7.4. Phosphate assay 
 
The PiBlue Phosphate Assay Kit (BioAssay Systems, Hayward, USA) was used to 
quantify levels of phosphate in the upper pahse of the HPLC-MS analysates. Standards 
ranging from 4 to 40µM phosphate were prepared from a stock 40µM solution as per 
the manufacturer’s instructions. Using a clean dry 96-well plate 50µL of standard or 
sample was added to each well followed by 100µL and incubated for 30 minutes at 
room temperature. The optical density at 620nm was then read in fresh cuvettes using a 
spectrometer (Unicam 8625 UV/VIS spectrometer, Cambridge, UK). Each sample and 
standard was assayed in triplicate and a mean taken. A standard curve was then 
constructed and the phosphate concentration was quantified for each sample. 
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4.8. Statistics 
 
Statistical analyses were performed using Minitab 15 (Minitab Incorporated, 
Pennsylvania, USA). Graphs were prepared using Prism 5 for Mac (GraphPad software, 
California, USA).  
 
Non-parametric statistical tests were used to test the null hypothesis using the most 
conservative approach possible. A P value <0.05 was considered to be significant. 
Where multiple comparisons were performed correction was performed using the Holm-
Bonferroni method. (Holm, 1979) The Holm–Bonferroni method is a closed test 
procedure that allows the performance of more than one hypothesis test simultaneously 
by adjusting the relevant P value accordingly. (Marcus et al., 1976) The specific 
statistical test used is stated in the figure caption directly below the graph in the thesis. 
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5. Chapter 5. Development of a method to culture primary bronchial 
epithelial cells from the lungs of people with cystic fibrosis removed 
at the time of transplantation 
 
 
Elements of the work described in this chapter have been previously reported in the 
form of presentations at medical and scientific meetings and in a peer-reviewed paper. 
(Brodlie et al., 2008a, Brodlie et al., 2008b, Brodlie et al., 2009f, Brodlie et al., 2010f) 
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5.1. Abstract 
 
Background: Lung disease is responsible for more than 95% of morbidity and mortality 
in cystic fibrosis. The exact pathogenesis of cystic fibrosis lung disease remains poorly 
understood. Experimental models are therefore vital for use in research. Animal models 
and immortalised cell lines both have inherent limitations. Explanted lungs removed 
from people with CF at the time of transplantation represent a potentially valuable but 
technically and logistically challenging source of primary cystic fibrosis bronchial 
epithelial cells. 
Methods: Pieces of segmental bronchus from explanted lungs were treated with patient-
specific antimicrobials prior to isolation of bronchial epithelial cells. Cultured cells 
were characterised by their morphology under light microscopy, cytokeratin and 
haematoxylin-eosin staining, electrophysiological profile and cytokine production. 
Results: Primary bronchial epithelial cells were successfully cultured from 23 of 34 
patients attempted. The cells exhibited typical epithelial morphology, staining for 
cytokeratin, lack of responsiveness to forskolin treatment, produced interleukin-8, 
interleukin-6 and granulocyte macrophage colony-stimulating factor and remained 
viable after storage in liquid nitrogen. Eleven unsuccessful cultures failed due to early 
infection with bacteria known to colonise the airways pre-transplant. 
Conclusions: Primary bronchial epithelial cell culture is possible from explanted cystic 
fibrosis lungs and provides an important cellular model to elucidate the pathogenic 
mechanisms in cystic fibrosis lung disease and to investigate potential therapeutic 
targets. 
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5.2. Introduction 
 
Promising developments in clinical care have yielded an increase in survival for people 
with CF over recent decades, however, the exact pathogenesis of CF lung disease 
remains poorly understood. (Dodge et al., 2007) It follows that valid experimental 
models are required to further elucidate the pathogenesis of CF lung disease and to 
evaluate novel, potentially therapeutic compounds. (Doring et al., 2007)   
 
Shortly after the cloning of the CFTR gene in 1989 it has been possible to develop 
animal models of CF. (Riordan et al., 1989) Work has principally focussed on murine 
models and has generated over 2500 publications to date. (Scholte et al., 2004) Mice 
with complete interruption of the CFTR gene, residual function and with specific, 
clinically relevant mutations have been developed. (Davidson and Rolfe, 2001, 
Guilbault et al., 2007) However, despite promising bioelectric features and replication 
of gastrointestinal pathology it has proved impossible to reproduce the human CF lung 
phenotype. Indeed, Scholte et al. (2004) in a review of this topic concluded that:  
 
 “the development of an ideal mouse model of CF lung disease, to enable the 
dissection of pathogenesis, or testing of novel therapeutics is yet to be achieved.”   
 
Possible explanations for this include inter-species differences in submucosal gland 
distribution, innate immunity, epithelial cell composition and chloride channels in the 
lung. (Pack et al., 1980, Grubb et al., 1994, Borthwick et al., 1999, Maxwell et al., 
2003)  
 
A major programme of work is under way to develop pigs and ferrets with mutant 
CFTR that may produce animals with a closer lung phenotype to that seen in CF but it 
will be a substantial number of years before they represent a practical tool for research. 
(Sun et al., 2008, Rogers et al., 2008c) 
 
Immortalised cell lines, derived from relevant tissues in people with CF, non-CF 
individuals and other mammals, have also been used extensively in research and have 
contributed to our current understanding of the disease. (Lundberg et al., 2002) There 
are a number of important limitations, however, that must be remembered if the results 
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of experiments involving immortalised cells are to be extrapolated to the situation in 
vivo.  
 
Firstly, a cell line is always derived from a fixed clone of a phenotypically diverse 
mixed primary cell culture. The phenotype of cells is also likely to change with multiple 
passages in vitro and furthermore karyotypic instability is a feature of immortalised 
cells that may lead to the emergence of diverse subpopulations that do not retain the 
phenotypic characteristics of interest. (Gruenert et al., 2004)   
 
In summary, both animal models and immortalised cell lines have contributed 
significantly to CF research but there are inherent limitations to both systems. 
(Carvalho-Oliveira et al., 2007, Gruenert et al., 2004, Guilbault et al., 2007) In 
particular, animal models have failed to reproduce the lung disease characterised by 
neutrophilic inflammation, chronic bacterial infection and mucus hypersecretion that is 
responsible for 95% of mortality and morbidity in CF. Immortalised cell lines are 
accessible and convenient but it is widely acknowledged that high passage cells are 
likely to significantly differ from those found in vivo and that they display karyotypic 
instability. 
 
Primary tissue and cells from people with CF therefore represent an important and rare 
experimental resource. The ex vivo culture of PBECs from people with CF is likely to 
produce a superior cellular model to that produced by immortalised cell lines with 
characteristics that replicate more accurately those found in vivo. Furthermore, well-
differentiated PBEC cultures maintained at ALI are an excellent model of airway 
epithelial function and have been integral to several important developments in our 
current knowledge of the pathophysiology of CF lung disease. (Matsui et al., 1998, 
Fulcher et al., 2005)    
 
Lung transplantation is the only life-sustaining option for end-stage CF lung disease. 
(Meachery et al., 2008, Corris, 2008) The organs explanted from people with CF during 
lung transplantation represent a potential source of CF PBECs. The culture of PBECs 
from explanted CF lungs poses scientific and logistical challenges however. The major 
practical obstacles to the successful culture of cells include firstly, actual procurement 
of appropriate lung tissue and secondly, infection of cell cultures by multi-resistant 
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organisms present in the copious mucopurulent secretions that are prevalent in end-
stage CF lungs. (Randell et al., 2001)  
 
To the best of my knowledge, prior to the commencement of this work PBECs were not 
cultured routinely from explanted CF lungs outside of a handful of centres in North 
America, most notably at the University of North Carolina, Chapel Hill. (Karp et al., 
2002, Yamaya et al., 1992, Randell et al., 2001) The Freeman Hospital in Newcastle 
upon Tyne is the largest lung transplantation centre in the United Kingdom. Lungs 
removed at the time of transplantation from people with CF in Newcastle therefore 
represent a previously under used and potentially highly valuable resource for CF 
research. 
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5.3. Aims 
 
The aims of the work described in this chapter were to: 
 
• Develop and optimise a method to culture PBECs from explanted CF lungs 
• Establish a programme to culture PBECs from lungs removed at the time of 
transplantation from people with CF at the Freeman Hospital in Newcastle upon 
Tyne  
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5.4. Hypothesis 
 
I hypothesised that it would be technically possible to culture PBECs from explanted 
CF lungs and to establish a programme to do this at the Freeman Hospital, Newcastle 
upon Tyne. 
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5.5. Results 
 
5.5.1. Development of a method to culture primary bronchial epithelial cells from 
explanted cystic fibrosis lungs 
 
The detailed method that I used to culture PBECs is described in Chapter 4. The 
technique published by Randell et al. (2001) was used as an initial template. This was 
subsequently optimised through personal experience, helpful discussions with Dr Scott 
Randell, University of North Carolina and Professor Christopher O’Callaghan, 
University of Leicester, input from my supervisors in Newcastle and further discussions 
with delegates and other invited speakers at the ‘Workshop on Epithelial Cells from 
Lung: Production, Cultivation and Characterization’ held by EuroCareCF in Lisbon, 
Portugal in July 2008. 
 
I developed the novel approach of using patient-specific combinations of antimicrobials. 
These were based on up to date knowledge of the organisms cultured from the sputum 
of patients in their clinical management pre-transplant. (Corris, 2008, Meachery et al., 
2008) The expert advice of Professor John Perry and Audrey Nicholson, Department of 
Medical Microbiology, Freeman Hospital, was invaluable in selecting an appropriate 
anti-microbial combination for each specific patient. 
       
A key consideration when using primary tissue in research is that the clinical care of 
patients is not compromised. The method that I developed allows clinical specimens to 
be collected from explanted lungs for microbiology and involves only modest dissection 
thereby enabling a full examination of the lungs to be performed by a pathologist.  
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5.5.2. Establishment of a programme to culture primary bronchial epithelial cells 
from explanted cystic fibrosis lungs at the Freeman Hospital, Newcastle upon 
Tyne   
 
In addition to the scientific challenges of culturing PBECs from end-stage CF lungs, the 
establishment of a programme to utilise explanted lungs relied on excellent working 
relationships with the entire multidisciplinary transplant team. This includes obtaining 
the appropriate ethical approval to perform such work and clearly the informed consent 
of the transplant recipients themselves. In my experience it is ideal if individuals are 
approached for consent at the time of visiting the transplant centre for assessment and 
not during the emergency admission immediately prior to a potential transplant 
occurring. Indeed, the Local Research Ethics Committee advised this timing of 
approach for consent when they considered our ethical application for this work.  
 
Furthermore, the helpful co-operation of cardiothoracic surgeons, transplant 
coordinators and theatre staff is essential in order to ensure that the research team is 
informed. Due to the unpredictable nature of transplantation in my experience a 
permanent ‘on-call’ commitment is important in facilitating and ensuring the 
appropriate timely procurement of tissue in the event of a transplant occurring. An 
onward stream of interested researchers is likely to be essential to sustain this 
programme of tissue procurement in the future.     
 
5.5.3. Outcome of primary bronchial epithelial cell cultures from explanted cystic 
fibrosis lungs 
 
I actively procured lungs between October 2007 and March 2010. During this period 36 
people with CF were transplanted at the Freeman Hospital. I attempted to culture 
PBECs from the lungs of 34 of the 36 patients. Figure 16 shows a typical explanted CF 
lung. 
 
Cultures were successful from 23 (68%) of the 34 patients attempted. When 
unsuccessful this was universally due to early bacterial overgrowth once the initial anti-
microbial cocktail had been removed from the culture medium. Routine microbiological 
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culture of infected supernatants was performed by Professor John Perry and Audrey 
Nicholson, which revealed that the bacteria responsible in each case were the same 
organisms that had colonised the lungs of the patients pre-transplantation. Table 9 
outlines the clinical details, the organisms isolated from sputum pre-transplant, 
antimicrobial combination used and the outcome of cell culture for each patient. Figure 
17 compares the success rate of cultures with the initial ‘best guess’ approach (50%) to 
that following adoption of a tailored patient-specific anti-microbial strategy (75%). 
 
 
 
 
Figure 16. Typical example of an explanted cystic fibrosis lung. 
Dimensions 230mm superior-inferior, 155mm anterior-posterior 
and 60mm medial-lateral 
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Table 9. Brief clinical details of patients, microbiology and outcome of primary 
bronchial epithelial cell cultures 
  
No. Age* CFTR 
variant$ 
FEV1^ 
 
Sputum 
microbiology 
Antimicrobials 
used in cell 
culture 
Outcome of 
cultures 
1 28 p.Phe508del 
p.Phe508del 
15 Pseudomonas 
aeruginosa, 
Aspergillus 
fumigatus 
Ceft, Tobr, 
Vanc, Amph 
Successful 
2 57 p.Arg117His  
p.Arg553X 
23 P. aeruginosa Ceft, Tobr, 
Vanc, Amph 
Successful 
3 32 Unknown 25 P. aeruginosa, 
Burkholderia 
vietnamiensis 
Ceft, Tobr, 
Vanc, Amph 
Not 
successful, B. 
vietnamiensis 
overgrowth 
4 25 p.Phe508del 
Unknown 
22 P. aeruginosa,  
Staphylococcus 
aureus 
Ceft, Tobr, 
Vanc, Amph 
Not 
successful, 
apparent 
infection, 
negative on 
culture 
5 23 Unknown 21 Scedosporium sp., 
Alcaligines sp., 
S. Aureus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Vori 
Successful 
6 39 p.Phe508del 
p.Phe508del 
14 P. aeruginosa Ceft, Tobr, 
Vanc, Amph 
Successful 
7 29 p.Phe508del 
p.Gly551Asp 
23 P. aeruginosa, 
Methicillin-
Resistant 
S. aureus 
Ceft, Tobr, 
Vanc, Amph, 
Mero 
Not 
successful, P. 
aeruginosa 
overgrowth 
8 27 p.Phe508del 
p.Phe508del 
22 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero 
Not 
successful, P. 
aeruginosa 
overgrowth 
9 43 p.Phe508del 
p.Arg560Thr 
15 Stenotrophomonas 
maltophilia, 
Acinetobacter sp. 
Ceft, Tobr, 
Vanc, Amph, 
Colo, CoTrim, 
Tim 
Successful 
10 28 p.Phe508del 
p.Asp443fs 
17 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo 
Successful 
11 29 p.Phe508del 
p.Phe508del 
20 P. aeruginosa, 
A. fumigatus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo 
Successful 
12 30 p.Phe508del 
p.Phe508del 
30 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim 
Successful 
 89 
 
13 40 Unknown 24 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Vori 
Not 
successful, P. 
aeruginosa 
overgrowth 
14 23 p.Phe508del 
p.Gly551Asp 
30 P. aeruginosa,    
A. fumigatus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Vori 
Successful 
15 46 Unknown 30 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
16 29 p.Phe508del 
p.Gln685fs 
17 B. multivorans, 
A. fumigatus, 
Geosmithia 
argillacae 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Vori 
Not 
successful, B. 
multivorans 
overgrowth 
17 22 p.Phe508del 
p.Phe508del 
23 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
18 20 p.Phe508del 
p.Phe508del 
21 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim 
Successful 
19 29 p.Phe508del 
c.317+10kbC>T 
29 P. aeruginosa, 
S. maltophilia 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Not 
successful, P. 
aeruginosa 
overgrowth 
20 28 Unknown 20 P. aeruginosa, 
Methicillin-
Resistant 
S. aureus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
21 48 p.Phe508del 
Unknown 
29 P. aeruginosa, 
S. aureus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
22 33 Unknown 23 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
23 22 p.Phe508del 
p.Phe508del 
25 P. aeruginosa, 
A. fumigatus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Not 
successful, P. 
aeruginosa 
overgrowth 
24 40 Unknown 36 P. aeruginosa, S. 
maltophilia, 
Achromobacter 
xylosoxidans 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
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25 24 p.Phe508del 
p.Phe508del 
26 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
26 21 Unknown 25 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
27 45 p.Phe508del 
p.Phe508del 
21 P. aeruginosa, 
A. fumigatus 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Not 
successful, P. 
aeruginosa 
overgrowth 
28 33 Unknown 17 P. aeruginosa, 
Mycobacterium 
gordonae 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
29 33 Unknown 18 P.aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
30 26 Unknown 25 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Not 
successful, P. 
aeruginosa 
overgrowth 
31 22 Unknown 20 B. multivorans Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Not 
successful, B. 
multivorans 
overgrowth 
32 29 p.Phe508del 
p.Phe508del 
19 P. aeruginosa, 
S. maltophilia, 
Achromobacter 
sp., 
M. avium, 
A. fumigatus, 
G. argillacea 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
33 23 Unknown 27 P. aeruginosa, 
P. putida, 
A. fumigatus, 
A. xylosoxidans, 
Paecilomyces sp., 
M. avium complex 
Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
34 27 Phe508del 
Gly551Asp 
22 P. aeruginosa Ceft, Tobr, 
Vanc, Amph, 
Mero, Colo, 
CoTrim, Tim 
Successful 
 
Abbreviations: *Age in years at time of transplant, $cystic fibrosis transmembrane 
conductance regulator genotype (where known), ^forced expiratory volume in 1 second 
(% predicted), Ceft: ceftazidime, Tobr: tobramycin, Vanc: vancomycin, Amph: 
amphotericin, Mero: meropenem, Vori: voriconazole, Colo: colomycin, CoTrim: co-
trimoxazole, Tim: timentin 
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Figure 17. Culture success rates with fixed and tailored antimicrobial strategies 
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5.5.4. Characterisation of primary bronchial epithelial cells 
	  
5.5.5. Morphology 
 
Brightfield light microscopy on repeated occasions revealed characteristic epithelial 
‘cobblestone’ morphology and growth characteristics as shown in Figure 18. 
(Borthwick et al., 2009, Ward et al., 2005)  
	  
5.5.6. Haematoxylin and eosin staining 
 
First passage PBECs were grown under submerged conditions to confluence on 
collagen coated eight-chamber slides and stained with haematoxylin and eosin as 
described in Chapter 4. The PBECs displayed typical ‘cobblestone’ epithelial 
morphology (Figure 19). 
	  
5.5.7. Cytokeratin immunohistochemistry 
 
First passage PBECs were grown under submerged conditions to confluence on 
collagen coated eight-chamber slides and stained with an epithelial, pan-cytokeratin 
marker, as described in section 4.5.1. The PBECs stained positively for cytokeratin in a 
similar pattern to that observed previously in PBECs cultured from bronchial brushings 
performed on lung transplant recipients  (Figure 20). (Forrest et al., 2005) 
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Figure 18. Brightfield light micrograph of primary bronchial epithelial cells 
cultured under submerged conditions from an explanted cystic fibrosis lung 
 
50 µm 
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Figure 19. Haematoxylin and eosin staining of primary bronchial epithelial cells 
cultured under submerged conditions from an explanted cystic fibrosis lung 
 
50 µm 
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Figure 20. Pan-cytokeratin staining of primary bronchial epithelial cells cultured 
under submerged conditions from an explanted cystic fibrosis lung 
 
50 µm 
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5.5.8. Electrophysiology 
 
A characteristic feature of CF airway epithelial cells is the lack of a cAMP/protein 
kinase A activated Cl- conductance, due to dysfunctional mutant CFTR channels. 
(Moran and Zegarra-Moran, 2008) However, CF epithelial cells do retain a Cl- 
conductance that can be activated by an elevation of intracellular calcium. (Mall et al., 
2003, Hartzell et al., 2005) In order to investigate whether my cultured PBECs retained 
this signature CF phenotype electrophysiological experiments were performed on cells 
grown as monolayers on glass coverslips. Whole cell Cl- currents were measured using 
the patch clamp technique.   
 
Exposure of PBECs to 5µM forskolin (a cAMP-elevating agent), for a minimum of 4 
minutes, failed to elevate whole cell current above basal levels (0/9), (Figure 21A). In 
contrast, treatment with 1µM ionomycin (a calcium elevating agent) initiated a rapid 
increase in whole cell current within 60 seconds of addition (7/12 cells). In 4 of these 
experiments, this current increase was transient in nature, however, in the remaining 
cells tested, this increase was sustained and the current was shown to be outwardly 
rectifying and possess the time dependent kinetics characteristic of a calcium-activated 
chloride current (CaCC) (Figure 21B). (Hartzell et al., 2005, Tarran et al., 2002) 
Furthermore, substitution of 100mM of bath Cl- with aspartate caused a shift in Erev of  
+22.5 ± 3.6mV (n = 3), indicating a predominantly Cl- selective current (under these 
conditions, a +29.3mV shift would indicate a perfectly Cl- selective current). These 
results therefore confirm that my cultured PBECs from explanted lungs retain the 
characteristic electrophysiological profile expected of CF cells.
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Figure 21. Representative current traces and summary data for cells treated 
with Forskolin (A) and Ionomycin (B). 
For summary data, current was measured at Erev +60 mV (upright bars) and -60 mV 
(inverted bars) and normalised to cell capacitance. 
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5.5.9. Cytokine production 
	  
5.5.10. Basal (unstimulated) cytokine production  
 
I investigated the production of the cytokines IL-8, IL-6 and GMCSF by submerged 
PBEC cultures by performing a multiplex ELISA on culture supernatants. Constitutive 
production of these cytokines is known to occur and would be expected to happen in 
viable airway epithelial cells. (Becker et al., 2004, Murphy et al., 2008a) As described 
fully in section 4.2, PBECS were rested for 24 hours prior to the medium being replaced 
with fresh resting medium for a further 24 hours and then harvested for analysis. 
Typical standard curves for the ELISA in my hands are shown in Figure 46 to Figure 48 
respectively. 
 
Figure 22 to Figure 24 display basal levels (unstimulated) of IL-8, IL-6 and GMCSF 
production by PBECs from people with advanced CF lung disease (see Table 9). As has 
been described previously by other researchers, there is variability in the baseline levels 
of production of these cytokines by PBECs from different individuals. (Becker et al., 
2004, Ribeiro et al., 2009) 
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Figure 22. Basal production of interleukin-8 by primary bronchial epithelial cells 
from people with advanced cystic fibrosis lung disease 
Horizontal lines indicate the median basal production of interleukin-8, results from four 
replicate experiments. The boxes indicate the 25th and 75th percentiles and whiskers 
minimum and maximum respectively. See Table 9 for clinical details relating to each 
patient number.  
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Figure 23. Basal production of interleukin-6 by primary bronchial epithelial cells 
from people with advanced cystic fibrosis lung disease 
Horizontal lines indicate the median basal production of interleukin-6, results from four 
replicate experiments. The boxes indicate the 25th and 75th percentiles and whiskers 
minimum and maximum respectively. See Table 9 for details relating to each patient 
number.  
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Figure 24. Basal production of granulocyte macrophage colony-stimulating factor 
by primary bronchial epithelial cells from people with advanced cystic 
fibrosis lung disease 
Horizontal lines indicate the median basal production of granulocyte macrophage 
colony-stimulating factor, results from four replicate experiments. The boxes indicate 
the 25th and 75th percentiles and whiskers minimum and maximum respectively. See 
Table 9 for details relating to each patient number. 
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5.5.11. Cytokine production following stimulation with flagellin 
 
Following on from the experiments described in section 5.5.10 investigating the basal 
production of the cytokines IL-8, IL-6 and GMCSF by PBECS from people with 
advanced CF lung disease I investigated the effect of stimulation with flagellin on the 
production of these cytokines. Flagellin is the major component of bacterial flagella and 
is found abundantly in flagellated bacteria, for example Salmonella typhimurium, 
Escherichia coli and P. aeruginosa. (Feldman et al., 1998) Importantly flagellin is 
expressed by motile forms of P. aeruginosa, which in the context of CF lung disease is 
most relevant in the early stages of infection and colonisation. (Raoust et al., 2009, 
Prince, 2006) Flagellin is a key target of epithelial innate immunity and toll-like 
receptor (TLR) 5 is a specific receptor. (Vijay-Kumar and Gewirtz, 2009) Flagellin 
therefore represents a potent pro-inflammatory stimulus to epithelial cells that triggers a 
number of signalling cascades, including the NFκB and MAPK pathways, and leads to 
the production of IL-8, IL-6 and GMCSF, amongst other mediators. (Pena et al., 2009, 
Lorenz et al., 2010, Sha et al., 2004) Appropriate responses would therefore be expected 
to occur in viable airway epithelial cells following challenge with flagellin. 
 
As described fully in section 4.2.15, PBECS were rested for 24 hours prior to the 
medium being replaced with fresh resting medium containing 1, 10 or 100ng/mL 
flagellin. After 24 hours the supernatant was harvested and analysed by multiplex 
ELISA. The flagellin used for these experiments was purified from S. typhimurium 
(Alexis Biochemicals). 
 
Figure 25 to Figure 27 display levels of IL-8, IL-6 and GMCSF produced by PBECs 
from people with advanced CF lung disease following stimulation with 1, 10 or 
100ng/mL. Typical standard curves for the ELISA in my hands are shown in Figure 46 
to Figure 48 respectively. Increases in IL-8 production were statistically significant 
following stimulation with 1, 10 and 100ng/mL of flagellin (Figure 25). Although there 
was also an increase in production of IL-6 and GMCSF in some experiments, see Figure 
26 and Figure 27, this was not consistent and was not statistically significant.
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Figure 25. Increase in interleukin-8 production by primary bronchial epithelial 
cells from people with advanced cystic fibrosis lung disease following 
stimulation with flagellin 
Each symbol represents an individual donor (n=9) and is the mean of three replicate 
experiments.  
Horizontal lines indicate the median.  
Median basal interleukin-8 production 242pg/mL.  
**P=0.009  
Wilcoxon signed-rank test for each concentration of flagellin compared to basal 
production. (Wilcoxon, 1945) Holm-Bonferonni correction applied. (Holm, 1979) 
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Figure 26. Increase in interleukin-6 production by primary bronchial epithelial 
cells from people with advanced cystic fibrosis lung disease following 
stimulation with flagellin 
Each symbol represents an individual donor (n=9) and is the mean of three replicate 
experiments.  
Horizontal lines indicate the median. 
Median basal interleukin-6 production 2pg/mL. 
Differences not significant by Wilcoxon signed-rank test for each concentration of 
flagellin compared to basal production. (Wilcoxon, 1945) Holm-Bonferonni correction 
applied. (Holm, 1979) 
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Figure 27. Change in granulocyte macrophage colony-stimulating factor 
production by primary bronchial epithelial cells from people with advanced 
cystic fibrosis lung disease following stimulation with flagellin 
Each symbol represents an individual donor (n=9) and is the mean of three replicate 
experiments.  
Horizontal lines indicate the median. 
Median basal granulocyte macrophage colony-stimulating factor production 8.1pg/mL  
Differences not significant by Wilcoxon signed-rank test for each concentration of 
flagellin compared to basal production. (Wilcoxon, 1945) Holm-Bonferonni correction 
applied. (Holm, 1979) 
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5.5.12. Cryopreservation 
 
Cells were reconstituted after a prolonged period of cryopreservation using the method 
described in section 4.2.5 on over 20 occasions with a success rate of 80% for 
subsequent submerged culture. 
 
5.5.13. Air-liquid interface culture 
 
Airway epithelial cells may be cultured most simply in vitro under submerged 
conditions, as was the case in the work described in this chapter so far. However, 
primary airway epithelial cells revert to a poorly differentiated phenotype within a 
limited number of passages. (Gruenert et al., 1995, Araya et al., 2007) More advanced 
culture techniques, such as within collagen gels, as three-dimensional spheroids or most 
commonly on semi-permeable membranes at ALI, allow recapitulation of a more 
accurate representation of the native airway epithelium. (de Jong et al., 1993) ALI 
cultures facilitate prolonged culture of cells in vitro, muco-ciliary differentiation and 
formation of a polarised epithelium characterised by tight junction formation and a 
raised trans-epithelial resistance. 
 
The successful culture of primary airway epithelial cells at ALI is widely acknowledged 
to be technically challenging and to require specialist expertise. (Personal 
communications with research groups in Liverpool, Sheffield, Edinburgh, Belfast, 
Leeds and Leicester) To date only a small amount of ALI culture work has been 
performed in our research group in Newcastle. I therefore performed some preliminary 
experiments in an attempt to establish ALI cultures with PBECs from people with CF. 
 
The method described in Chapter 4 that I used to establish the ALI cultures was largely 
based on personal discussions with Dr Scott Randell, University of North Carolina, and 
Professor Chris O’Callaghan, University of Leicester and the method published by 
Fulcher et al. (2005). In essence the technique involved the submerged culture of first 
passage cells to confluence on semi-permeable filters coated with type IV collagen 
using standard supplemented bronchial epithelial growth medium. Followed by 
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exposure of the apical membrane to air and switching of the basolateral media to a 
different, ‘ALI medium’. 
 
A trans-epithelial resistance in excess of 500Ω/cm2, indicative of a polarised epithelium, 
was routinely achieved at ALI. (Zabner et al., 2003, Fulcher et al., 2005) An example of 
trans-epithelial resistance measurements for PBECs cultured from a person with CF is 
shown in Figure 28. The morphology of the apical surface of PBECs cultured at ALI is 
shown in Figure 29 with areas of mucus accumulation indicated. Washings from the 
apical surface of the cultures were positive for the gel-forming airway mucin MUC5B 
detected by slot-blot ELISA (Figure 30). Periodic acid-Schiff staining of formalin-fixed 
ALI cultures was also positive (Figure 31). These results confirm the presence of 
different cell types, including well-differentiated mucus-secreting cells. Scanning 
electron micrographs of PBECs from a person with CF cultured at an air-liquid 
interface, illustrating morphology at different time points and tight junction formation 
are shown in Figure 32. 
 
In summary, it has been possible to generate polarised cultures with a consistently 
raised trans-epithelial resistance, which secrete mucus and form tight inter-cellular 
junctions and maintain them in vitro for over 6 weeks. True ciliogenesis did not occur 
and the cells appeared to be squamous rather than columnar in morphology after 
prolonged culture. 
 
Alternative approaches to establishing well-differentiated airway epithelial cell cultures 
that have been used by other researchers include 3-dimensional models involving 
collagen gels and co-culture with fibroblasts alone or along with other inflammatory 
cells such as eosinophils. (Choe et al., 2003, Ulrich and Doring, 2004, Bals et al., 2004, 
Parker et al., 2010, Zhang et al., 1999)  This suggests that ‘cross-talk’ between epithelial 
and other cell types is likely to be important in maintaining epithelial homeostasis and 
function. (Xu et al., 2002, Wang et al., 2009)  
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Figure 28. Trans-epithelial resistance measurements for primary bronchial 
epithelial cells cultured at an air-liquid interface for 22 days from an 
explanted cystic fibrosis lung 
Horizontal bars represent the median resistance. 
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Figure 29. Light micrograph of primary bronchial epithelial cells cultured at an 
air-liquid interface from an explanted cystic fibrosis lung 
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Figure 30. Example of positive slot-blot enzyme-linked immunosorbent assay for 
the gel-forming airway mucin MUC5B from washings from the apical 
surface of primary bronchial epithelial cells cultured at an air-liquid 
interface from explanted cystic fibrosis lungs 
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Figure 31. Periodic acid-Schiff staining of primary bronchial epithelial cells 
cultured at an air-liquid interface from an explanted cystic fibrosis lung 
50 µm 
 112 
Figure 32. Scanning electron micrographs of primary bronchial epithelial cells 
from a person with cystic fibrosis cultured at an air-liquid interface, illustrating 
morphology at different time points and tight junction formation (a), (b) and (c), 
and microvilli formation (d) 
	  
	  
(a)  Day 14 
 
 
b)  Day 21 
Tight junctions 
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c)  Day 28 
 
 
d) Microvilli formation 
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5.6. Discussion 
 
Despite the presence of multidrug resistant microorganisms and copious muco-purulent 
secretions I have been successful in establishing a programme to culture PBECs from 
explanted CF lungs in Newcastle. The PBECs were characterised in terms of their 
morphology (light microscopy and haematoxylin and eosin staining) and cytokeratin 
staining (immunohistochemistry). In addition, it was possible to perform whole-cell 
patch clamp experiments to demonstrate the absence of a forskolin-induced CFTR 
current and the presence of an ionomycin-induced CaCC. Under submerged 
unstimulated conditions the PBECs produced IL-8, IL-6 and GMCSF. 
 
Experience of culturing PBECs from end-stage CF lung tissue has been previously 
described in North America. (Karp et al., 2002, Randell et al., 2001, Yamaya et al., 
1992) The present study has established an optimised culture method with the novel 
aspect of using patient-specific combinations of antimicrobials. These were based on up 
to date knowledge of the organisms cultured from the sputum of patients, in their 
clinical management pre-transplant. I feel that this has been a significant factor in 
achieving a favourable success rate (67% overall, 50% using a fixed ‘best guess’ 
antimicrobial cocktail and 75% with a patient-specific approach).  
 
In a European setting there are also particular logistical, infrastructure and resource 
considerations. I have shown that it is possible to utilise tissue from a supra-regional 
National Health Service clinical transplant programme to set up CF primary culture 
research. Though mostly generated ‘out of hours’, tissue was transferred successfully to 
associated university research facilities, with successful cultures the most common 
outcome. 
 
It is clearly essential that microorganisms are eliminated from cell cultures and that this 
is balanced against the potential cytotoxic effects of antimicrobials on epithelial cells. 
The concentration of each antimicrobial used was guided where available by 
cytotoxicity data published by Randell et al. (2001). Anecdotally, I concur with the 
finding that the deleterious effects of antimicrobials are manifested by a reduction in 
growth rate rather than any noticeable effect on cell attachment. (Randell et al., 2001) In 
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my experience antimicrobials should be removed from the culture medium as early as is 
practicable to ensure optimal growth rates.  
 
One advantage of an ex vivo culture system is that significantly higher and sustained 
concentrations of antimicrobials can be used compared to those possible in the lungs of 
patients in vivo. Clearly the choice of agents is also not hampered by the frequent 
allergies encountered clinically in people with end-stage CF lung disease. (Parmar and 
Nasser, 2005) In patients where cell culture was unsuccessful this was universally due 
to early overgrowth of cultures with organisms known to colonise the lungs pre-
transplant once antimicrobials had been withdrawn from the medium. It has previously 
been demonstrated that undifferentiated airway epithelial cells, cultured under 
submerged conditions, are much less resistant to the internalisation of P. aeruginosa 
than differentiated cells that form a tight epithelium. (Plotkowski et al., 1999, 
Plotkowski et al., 2001)  One potential explanation for the recrudescence of infection is 
the persistence of bacteria in epithelial cells. (Garcia-Medina et al., 2005)  In the 
context of bronchial brushings from clinically stable patients post-lung transplantation it 
has been noted that respiratory pathogens are sometimes cultured from epithelial cell 
cultures when bronchoalveolar lavage fluid bacterial culture is negative. (Forrest et al., 
2005)          
 
The culture of PBECs from explanted CF lungs is demanding, both in terms of effort 
and expense, and is limited by their finite lifespan, however, ultimately it yields a model 
system that is likely to more accurately recapitulate the situation in vivo than 
immortalised cell lines. (Karp et al., 2002) In people with CF there is a diverse 
spectrum of disease and often a weak correlation between CFTR genotype and clinical 
lung disease phenotype. (Rowntree and Harris, 2003) It is important to remember that 
PBECs are likely to reflect this inherent biological heterogeneity in terms of their 
function. This is illustrated by the variable levels of the cytokines IL-8, IL-6 and 
GMCSF produced by cells from different donors that I found in the work described in 
this chapter. Indeed, for some experiments the homogeneity of an immortalised cell line 
along with isogenic controls may be preferable. Clearly, cultured PBECs from people 
with CF may be used to establish valuable novel immortalised cell lines. (Fulcher et al., 
2009)  
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Flagellin is the principal component of the flagellum of bacteria and is an agonist of 
TLR-5 along with a number of other receptors. (Vijay-Kumar and Gewirtz, 2009) In 
proof-of-principle experiments stimulation of the cultured PBECs with flagellin resulted 
in a significant increase in IL-8 production and also in cells from some donors IL-6 and 
GMCSF although this was not a consistent phenomenon. The increase in IL-8 
production is in keeping with the findings of others in the published literature and has 
been demonstrated to involve the NFκB pathway. (Pena et al., 2009) It is biologically 
plausible that the stimuli that I used of 1-100ng/mL of flagellin are supraphysiological 
compared to the situation in the airway in vivo, however such concentrations are orders 
of magnitude lower than those employed by other researchers in ex vivo experiments. 
(Kunzelmann et al., 2006) When considering Figure 25 it would seem likely that further 
experiments, for example using 0.1 and 0.01ng/mL flagellin, would be necessary to 
establish the threshold concentration of flagellin required to elicit an IL-8 response. In 
work performed by Schmeck et al. (2007) investigating the inflammatory response of 
immortalised A549 alveolar epithelial cells to infection by the flagellated bacterium 
Legionella pneumophila it was found that infection resulted in production of several 
pro-inflammatory mediators, including IL-8 and IL-6, but not GMCSF. (Schmeck et al., 
2007)  
 
Further experiments involving an increased number of donors would be necessary to 
robustly conclude about the effects of flagellin stimulation on IL-6 and GMCSF 
responses on PBECs from people with advanced CF lung disease. There are numerous 
other pathogen-associated molecular patterns that could be studied using this cellular 
model. (Govan and Deretic, 1996) This includes lipopolysaccharides produced by P. 
aeruginosa and Burkholderia cepacia complex that are highly relevant to the 
pathophysiology of advanced CF lung disease. (De Soyza et al., 2008, Pier, 2007)    
Another important area for potential future experiments is investigation of the signalling 
pathways involved in the transduction of pro-inflammatory responses by PBECs. The 
careful use of tools such as receptor-blocking antibodies or antagonism of specific steps 
by small molecules or small interfering RNAs would allow further dissection of the 
pathways involved. (Chakraborty and Mann, 2010, Murphy, 2008)   
 
PBECs represent an important resource, particularly so in the new emerging era of 
targeted therapies for the molecular defect associated with specific CFTR mutations. 
(O'Sullivan and Freedman, 2009) The problems outlined earlier in this thesis with the 
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murine models of CF lung disease clearly limit their utility in drug discovery. (Scholte 
et al., 2004) Although immortalised cell lines are extremely valuable in the early stages 
of high-throughput screening, as evidenced by the recent identification of novel 
compounds, primary cells are vital to confirm and validate any initial findings in a cell 
line prior to more advanced stages of analysis (Figure 10). (Pedemonte et al., 2005, Van 
Goor et al., 2006, Ma et al., 2002, O'Sullivan and Freedman, 2009)  
 
An alternative approach to performing electrophysiology experiments is to use cells 
grown to confluence and forming a tight epithelium on Transwell inserts in an Ussing 
chamber system. (Illek et al., 2010) This would allow more complex and prolonged 
experimentation and is certainly an area worthy of future exploration using the CF 
PBECs described in this chapter. 
          
In addition to the scientific challenges of culturing PBECs from end-stage CF lungs, the 
establishment of a programme to utilise explanted lungs has relied on excellent working 
relationships with the entire multidisciplinary transplant team. This includes obtaining 
the appropriate ethical approval to perform such work and clearly the informed consent 
of the transplant recipients themselves. In my experience it is ideal if individuals are 
approached for consent at the time of visiting the transplant centre for assessment and 
not during the emergency admission prior to a potential transplant. Furthermore, the 
helpful cooperation of cardiothoracic surgeons, transplant coordinators and theatre staff 
is essential in order to ensure that the research team is informed. Due to the 
unpredictable nature of transplantation in my experience an ‘on-call’ commitment is 
essential to facilitate and ensure the appropriate timely procurement of tissue in the 
event of a transplant occurring.    
 
A key consideration when using primary tissue in research is that the clinical care of 
patients is not compromised. The method described in this chapter allows clinical 
specimens to be collected from explanted lungs for microbiology and involves only 
modest dissection thereby enabling a full examination of the lungs to be performed by a 
pathologist. This is important because rarely clinically significant findings may be 
identified solely by pathological examination of explanted lungs, such as a previously 
undetected neoplasm. (Abrahams et al., 2004) Theoretically the risk is lower in CF than 
some other disease groups that are transplanted however. Conversely, a more radical 
dissection technique would undoubtedly yield a greater number of cells from each lung. 
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In this chapter I have described the initial results and experiences in establishing a 
programme to culture PBECs from CF lungs removed at the time of transplantation. 
The culture of PBECs from chronically infected lungs poses technical and logistical 
challenges but ultimately yields a valuable cellular model to study CF lung disease.    
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6. Chapter 6. Interleukin-17 and advanced cystic fibrosis lung disease 
 
 
Elements of the work described in this chapter have been previously reported in the 
form of a presentation at a scientific meeting and a peer-reviewed paper. (Brodlie et al., 
2009c, Brodlie et al., 2010c) 
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6.1. Abstract 
 
Background: Interleukin-17 is pivotal to pulmonary host defence by orchestrating the 
activity of neutrophils. Neutrophilic inflammation is the dominant pathology in cystic 
fibrosis lung disease. I investigated interleukin-17 protein expression in the lower 
airway in advanced cystic fibrosis lung disease, including the cellular 
immunolocalisation and the effects of interleukin-17 on cystic fibrosis primary 
bronchial epithelial cells. 
Methods: I performed immunohistochemistry for interleukin-17 on explanted cystic 
fibrosis lungs and compared findings to the non-suppurative condition pulmonary 
hypertension. Primary bronchial epithelial cell cultures were also generated from some 
of the explanted cystic fibrosis lungs and treated with interleukin-17.    
Results: Immunoreactivity for interleukin-17 was significantly increased in the lower 
airway epithelium in cystic fibrosis (median 14.1% of surface area) compared to 
pulmonary hypertension (2.95%, P=0.0001). The number of cells staining positive for 
interleukin-17 in the lower airway mucosa was also increased (64 compared to 9/mm 
basement membrane, P=0.0005) and included both neutrophils, which were frequently 
intra-epithelial, in addition to mononuclear cells. Treatment of primary bronchial 
epithelial cells with interleukin-17 increased production of interleukin-8, interleukin-6 
and granulocyte macrophage colony-stimulating factor. 
Conclusion: Interleukin-17 protein expression is raised in the lower airway of people 
with cystic fibrosis in terms of surface area of the airway epithelium staining postive 
and number of inflammatory cells staining positive in the mucosa, including both 
neutrophils and mononuclear cells. Interleukin-17 increases production of pro-
neutrophilic mediators by primary bronchial epithelial cells from people with cystic 
fibrosis. The immunolocalisation of IL-17 to neutrophils suggests a novel potential 
positive feedback loop of neutrophilic inflammation in the CF airway. 
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6.2. Introduction 
 
As outlined earlier in this thesis, CF is caused by abnormalities in the CFTR gene and is 
associated with life-long morbidity and premature mortality, principally from lung 
disease. (O'Sullivan and Freedman, 2009) The CF airway is characterised by 
neutrophilic inflammation, lymphocytic infiltration of the mucosa, retention of 
mucopurulent secretions and chronic endobronchial infection. (O'Sullivan and 
Freedman, 2009, Hubeau et al., 2001a)  
 
The cytokine IL-17 plays a central role in pulmonary host defence by orchestrating the 
accumulation and associated activity of neutrophils in the bronchoalveolar space. 
(Linden et al., 2005, Aujla et al., 2007) A family of IL-17 cytokines has been described, 
however IL-17A (referred to as IL-17 onwards in this chapter), and to a lesser extent IL-
17F, are the best characterised. (Gaffen, 2009) The orchestrating effect of IL-17 on 
neutrophils is achieved indirectly via the local release of neutrophil-mobilising factors, 
including CXC chemokines, from cells resident in the lung. (Linden et al., 2005) 
Treatment with IL-17 has also been shown to increase expression of the mucin genes 
MUC5AC and MUC5B by bronchial epithelial cells in vitro. (Chen et al., 2003)  
 
IL-17 is the signature cytokine produced by TH-17 lymphocytes and therefore represents 
a strategic link between acquired and innate immunity via its orchestrating effect on 
neutrophils. (Glader et al., 2010) TH-17 cells are not the only source of IL-17 identified 
however. IL-17 is also known to be produced by γδ T-cells and natural killer T-cells. 
(Michel et al., 2007, Roark et al., 2008) Apart from lymphocytes it has also recently 
been shown that mast cells express IL-17 in rheumatoid arthritis synovium. (Hueber et 
al., 2010) Moreover, it has also been suggested in human alcoholic liver disease and 
rodent models of lipopolysaccharide-induced airway inflammation, perinuclear anti-
cytoplasmic neutrophil antibodies (p-ANCA) positive vasculitis and kidney ischaemia-
reperfusion injury that neutrophils themselves are a potential source of IL-17. (Lemmers 
et al., 2009, Ferretti et al., 2003, Li et al., 2010, Hoshino et al., 2008)  
 
IL-17 is therefore linked to neutrophilic inflammation and mucus excess, two cardinal 
features of CF lung disease, in addition to dysregulation of acquired immunity. (Chen et 
al., 2003, Bettelli et al., 2007, Aujla et al., 2007) Published human studies of IL-17 in 
CF are rare but some support the importance of this axis. Increased levels of IL-17 have 
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been found in bronchoalveolar lavage from children and adults during infective 
exacerbations, and in the serum of clinically stable adults. (McAllister et al., 2005, 
Dubin et al., 2007, Aujla et al., 2008, Dufresne et al., 2009) In addition, people with CF 
who exhibit robust T-cell responses to P. aeruginosa manifest more severe lung disease. 
(Winnie and Cowan, 1991) Such work emphasises the need for further translational 
studies.  
 
In the work described in this chapter I have examined the hypothesis that increased IL-
17 protein expression occurs in advanced CF lung disease. To investigate this 
hypothesis I used airway samples that I had collected from CF lungs removed at the 
time of transplantation to perform immunohistochemistry and compared findings to 
those in the non-suppurative condition pulmonary hypertension (PH). I also analysed 
airway lavage samples from explanted CF lungs for IL-17. In view of the recent reports 
of myeloid cells producing IL-17 I also investigated the cellular localisation of the 
positive IL-17 staining in explanted CF lungs. (Li et al., 2010, Hueber et al., 2010, 
Ferretti et al., 2003, Lemmers et al., 2009) In addition I generated PBEC cultures from 
some of the same CF lungs, as outlined in Chapter 5. These were used in proof of 
concept experiments, which examined the effects of IL-17 stimulation on the production 
of inflammatory mediators in ex vivo PBEC cultures. 
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6.3. Aims 
 
The aims of the work described in this chapter were to: 
• Investigate the protein expression of interleukin-17 in the lower airway of 
people with advanced cystic fibrosis lung disease using  
o immunohistochemistry of the airway epithelium in comparison to the 
non-suppurative condition pulmonary hypertension. 
o airway lavage fluid in comparison to healthy volunteers 
• Describe the cellular localisation of interleukin-17 in the lower airway of people 
with advanced cystic fibrosis lung disease. 
• Investigate the effects of stimulation with interleukin-17 on the production of the 
pro-neutrophilic mediators interleukin-8, interleukin-6 and granulocyte 
monocyte colony-stimulating factor by ex vivo primary bronchial epithelial cell 
cultures from people with advanced cystic fibrosis lung disease.  
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6.4. Hypothesis 
 
Interleukin-17 is pivotal in the orchestration and accumulation of neutrophils in 
pulmonary host defence and neutrophilic inflammation is the dominant pathology in 
cystic fibrosis lung disease. I therefore hypothesised that expression of interleukin-17 
would be raised in the lower airway of people with advanced cystic fibrosis lung 
disease. Furthermore I also hypothesised that interleukin-17 may be localised to cells 
other than lymphocytes in the lower airway of people with cystic fibrosis and that 
stimulation with interleukin-17 would increase the production of pro-neutrophilic 
mediators by ex vivo cultures of primary bronchial epithelial cells from people with 
advanced cystic fibrosis lung disease.  
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6.5. Results 
 
6.5.1. Detection of interleukin-17 in airway lavage fluid from explanted cystic 
fibrosis lungs 
 
I performed a standardised airway lavage  of 15mL phosphate buffered saline on freshly 
explanted CF lungs as outlined in section 4.2.2. This involved a total lavage volume of 
30mL/patient. I then assayed the lavage fluid supernatant from 28 CF lungs for IL-17 
using an ultrasensitive IL-17 ELISA kit with a lower limit of detection of 0.2pg/mL 
(MesoScale Discovery). Brief clinical details of the people with CF whose explanted 
lung lavage fluid was assayed for IL-17 are provided in Table 10. The standard curve 
for the IL-17 ELISA is displayed in Figure 33. Figure 34 displays the concentrations of 
IL-17 detected in airway lavage fluid from each CF lung (n=28, median 56.9pg/mL, 
interquartile range 34.9-79.7pg/mL). Comparison is made with data from the previous 
work of Dr Des Murphy in Newcastle where IL-17 was undetectable in bronchoscopic 
BAL (3x60mL) fluid from 4 healthy volunteers. (Murphy, 2008) Dr Murphy used the 
same IL-17 ELISA kit manufactured by MesoScale Discovery along with a kit with a 
higher limit of detection manufactured by R&D Systems. (Murphy, 2008)   
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Table 10. Clinical details of the people with cystic fibrosis that bronchoalveolar 
lavage fluid was assayed for interleukin-17  
 
Age* CFTR 
Variant$ 
FEV1^ 
 
Sputum microbiology 
32 Unknown 25 Pseudomonas aeruginosa,  
Burkholderia vietnamiensis 
25 p.Phe508del 
Unknown 
22 P. aeruginosa,  
Staphylococcus aureus 
23 Unknown 21 Scedosporium sp.,  
Alcaligines sp.,  
S. Aureus 
39 p.Phe508del 
p.Phe508del 
14 P. aeruginosa 
27 p.Phe508del 
p.Phe508del 
22 P. aeruginosa 
43 p.Phe508del p.Arg560Thr 15 Stenotrophomonas maltophilia, 
Acinetobacter sp. 
28 p.Phe508del 
p.Asp443fs 
17 P. aeruginosa 
29 p.Phe508del 
p.Phe508del 
20 P. aeruginosa, 
A. fumigatus 
30 p.Phe508del 
p.Phe508del 
30 P. aeruginosa 
40 Unknown 24 P. aeruginosa 
23 p.Phe508del 
p.Gly551Asp 
30 P. aeruginosa,     
A. fumigatus 
46 Unknown 30 P. aeruginosa 
29 p.Phe508del  
p.Gln685fs 
17 B. multivorans,  
A. fumigatus,  
Geosmithia argillacae 
22 p.Phe508del 
p.Phe508del 
23 P. aeruginosa 
20 p.Phe508del 
p.Phe508del 
21 P. aeruginosa 
29 p.Phe508del 
c.317+10kbC>T 
29 P. aeruginosa,  
S. maltophilia 
28 Unknown 20 P. aeruginosa,  
Methicillin-Resistant S. aureus 
48 p.Phe508del 
Unknown 
29 P. aeruginosa,  
S. aureus 
33 Unknown 23 P. aeruginosa 
22 p.Phe508del 
p.Phe508del 
25 P. aeruginosa,  
A. fumigatus 
24 p.Phe508del 
p.Phe508del 
26 P. aeruginosa 
21 Unknown 25 P. aeruginosa 
45 p.Phe508del 
p.Phe508del 
21 P. aeruginosa,  
A. fumigatus 
33 Unknown 17 P. aeruginosa,  
Mycobacterium gordonae 
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26 Unknown 25 P. aeruginosa 
22 Unknown 20 B. multivorans 
29 p.Phe508del 
p.Phe508del 
19 P. aeruginosa,  
S. maltophilia,  
Achromobacter sp.,  
M. avium,  
A. fumigatus,  
G. argillacea 
23 Unknown 27 P. aeruginosa,  
P. putida,  
A. fumigatus,  
A. xylosoxidans,  
Paecilomyces sp.,  
M. avium complex 
 
Abbreviations: *Age in years at time of transplantation. $Cystic fibrosis transmembrane 
conductance regulator genotype (where known). ^Percentage predicted forced 
expiratory volume in 1 second pre-transplant.  
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Figure 33. Standard curve for interleukin-17 enzyme-linked immunosorbent 
assay 
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Figure 34. Interleukin-17 in airway lavage fluid from explanted cystic fibrosis 
lungs 
Each symbol represents an individual patient and concentrations account for a dilution 
factor of 30 in the cystic fibrosis group.  
The horizontal line represents the median (56.9pg/mL).  
The lower limit of detection was 0.2pg/mL.  
The healthy volunteer data relates to 180mL bronchoalveolar lavages performed and 
assayed by Dr Des Murphy in Newcastle where IL-17 was universally undetectable. 
(Murphy, 2008)  
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6.5.2. Measurement of interleukin-23 in airway lavage fluid from explanted cystic 
fibrosis lungs 
 
Following on from the detection of IL-17 in lavage fluid from explanted CF lungs I 
performed an ELISA for IL-23 on the same samples. The rationale behind this was that 
IL-23 is known to be essential for the maintenance of TH-17 cells. (Wilson et al., 2007, 
Volpe et al., 2008, Cosmi et al., 2008) IL-23 is principally produced by dendritic cells 
and macrophages in the lung. (Nembrini et al., 2009) The ELISA kit used (Quantikine 
human IL-23 immunoassay, R&D Systems) had a limit of detection of 6.8pg/mL. The 
standard curve for the IL-23 ELISA is displayed in Figure 35. Figure 36 shows the BAL 
fluid results, IL-23 was undetectable in 18 of the 26 patient samples assayed. 
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Figure 35. Standard curve for interleukin-23 enzyme-linked immunosorbent assay 
y=0.009x+0.027. R square 0.998 
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Figure 36. Interleukin-23 in airway lavage fluid from explanted cystic fibrosis 
lungs 
Each symbol represents an individual patient and concentrations account for a dilution 
factor of 30.  
The median concentration of IL-23 detected was 0pg/mL (undectable in 18/26 samples). 
The lower limit of detection of the assay was 6.8pg/mL. 
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6.5.3. Immunoreactivity for interleukin-17 is increased in the lower airway 
epithelium of people with advanced cystic fibrosis lung disease 
 
Immunohistochemistry was performed on sections of medium-large lower airway from 
explanted lungs removed at the time of transplantation from 19 people with advanced 
CF lung disease and 8 with PH. Brief details of the 27 patients used for 
immunohistochemistry are provided in Table 11.  
 
The percentage area of lower airway epithelium positive for IL-17 (mean of 5 randomly 
selected high power fields) in each individual is displayed in Figure 37. Staining for IL-
17 was significantly higher in the CF group, median 14.1%, compared to PH, 3.0% 
(P=0.0001). Figure 38 shows representative IL-17 staining, in an explanted CF (a) and 
PH (b) lung, and negative control (c).   
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Table 11. Brief clinical details of patients undergoing lung transplantation used for 
interleukin-17 immunohistochemistry and stimulation of primary bronchial 
epithelial cells 
 
IHC 
 
Patient 
number 
Diagnosis Pre-operative sputum 
microbiology 
IL-
17 
Neu. 
PBEC 
culture 
1 CF Pseudomonas aeruginosa + - - 
2 CF P. aeruginosa,  
Staphylococcus aureus 
+ - - 
3 CF P. aeruginosa,  
S. aureus,  
Stenotrophomonas maltophilia, 
Aspergillus fumigatus 
+ + - 
4 CF P. aeruginosa,  
S. aureus 
+ + - 
5 CF P. aeruginosa,  
Aspergillus fumigatus 
+ + - 
6 CF P. aeruginosa,  
Stenotrophomonas maltophilia 
+ - - 
7 CF P. aeruginosa,  
Methicillin-Resistant S. aureus 
+ - - 
8 CF P. aeruginosa,  
Burkholderia vietnamiensis 
+ + - 
9 CF P. aeruginosa + - + 
10 CF Scedosporium aspiospermum,  
S. aureus,  
Alcaligines sp. 
+ - + 
11 CF P. aeruginosa + + - 
12 CF P. aeruginosa,  
S. aspiospermum 
+ - - 
13 CF P. aeruginosa,  
A. fumigatus 
+ - + 
14 CF P. aeruginosa + + - 
15 CF P. aeruginosa + - - 
16 CF P. aeruginosa + - + 
17 CF P. aeruginosa,  
S. aureus 
+ - - 
18 CF P. aeruginosa,  
S. aureus 
+ - - 
19 CF P. aeruginosa + +  
20 CF Stenotrophomonas maltophilia, 
Acinetobacter sp. 
- - + 
21 CF P. aeruginosa - - + 
22 CF P. aeruginosa - - + 
23 CF P. aeruginosa,  
A. fumigatus 
- - + 
24 CF P. aeruginosa,  
A. fumigatus 
- - + 
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25 PH Negative + - - 
26 PH Negative + - - 
27 PH Negative + - - 
28 PH Negative + - - 
29 PH Negative + - - 
30 PH Negative + - - 
31 PH Negative + - - 
32 PH Negative + - - 
 
Abbreviations: IHC patient used for immunohistochemistry, Neu patient used for 
percentage of neutrophils positive for IL-17, PBEC patient used for primary bronchial 
epithelial cell culture, CF cystic fibrosis, PH pulmonary hypertension 
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Figure 37. Percentage of epithelium surface area staining positive for interleukin-
17 in people with advanced cystic fibrosis lung disease compared to 
pulmonary hypertension 
 
Each symbol represents an individual patient and represents the mean from 5 high-
power fields.  
Horizontal bar indicates median for each group.  
Mann-Whitney test used to compare the two groups.
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Figure 38. Representative immunohistochemistry for interelukin-17 in the lower 
airway mucosa of an explanted lung from a person with a) advanced cystic 
fibrosis lung disease, b) pulmonary hypertension and c) negative control 
(normal goat immunoglobulins) 
a) Advanced cystic fibrosis lung disease 
 
 
b) Pulmonary hypertension 
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c) Negative control (normal goat immunoglobulins) 
 
 
 
 139 
 
6.5.4. Interleukin-17 positive cells are increased in the lower airway mucosa in cystic 
fibrosis and include neutrophils 
 
The number of IL-17 positive cells in the mucosa was significantly increased in the CF 
group, median 64/mm of basement membrane and included both neutrophils and 
mononuclear cells, compared to PH, 9/mm basement membrane (P=0.0005, Mann-
Whitney test). The mean number of positive cells per mm of basement membrane in 
each individual is displayed inFigure 39. In the CF group substantial numbers of 
inflammatory cells staining positive for IL-17 were found in the epithelium, of note this 
frequently included neutrophils  (Table 12 and Figure 40) in addition to mononuclear 
cells (Figure 41). In the PH group IL-17 positive inflammatory cells were absent from 
the epithelium (Table 12). 
 
The percentage of mucosal neutrophils staining positive for IL-17 was quantified in a 
subset of 7 people with CF (identified in Table 11). The percentage of neutrophils 
staining positive for IL-17 in these individuals is displayed in Figure 42, median 38% 
(interquartile range 34). 
 
I also performed immunohistochemistry for the transcription factor RORγ on sections of 
lower airway mucosa from people with advanced CF lung disease. RORγ is a 
transcription factor that is encoded by the retinoic acid receptor-related orphan receptor 
C (RORC) gene. RORC expression is known to be important in production of IL-17 by 
TH-17 cells and mast cells. (Bettelli et al., 2007, Hueber et al., 2010) Figure 43 displays 
a low power view of the lower airway mucosa from an explanted lung from a person 
with advanced CF lung disease showing several positive cells for RORγ in the mucosa. 
At higher power, as shown in Figure 44, it is evident that the positive cells are 
neutrophils. Staining was universally absent in isotype negative controls (normal rabbit 
immunoglobulins), as exemplified in Figure 45. 
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Figure 39. Number of interleukin-17 positive cells/mm basement membrane in the 
lower airway mucosa in cystic fibrosis and pulmonary hypertension lungs  
Each symbol represents an individual patient and represents the mean from 5 high-
power fields.  
The horizontal bar indicates the median for each group.  
Mann-Whitney test used to compare the two groups.
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 Cystic 
fibrosis 
Pulmonary 
hypertension 
Median IL-17 positive cells/mm basement 
membrane (mucosa) 
[IQR] 
63.9** 
[37.0-81.9] 
8.8 
[2.4-19.9] 
Median IL-17 positive cells/mm basement 
membrane (epithelium) 
[IQR] 
17.6 
[8.5-23.8] 
0 
Median IL-17 positive cells/mm basement 
membrane (lamina propria) 
[IQR] 
41.1* 
[19.0-59.9] 
8.8 
[2.4-19.9] 
 
Table 12. Number of interleukin-17 positive cells in the mucosa, epithelium and 
lamina propria in lungs explanted from people with cystic fibrosis and 
pulmonary hypertension 
Abbreviations: *P=0.032, **P=0.0005, IQR Inter-quartile range. 
Mann-Whitney test used to compare the two groups. 
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Figure 40. Example of neutrophil (N) staining positive for interleukin-17 in the 
epithelium of an explanted lung from a person with advanced cystic fibrosis 
lung disease 
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Figure 41. Example of mononuclear cells (M) staining positive for interleukin-17 in 
the explanted lung of a person with advanced cystic fibrosis lung disease 
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Figure 42. Percentage of neutrophils staining positive for interleukin-17 in the 
lower airway mucosa of explanted cystic fibrosis lungs (n=7) 
Mean of 5-high power fields. 
Horizontal line indicates the median.
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Figure 43. Immunohistochemistry for retinoic acid receptor-related orphan 
receptor gamma in advanced cystic fibrosis lung disease lower airway (x20 
objective) 
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Figure 44. Immunohistochemistry for retinoic acid receptor-related orphan 
receptor gamma in advanced cystic fibrosis lung disease lower airway 
(higher power, x40 objective), including evidence of positive staining in 
neutrophils (N) 
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Figure 45. Example of isotype negative control (normal rabbit immunoglobulins) 
for retinoic acid receptor-related orphan receptor gamma 
immunohistochemistry cystic fibrosis airway 
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6.5.5. Stimulation of primary bronchial epithelial cells isolated from people with 
advanced cystic fibrosis lung disease with interleukin-17 increases production of 
the pro-neutrophilic mediators interleukin-8, interleukin-6 and granulocyte 
macrophage colony-stimulating factor 
 
The lower airway epithelium is the predominant site of neutrophilic inflammation in CF 
lung disease. (Hubeau et al., 2001a) Airway epithelial cells are increasingly recognised 
to operate as ‘effector’ cells that produce a wide range of inflammatory cytokines and 
growth factors. (Ward et al., 2009, Brodlie et al., 2009a) The cytokines IL-8, IL-6 and 
GMCSF are important in neutrophil activation, recruitment and longevity. (Gabay, 
2006, Standiford et al., 1993, Barreda et al., 2004) I therefore investigated the effects of 
IL-17 on the production of these mediators by ex vivo cultures of PBECs from people 
with CF.  
 
PBEC cultures were established from people with CF as outlined in Chapter 3. Table 11 
provides brief clinical details of the 9 individual donors, some of whom were also used 
for immunohistochemistry. There was a significant increase in IL-8 production from 
control conditions following stimulation with 1 (P=0.033), 10 (P=0.009) and 100ng/mL 
(P=0.009) of IL-17 (Figure 49, n=9 individual patient donors). There was also a 
statistically significant increase in IL-6 production (Figure 50) from control following 
stimulation with 10 and 100ng/mL of IL-17 (P=0.009). There was a clear trend towards 
increased production of IL-6 following stimulation with 1ng/mL of IL-17 although this 
was not statistically significant (P=0.076). Increase in production of GMCSF (Figure 
51) was statistically significant following stimulation with IL-17 100 ng/mL only 
(P=0.013). There was a non-significant trend towards increased levels following 
stimulation with IL-17 at 1 and 10ng/mL (P=0.407 and 0.193). 
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Figure 46. Standard curve for interleukin-8 enzyme-linked immunosorbent assay 
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Figure 47. Standard curve for interleukin-6 enzyme-linked immunosorbent assay 
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Figure 48. Standard curve for granulocyte macrophage colony-stimulating factor 
enzyme-linked immunosorbent assay 
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Figure 49. Increase in interleukin-8 production by primary bronchial epithelial 
cells from people with advanced cystic fibrosis lung disease from control 
following stimulation with 1, 10 and 100ng/mL interleukin-17. 
Each symbol represents an individual patient and is the mean of 3 replicate experiments  
(n=9 individual patient donors).  
Median basal IL-8 production 242pg/mL.  
*P=0.033, **P=0.009.  
Wilcoxon signed-rank test comparing each concentration of IL-17 to basal 
production. (Wilcoxon, 1945) Holm-Bonferonni correction applied. (Holm, 1979) 
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Figure 50. Increase in interleukin-6 production by primary bronchial epithelial 
cells from people with advanced cystic fibrosis lung disease from control 
following stimulation with 1, 10 and 100ng/mL interleukin-17. 
Each symbol represents an individual patient and is the mean of 3 replicate experiments  
(n=9 individual patient donors).  
Median basal IL-6 production 2.04pg/mL.  
**P=0.009. 
Wilcoxon signed-rank test comparing each concentration of IL-17 to basal production 
(1ng/mL not significant). (Wilcoxon, 1945) Holm-Bonferonni correction applied. 
(Holm, 1979) 
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Figure 51. Increase in granulocyte macrophage colony-stimulating factor 
production by primary bronchial epithelial cells from people with advanced 
cystic fibrosis lung disease from control following stimulation with 1, 10 and 
100ng/mL interleukin-17. 
Each symbol represents an individual patient and is the mean of 3 replicate experiments  
(n=9 individual patient donors).  
Median basal GMCSF production 8.08pg/mL.  
*P=0.013.  
Wilcoxon signed-rank test comparing each concentration of IL-17 to basal production 
(only 100ng/mL significant). (Wilcoxon, 1945) Holm-Bonferonni correction applied. 
(Holm, 1979) 
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6.6. Discussion 
 
In this chapter I have demonstrated that IL-17 is expressed and raised in the lower 
airway of people with advanced CF lung disease, using immunohistochemistry 
compared to the non-suppurative condition PH and measured in airway lavage fluid 
compared to healthy volunteers. I also identified substantially increased numbers of 
inflammatory cells staining positive for IL-17 present in the lower airway mucosa of 
people with CF. Some of these were mononuclear cells, in keeping with the literature 
indicating that TH-17 cells are a source of IL-17. (Glader et al., 2010) However, I also 
consistently identified abundant IL-17 positive neutrophils - a new finding, which may 
be significant in CF lung disease. In addition I found neutrophils in the lower airway 
mucosa to stain positively for the transcription factor RORγ. 
 
There are no previous descriptions of which I am aware showing that IL-17 protein is 
localised to neutrophils in human lung, with a strong emphasis on TH-17 biology in the 
current literature. IL-17 staining has been described in neutrophils previously in the 
context of human liver disease and complicated atherosclerotic plaques, and in the lungs 
of mice, however. (Lemmers et al., 2009, Ferretti et al., 2003, de Boer et al., 2010) IL-
17 has also been co-localised to mast cells in rheumatoid arthritis synovium. (Hueber et 
al., 2010) 
 
Elegant work, only achievable in a mouse setting, recently showed that renal ischaemia-
reperfusion injury is IL-17 dependent, and that IL-17 is produced by neutrophils. (Li et 
al., 2010) This work used IL-17 knockouts, IL-17 production assays, as well as bone 
marrow transplantation to produce chimeric mice. A series of experiments showed that 
kidney damage was IL-17 mediated and that this was produced by bone marrow derived 
neutrophils. Hence, protection from kidney injury was shown in IL-17–/– mice, and this 
was reversed following transfer of wild type neutrophils, but not IL-17–/– neutrophils. 
Where reconstituted the injury was in turn attenuated by antibody neutralization of IL-
17. 
 
If neutrophils are a source of IL-17, as evidenced by my current human lung work, the 
aforementioned human liver study and in more detailed animal model work, this 
suggests that IL-17 mediated injury may have an amplifying positive autocrine feedback 
element. (Li et al., 2010, Lemmers et al., 2009, Ferretti et al., 2003) IL-17 causes 
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neutrophil recruitment, which themselves may be potential sources of this key cytokine. 
(Ferretti et al., 2003) Figure 52 illustrates this potential positive feedback loop of 
neutrophilic inflammation involving IL-17. IL-17 also has a modulatory post-
transcriptional effect on IL-8 and IL-6 responses by epithelial cells in addition to 
stimulatory effects. (van den Berg et al., 2005)  
 
 
 
 
Figure 52. Illustrative diagram of potential positive feedback loop of neutrophilic 
inflammation involving interleukin-17 in cystic fibrosis airway 
Abrreviations: Ep. Epithelium, IL. Interleukin, DC dendritic cell, N neutrophil, Pa 
Pseudomonas aeruginosa. 
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A potential for positive feedback was further suggested by my proof of concept 
experiments. In these I assessed the effect of IL-17 stimulation on CF airway epithelial 
cells. IL-17 is known to exert effects on neutrophil accumulation and activation in the 
bronchoalveolar space indirectly via the local release of neutrophil-mobilising factors. 
(Aujla et al., 2007, Linden et al., 2005) I therefore investigated the effects of treatment 
with IL-17 on the production of the key pro-neutrophilic cytokines and chemokines IL-
8, IL-6 and GMCSF by PBEC cultures from people with CF. This showed that 
stimulation of PBECs with IL-17 resulted in significant increases in the release of these 
key mediators.  
 
IL-8 is a potent chemoattractant and activator of neutrophils and is the dominant 
neutrophil chemokine in the sputum of people with CF during an infective exacerbation. 
(Standiford et al., 1993, McAllister et al., 2005, Downey et al., 2009) A substantial 
literature also shows that IL-8 is involved in airway angiogenic structural remodelling. 
(Walters et al., 2008) Stimulation with IL-17 resulted in a significant increase in IL-8 
production in all of my CF PBEC experiments. This data is therefore consistent with a 
potential contributory role in neutrophilic airway inflammation and remodelling in CF. 
The growth factor GMCSF displays pleiotropic effects on neutrophil proliferation, 
maturation, activation and inhibition of apoptosis. (Barreda et al., 2004) My finding that 
treatment of PBECs with IL-17 caused increased GMCSF production, is also therefore 
consistent with a broad association between IL-17, epithelial cells and neutrophilic 
inflammation in CF. Furthermore, in the context of myocarditis, there is evidence to 
suggest that GMCSF plays a key role in the generation and maintenance of TH-17 cells 
via regulation of IL-23 and IL-6 in vivo. (Sonderegger et al., 2008) 
 
Production of IL-6 was also increased significantly following treatment with 10 and 100 
ng/mL IL-17 with a clear but non-significant trend towards increased levels at 1 ng/mL. 
IL-6 plays a key role in the acute phase inflammatory response. (Gabay, 2006) 
Furthermore, IL-6 induces IL-17 production from human central memory CD4+ T-cells. 
(Yang et al., 2008) Together with my finding that neutrophils themselves are a source 
of IL-17, the increase in IL-6 production by PBECs following IL-17 treatment 
represents a further potential aspect of a positive feedback loop, and augmentation of 
IL-17 responses. Furthermore, it has recently been shown that following stimulation 
with IL-17, IL-6 production by bronchial epithelial cells with intact CFTR function is 
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enhanced when co-cultured with basophils compared to when cultured alone. (Wong et 
al., 2010)              
 
It was apparent that there was a high degree of variability in the production of IL-8, 
GMCSF and IL-6 in PBECs isolated from different individuals. This reflects previously 
described inherent biological heterogeneity in chemokine and cytokine production, and 
is in keeping with the experiences of other researchers with PBECs. (Becker et al., 
2004) Interestingly the findings in my ex vivo system resonate with the biological 
variability seen in the human CF lung disease phenotype, although all of these patients 
ultimately developed advanced lung disease. (O'Sullivan and Freedman, 2009, 
Rowntree and Harris, 2003)   
 
The finding that airway wall neutrophils stain positively for IL-17 does not necessarily 
mean that they are the source of the ligand. Neutrophils express the IL-17 receptor and 
can bind IL-17. (Ye et al., 2001b) However, this would appear to be an unlikely sole 
explanation due to the diffuse intra-cellular staining that we identified. If IL-17 is 
adherent to receptors on neutrophils this may also represent a biologically significant 
reservoir that is potentially released in to the microenvironment following neutrophil 
necrosis. (Watt et al., 2004, Haslett, 1999) My finding of positive staining for RORγ in 
airway mucosa neutrophils provides further evidence to support the hypothesis that 
neutrophils themselves may be a source of IL-17 in the airway. 
 
Other findings in the published literature pertinent to a role for IL-17 in CF lung disease 
include the report that immortalised airway epithelial cells that do not express 
functional CFTR upregulate their innate immune responses following stimulation with 
IL-17. (Roussel and Rousseau, 2009) In particular, nucleotide-binding oligomerisation 
domain 1 is increased. (Roussel and Rousseau, 2009) IL-17 has also been demonstrated 
to modulate bicarbonate secretion in normal airway epithelial cells. (Kreindler et al., 
2009) 
 
Although my study includes potentially significant observations, it has limitations. This 
work was clearly limited to a study of advanced CF lung disease, utilising a well-
characterised and substantive tissue archive that I helped establish.  However, this 
precluded any meaningful exploration of clinical associations and did not include any 
individuals with less severe lung disease. Further work, in earlier stages of CF lung 
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disease, in less severe phenotypes and in patients with differing microbiology are 
therefore warranted. Lung tissue from people with non-CF bronchiectasis would also be 
an important future comparative group. 
 
The suggestion that IL-17 is produced by airway neutrophils was achieved using 
unambiguous, immunolocalisation using an affinity-purified, specific antibody. (Le 
Gouvello et al., 2008) I clearly showed IL-17 positive, intra-epithelial neutrophils. My 
results do not however indicate what the levels of local IL-17 release are at this precise 
intra-epithelial site. In particular, concentrations at the immunological interface between 
neutrophils, lymphocytes and epithelial cells are not known. 
 
The detection of IL-17 in airway lavage fluid from explanted CF lungs is an important 
finding, albeit at relatively low levels. It is particularly significant when considered in 
the context of the previous work performed by Dr Des Murphy in Newcastle where IL-
17 was universally undetectable using the same ultrasensitive ELISA, in addition to a 
number of other commercially available ELISA kits, in 180ml BALs from healthy 
volunteers and lung allograft recipients at the time of clinical stability, acute rejection or 
with broncholitis obliterans syndrome. (Murphy, 2008) (DM Murphy, personal 
communication) The inevitable difference in lavage technique between the BAL in 
healthy volunteers performed by Dr Murphy and the smaller volume airway lavages of 
explanted CF lungs should be noted however.  
 
In agreement with my findings in CF, researchers in Pittsburgh, USA, have found 
similar levels of IL-17 (in the region of 40-200pg/mL) to my results in BAL from adults 
and children with CF during an infective exacerbation. (McAllister et al., 2005, Dubin 
et al., 2007)  Lower levels of IL-17 (0.5-1.5pg/mL) have recently been reported by 
Glader et al. in BAL fluid from healthy human volunteers following experimental 
airway exposure to endotoxin. (Glader et al., 2010)  
 
Interestingly in the same study IL-23 was undetectable in BAL following challenge 
with vehicle alone but was detectable at low levels (2-20pg/mL) in some samples post-
endotoxin challenge. (Glader et al., 2010) I measured detectable levels of IL-23 in BAL 
from 8 of 26 explanted CF lungs.  
 
 160 
The work in this chapter describes elevated IL-17 in the airways of patients with 
advanced CF lung disease and the first description that neutrophils are a potential source 
of this key cytokine in human airway. This should stimulate further translational work 
as well as other approaches including appropriate animal models. Such work may be 
particularly important in CF, but may also be relevant in other lung pathophysiologies 
involving neutrophil biology such as chronic obstructive pulmonary disease, asthma, 
non-CF bronchiectasis, adult respiratory distress syndrome, chronic allograft rejection 
and viral bronchiolitis. (Alcorn et al., 2010, Tsushima et al., 2009, Robertson et al., 
2009, McNamara et al., 2003, Eastham et al., 2004) 
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7. Chapter 7. Ceramide and cystic fibrosis lung disease 
 
 
Elements of the work described in this chapter have been previously reported in the 
form of presentations at medical and scientific meetings and in a peer-reviewed paper. 
(Brodlie et al., 2009b, Brodlie et al., 2009d, Brodlie et al., 2010b, Brodlie et al., 2010a) 
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7.1. Abstract 
 
Background: Ceramide accumulates in the airway epithelium of cystic fibrosis 
transmembrane conductance regulator-deficient mice resulting in susceptibility to 
Pseudomonas aeruginosa infection and inflammation. The primary aim of the work 
described in this chapter was to quantitatively investigate ceramide levels in the lower 
airway of people with cystic fibrosis compared to pulmonary hypertension, emphysema 
and lung donors. In addition I examined relationships between levels of immunoreactive 
ceramide in the lower airway epithelium and markers of neutrophils and colonisation 
with Pseudomonas aeruginosa.  
Methods: Immunohistochemistry was performed on the lower airway epithelium of 
explanted lungs (8 cystic fibrosis, emphysema and pulmonary hypertension 
respectively) and 8 donor lungs using ceramide, neutrophil elastase and 
myeloperoxidase antibodies. High performance liquid chromatography-mass 
spectrometry was performed on tissue from 5 cystic fibrosis and 5 pulmonary 
hypertension lungs.  
Results: Staining for ceramide was significantly increased in the lower airway 
epithelium of people with cystic fibrosis (median 14.11% surface area) compared to 
pulmonary hypertension (3.03%, P=0.0009), unused lung donors (3.44%, P=0.0009) 
and emphysema (5.06%, P=0.01). Ceramide staining was increased in emphysematous 
lungs compared to pulmonary hypertension (P=0.0135) and unused donors (P=0.0009). 
The number of neutrophil elastase and myeloperoxidase positive cells in the airway was 
positively correlated with the percentage of epithelium staining for ceramide (P=0.001). 
Ceramide staining was significantly increased in lungs colonised with Pseudomonas 
aeruginosa (10.1%) compared to those not colonised (3.14%, P=0.0106). Significantly 
raised levels of ceramides C16:0, C18:0 and C20:0 were detected by mass spectrometry 
in cystic fibrosis lungs compared to pulmonary hypertension. Differences in C22:0 were 
not significant. 
Conclusion: Immunoreactive ceramide is increased in the lower airway epithelium of 
people with advanced cystic fibrosis. Detected by mass-spectrometry ceramide species 
C16:0, C18:0 and C20:0 but not C22:0 are increased. 
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7.2. Introduction 
 
As outlined in earlier chapters of this thesis, CF is a chronic condition caused by 
abnormalities in the CFTR gene that is associated with life-long morbidity and 
mortality. (Ratjen, 2009, Davies et al., 2007) Over 95% of morbidity and mortality in 
CF is associated with lung disease. (Doring et al., 2007) Promising developments in 
clinical care have yielded an increase in survival for people with CF over recent 
decades, however, the exact pathogenesis of CF lung disease remains poorly 
understood. (Dodge et al., 2007, O'Sullivan and Freedman, 2009)  
 
The sphingolipid ceramide is an essential component of plasma membranes and 
regulates many physiological cellular functions including apoptosis and responses to 
stress and cytokines. (Uhlig and Gulbins, 2008) There is also growing evidence that 
sphingolipids play a central role in the pathogenesis of several lung diseases, including 
acute lung injury, viral infection, asthma, emphysema and CF. (Niessen et al., 2008, 
Oskeritzian et al., 2007, Teichgraber et al., 2008, Petrache et al., 2005, Grassme et al., 
2005, Noe et al., 2009)  
 
Chronic infection with P. aeruginosa and intense neutrophilic inflammation are two 
hallmarks of CF lung disease. (Davidson et al., 1995, Downey et al., 2009) Teichgraber 
et al. (2008) recently demonstrated that CFTR-deficient mice accumulate ceramide in 
airway epithelial cells.  Furthermore, ceramide accumulation triggered chronic 
pulmonary inflammation, death of airway epithelial cells and extracellular deposition of 
DNA in the airways, thereby increasing susceptibility to infection with P. aeruginosa. 
(Teichgraber et al., 2008) Treatment with the tricyclic antidepressant amitriptyline 
normalised pulmonary ceramide and susceptibility to P. aeruginosa infection in CFTR-
deficient mice. (Becker et al., 2010b, Teichgraber et al., 2008) Ceramide accumulation 
was also shown in nasal epithelial cells and demonstrated at a qualitative level in three 
sections of airway from people with CF. (Teichgraber et al., 2008)  
 
In contrast, low plasma levels of ceramide have been reported by Guilbault et al. (2008a 
and 2008b) in people with CF compared to healthy volunteers.  The same researchers 
also found reduced levels of ceramide in the plasma, lungs, pancreas and ileum of 
CFTR-deficient mice that could be corrected by treatment with fenretinide. (Guilbault et 
al., 2008b, Guilbault et al., 2008a) The potential broad importance of ceramide biology 
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to lung homeostasis is indicated by the recent finding that in lung endothelial cells 
CFTR function is required for stress-induced apoptosis by maintaining ceramide 
activation. (Noe et al., 2009)  
 
The findings of current research into ceramide and CF pathophysiology are divergent 
however, and possibly specific to the model systems studied. (Guilbault et al., 2008b, 
Guilbault et al., 2008a, Teichgraber et al., 2008)  Hence, Yu et al. found no significant 
difference in basal ceramide levels in IB3-1 immortalised CF bronchial epithelial cells 
and lung homogenate from CFTR knock out mice compared to wild type cells and mice. 
(Yu et al., 2009)  
 
The lower airways are the site of major pathology in human CF lung disease. (Hamutcu 
et al., 2002) The aim of the work described in this chapter was therefore to investigate 
the hypothesis that ceramide accumulates in the lower airway of people with advanced 
CF lung disease. In light of the findings of Teichgraber et al. (2008) outlined above, 
relationships between levels of epithelial ceramide and markers of neutrophilic 
inflammation and colonisation with P. aeruginosa were also investigated.  
 
 
 
 
 
 
 165 
7.3. Aims 
 
The aims of the work described in this chapter were to: 
  
• Investigate levels of ceramide in the lower airway of people with advanced 
cystic fibrosis lung disease. More specifically to: 
o Quantify immunoreactive ceramide localised to the lower airway 
epithelium in advanced CF lung disease compared to pulmonary 
hypertension, emphysema and, previously healthy, unused lung donors. 
o Quantify the specific ceramide species C16:0, C18:0, C20:0 and C22:0 
in whole lung tissue from people with advanced CF lung disease 
compared to pulmonary hypertension by the independent technique of 
high performance liquid chromatography-mass spectrometry. 
• Correlate the amount of immunoreactive ceramide in the lower airway 
epithelium in advanced CF lung disease, pulmonary hypertension, emphysema 
and unused lung donors with levels of neutrophilic inflammaion in the lower 
airway mucosa, as measured by the number of cells staining positive for 
neutrophil elastase and myeloperoxidase per mm of basement membrane. 
• Investigate the relationship between the amount of immunoreactive ceramide in 
the lower airway epithelium in advanced cystic fibrosis lung disease, pulmonary 
hypertension and emphysema, and colonisation with Pseudomonas aeruginosa. 
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7.4. Hypothesis 
 
The work in this chapter examines the hypothesis that ceramide is raised in the lower 
airway epithelium of people with advanced CF lung disease. 
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7.5. Results 
 
7.5.1. Immunohistochemistry for ceramide in the lower airway epithelium in 
advanced cystic fibrosis lung disease, pulmonary hypertension, emphysema and 
unused lung donors 
 
Immunohistochemistry was performed on sections of medium-large lower airway from 
explanted lungs removed at the time of transplantation from 8 people with advanced CF 
lung disease, PH and emphysema respectively. The clinical details of these 24 patients 
are provided in Table 13. Airway sections were also obtained from 8 donor lungs that 
were assessed but not used for lung transplantation. Haematoxylin and eosin stained 
sections of airway from these blocks were independently evaluated to be free from 
fibrosis and significant inflammation as previously described. (Ward et al., 2005) 
 
Historically a lack of appropriate antibodies has limited the study of ceramide and other 
sphingolipids in biological systems. However, two antibodies have become 
commercially available in recent years, namely a mouse IgM anti-ceramide monoclonal 
antibody (Clone MID 15B4, Sigma-Aldrich) and a polyclonal mouse, antiserum 
enriched for IgM, anti-ceramide antibody (Clone S58-9, Glycobiotech). In lipid overlay 
assays the polyclonal antibody has been demonstrated to have favourable specificity for 
ceramide and dihydroceramide compared to the monoclonal antibody. (Cowart et al., 
2002) In order to adopt the most thorough approach possible I performed 
immunohistochemistry using each of the antibodies.  
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Age* Transplant† Diagnosis    
(CFTR variant) 
Sputum microbiology 
23§ SSL Cystic fibrosis  
(p.Phe508del / p.Phe508del) 
P. aeruginosa,  
S. maltophilia 
26 SSL Cystic fibrosis 
(p.Phe508del / p.Phe508del) 
P. aeruginosa,  
S. apiospermum 
25§ SSL Cystic fibrosis  
(Unknown) 
P. aeruginosa 
57 SSL Cystic fibrosis  
(p.Arg117His / p.Arg553X) 
P. aeruginosa 
26§ SSL Cystic fibrosis  
(Unknown) 
P. aeruginosa,  
A. fumigatus 
28§ SSL Cystic fibrosis  
(F508del/F508del) 
P. aeruginosa,  
A. fumigatus 
14 SSL Cystic fibrosis  
(Unknown) 
P. aeruginosa,  
C. parapsilosis 
32 SSL Cystic fibrosis  
(Unknown) 
P. aeruginosa,  
B. vietnamiensis 
53 HL Pulmonary hypertension Nil 
60 HL Pulmonary hypertension Nil 
52 HL Pulmonary hypertension Nil 
25 HL Pulmonary hypertension Nil 
36 HL Pulmonary hypertension Nil 
51 HL Pulmonary hypertension Nil 
37§ HL Pulmonary hypertension Nil 
52 HL Pulmonary hypertension Nil 
46 SL Emphysema Nil 
59 SSL Emphysema P. aeruginosa 
37 SSL Emphysema P. aeruginosa 
51 SSL Emphysema M. catarrhalis,  
Serratia sp. 
47 SL Emphysema Nil 
33 SSL Emphysema P. aeruginosa 
54 SSL Emphysema M. catarrhalis 
58 SSL Emphysema P. aeruginosa 
 
Table 13. Clinical details of the patients undergoing lung transplantation used for 
ceramide immunohistochemistry 
Abbreviations: *Age in years at time of transplant (complete years only). †SSL bilateral 
single sequential lung transplant, SL single lung transplant, HL heart-lung transplant. 
§Patient also used for high performance liquid chromatography-mass spectrometry 
(Table 14). 
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7.5.2. Glycobiotech polyclonal mouse, antiserum enriched for IgM, anti-ceramide 
antibody 
 
Staining for ceramide using the Glycobiotech antibody was significantly increased in 
the lower airway epithelium of people with CF (median 14.11%) compared to PH 
(3.03%, P=0.0009), unused lung donors (3.44%, P=0.0009) and emphysema (5.06%, 
P=0.01) (Figure 53). Ceramide staining was significantly increased in emphysematous 
lungs compared to PH (P=0.0135) and unused donors (P=0.0009) (Figure 53). 
Representative staining using the Glycobiotech antibody is illustrated from people with 
CF, emphysema, PH and unused lung donors in Figure 54. Appropriate negative 
controls; no primary antibody added and istotype control are also shown in Figure 54. 
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Figure 53. Percentage of epithelium staining positive for ceramide with 
Glycobiotech antibody. 
Each symbol represents an individual patient and is the mean of the percentage 
epithelium staining positive in five randomly selected high power fields.  
The horizontal bar represents the median for each group. 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, UD unused lung donors, 
Em emphysema. 
*P=0.0135, **P=0.01, ***P=0.0009. Mann-Whitney tests, Holm-Bonferonni correction 
applied. (Mann and Whitney, 1947, Holm, 1979) 
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Figure 54. Representative staining for ceramide with Glycobiotech antibody, (a) in 
a person with advanced cystic fibrosis lung disease, (b) emphysema, (c) 
pulmonary hypertension, (d) emphysema and (e) negative control (isotype 
IgM cystic fibrosis airway). 
 
(a) 
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7.5.3. Sigma monoclonal IgM anti-ceramide antibody 
 
Staining for ceramide using the Sigma antibody was significantly increased in the lower 
airway epithelium of people with CF (median 13.45%) compared to PH (4.62%, 
P=0.01) and unused lung donors (3.22%, P=0.005) (Figure 55). There was no 
statistically significant difference between people with CF (13.45%) and emphysema 
(6.35%, P=0.1278) using the monoclonal antibody (Figure 55). Staining for ceramide 
was significantly greater in emphysematous lungs (6.35%) compared to PH (4.62%, 
P=0.0136) and unused donors (3.22%, P=0.0009) (Figure 55). Representative staining 
using the Sigma antibody is illustrated from people with CF, emphysema, PH and 
unused lung donors in Figure 56. Appropriate negative controls; no primary antibody 
added and istotype control are also shown in Figure 56. 
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Figure 55. Percentage of epithelium staining positive for ceramide with Sigma 
antibody. 
Each symbol represents an individual patient and is the mean of the percentage 
epithelium staining positive in five randomly selected high power fields.  
The horizontal bar represents the median for each group. 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, UD unused lung donors, 
Em emphysema. 
*P=0.01, **P=0.005, ***P=0.0009, n/s non-significant. Mann-Whitney tests, Holm-
Bonferonni correction applied. (Mann and Whitney, 1947, Holm, 1979) 
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Figure 56. Representative staining for ceramide with Sigma antibody, (a) in a 
person with advanced cystic fibrosis lung disease, (b) emphysema, (c) 
pulmonary hypertension, (d) emphysema and (e) negative control (isotype 
IgM cystic fibrosis airway). 
 
(a)
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(b) 
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(c)
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(d) 
 
 182 
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7.5.4. Comparison of Glycobiotech polyclonal mouse, antiserum enriched for IgM, 
anti-ceramide antibody and Sigma monoclonal IgM anti-ceramide antibody 
 
As mentioned earlier in this chapter, in lipid overlay assays the Glycobiotech polyclonal 
antibody has been demonstrated to have favourable specificity for ceramide and 
dihydroceramide compared to the Sigma monoclonal antibody. (Cowart et al., 2002) 
Examination of Figure 54 and Figure 56 allows comparison of the typical staining 
appearances with each antibody. A Bland-Altman plot of average against difference is 
shown in Figure 57. (Bland and Altman, 1986) As one would expect there was a degree 
of variability in staining between the two antibodies. However, there was no systematic 
bias in the measurements, i.e. one antibody was not systematically providing higher 
percentage staining compared to the other (bias -0.07742%, standard deviation of bias 
±3.164, 95% limits of agreement -6.280% and +6.125%) (Figure 57). 
 
 
 
 
Figure 57. Bland-Altman plot comparing lower airway epithelial staining with the 
Glycobiotech polyclonal mouse, antiserum enriched for IgM, anti-ceramide 
antibody and Sigma monoclonal IgM anti-ceramide antibody 
Bias -0.07742% (standard deviation of bias ±3.164) 
95% limits of agreement (dashed lines) -6.280% and +6.125% 
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7.5.5. Investigation of the reproducibility of percentage epithelium staining positive 
measurements 
 
In order to investigate the reproducibility of my measurements of the percentage 
epithelium staining positive I performed a Bland-Altman analysis. I blindly repeated the 
measurements on a random selection of three patients from each group stained with the 
Glycobiotech ceramide antibody. Figure 58 displays the Bland-Altman plot. A degree of 
variability is evident but no systematic bias between each occasion. 
 
 
 
 
Figure 58. Bland-Altman plot of difference against average for repeat 
measurements of percentage epithelium positive for ceramide using 
Glycobiotech ceramide antibody 
Bias -0.4813, 95% limits of agreement -3.622 to 2.659 (dotted lines)  
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7.5.6. Immunohistochemistry for neutrophil elastase in the lower airway mucosa in 
advanced cystic fibrosis lung disease, pulmonary hypertension, emphysema and 
unused lung donors 
 
The CF airway is characterised by neutrophilic inflammation and as one would expect I 
found significantly more neutrophil elastase positive cells/millimetre basement 
membrane in people with CF (median 203.5) compared to PH (2.8, P=0.0002), 
emphysema (14.9, P=0.0003) and unused donors (9.2, P=0.0002) (Figure 59). (Hays 
and Fahy, 2006, Downey et al., 2009) Representative staining for neutrophil elastase in 
each of the respective groups is shown in Figure 60. A negative isotype control is also 
shown in Figure 60. 
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Figure 59. Number of neutrophil elastase positive cells in the lower airway mucosa 
in advanced cystic fibrosis lung disease, pulmonary hypertension, 
emphysema and unused lung donors 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, UD unused lung donors, 
Em emphysema. 
Horizontal bars indicate the median for each group. 
Mann-Whitney tests, Holm-Bonferonni correction applied. (Mann and Whitney, 1947, 
Holm, 1979)
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Figure 60. Representative staining for neutrophil elastase in the lower 
airway mucosa in advanced cystic fibrosis lung disease (a), pulmonary 
hypertension (b), emphysema (c), unused lung donor (d) and 
immunoglobulin G1 isotype negative control (e). 
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(d) 
 
 191 
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7.5.7. Immunohistochemistry for myeloperoxidase in the lower airway mucosa in 
advanced cystic fibrosis lung disease, pulmonary hypertension, emphysema and 
unused lung donors 
 
Similarly to neutrophil elastase, I found significantly increased myeloperoxidase 
positive cells/millimetre basement membrane in people with CF (median 299.3) 
compared to PH (14.8, P=0.0002), emphysema (20.5, P=0.0002) and unused lung 
donors (6.8, P=0.0002) (Figure 61).  Representative staining for myeloperoxidase in 
each of the respective groups is shown in Figure 62. A negative isotype control is also 
shown in Figure 62. 
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Figure 61. Number of myeloperoxidase positive cells in the lower airway mucosa in 
advanced cystic fibrosis lung disease, pulmonary hypertension, emphysema 
and unused lung donors 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, UD unused lung donors 
and Em emphysema. 
Horizontal bars indicate the median for each group. 
Mann-Whitney tests, Holm-Bonferonni correction applied. (Mann and Whitney, 1947, 
Holm, 1979) 
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Figure 62. Representative staining for myeloperoxidase in the lower airway 
mucosa in advanced cystic fibrosis lung disease (a), pulmonary 
hypertension (b), emphysema (c), unused lung donors (d) and rabbit 
immunoglobulins negative control (e) 
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(e) 
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7.5.8. Correlation between epithelial staining for ceramide and neutrophilic 
inflammation 
 
There was a positive correlation between the number of neutrophil elastase positive 
cells/millimetre basement membrane and percentage of epithelium staining positive for 
ceramide with the Glycobiotech antibody (Pearson correlation 0.634, P<0.000) and the 
Sigma antibody (Pearson correlation 0.574, P=0.001) across all groups (Figure 63 and 
Figure 64 respectively). Similarly, I found a positive correlation between the number of 
myeloperoxidase positive cells/millimetre basement membrane and percentage of 
epithelium staining positive for ceramide with the Glycobiotech antibody (Pearson 
correlation 0.704, P<0.000) and the Sigma antibody (Pearson correlation 0.577 
P=0.001) across all groups (Figure 65 and Figure 66). 
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Figure 63. Scatter plot of number of neutrophil elastase positive cells in the lower 
airway mucosa against percentage of epithelium staining positive for 
ceramide with Glycobiotech antibody across all groups 
Pearson correlation 0.634 (P<0.000) 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, Em emphysema, UD 
unused donor 
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Figure 64. Scatter plot of number of neutrophil elastase positive cells in the lower 
airway mucosa against percentage of epithelium staining positive for 
ceramide with Sigma antibody across all groups 
Pearson correlation 0.574 (P=0.001) 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, Em emphysema, UD 
unused donor 
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Figure 65. Scatter plot of number of myeloperoxidase positive cells in the lower 
airway mucosa against percentage of epithelium staining positive for 
ceramide with Glycobiotech antibody across all groups 
Pearson correlation 0.704 (P<0.000) 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, Em emphysema, UD 
unused donor 
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Figure 66. Scatter plot of number of myeloperoxidase positive cells in the lower 
airway mucosa against percentage of epithelium staining positive for ceramide 
with Sigma antibody across all groups 
Pearson correlation 0.577 (P=0.001) 
Abbreviations: CF cystic fibrosis, PH pulmonary hypertension, Em emphysema, UD 
unused donor 
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7.5.9. Relationship between epithelial staining for ceramide and colonisation with 
Pseudomonas aeruginosa 
 
In view of the finding that ceramide accumulation in CFTR-deficient mice has been 
shown to increase susceptibility to infection with P. aeruginosa. (Teichgraber et al., 
2008) I analysed my results for ceramide staining in people with CF, PH and 
emphysema with regard to the presence or absence of colonisation with P. aeruginosa, 
as judged by standard pre-operative sputum culture (Table 13). (Forrest et al., 2005, 
Meachery et al., 2008, Corris, 2008) Ceramide staining with the Glycobiotech antibody 
was significantly increased in lungs colonised with P. aeruginosa (median 10.1%) 
compared to those not colonised across all disease groups (3.1%, P=0.0106) (Figure 
67). It was also significantly increased with the monoclonal antibody in lungs colonised 
with P. aeruginosa (median 11.9%) compared to those not colonised (5.3%, P=0.0337) 
(Figure 68). 
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Figure 67. Percentage of epithelium staining positive for ceramide with 
Glycobiotech antibody in patients colonised with Pseudomonas aeruginosa 
compared to those not colonised across all disease groups 
Abbreviations: PA patients colonised with Pseudomonas aeruginosa, No PA patients 
free of Pseudomonas aeruginosa. 
Legend:  cystic fibrosis, pulmonary hypertension,  emphysema 
Mann-whitney test comparing each group. 
The horizontal lines indicate the median in each group. 
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Figure 68. Percentage of epithelium staining positive for ceramide with Sigma 
antibody in patients colonised with Pseudomonas aeruginosa compared to 
those not colonised across all disease groups 
Abbreviations: PA patients colonised with Pseudomonas aeruginosa, No PA patients 
free of Pseudomonas aeruginosa. 
Legend:  cystic fibrosis, pulmonary hypertension,  emphysema 
Mann-whitney test comparing each group. 
The horizontal lines indicate the median in each group. 
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7.5.10. Quantification of specific ceramide species in lung tissue from people with 
advanced cystic fibrosis lung disease and pulmonary hypertension by high-
performance liquid chromatography mass spectrometry 
 
When considered in more detail ceramides are in reality a family of more than 50 
molecularly distinct molecules. (Novgorodov and Gudz, 2009) Each specific ceramide 
consists of sphingosine and a fatty acid. (Hannun and Obeid, 2008) It is highly probable 
that specific species of ceramide are of particular importance to disease, as highlighted 
by the work of Guilbault et al. in the plasma of people with CF and by Hamai et al. in 
immortalised epithelial cell lines that express defective CFTR. (Guilbault et al., 2008a, 
Hamai et al., 2009) I therefore also used the independent technique of HPLC-MS to 
quantify levels of the specific ceramide species C16:0, C18:0, C20:0 and C22:0 in 
homogenates of 5 explanted CF lungs and 5 PH lungs. The clinical details of these 
patients are provided in Table 14. 
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Age* Patient 
number§ 
Transplant† Diagnosis 
(CFTR genotype) 
Sputum microbiology 
15 1 HL Pulmonary 
hypertension 
Negative 
37‡ 2 HL Pulmonary 
hypertension 
Negative 
45 3 HL Pulmonary 
hypertension 
Negative 
32 4 HL Pulmonary 
hypertension 
Negative 
32 5 HL Pulmonary 
hypertension 
Negative 
26‡ 6 SSL Cystic fibrosis 
(Unknown) 
Alcaligines xylosoxidans 
Aspergillus fumigatus 
22 7 SSL Cystic fibrosis 
(Unknown) 
Burkholderia multivorans 
25‡ 8 SSL Cystic fibrosis 
(Unknown) 
Pseudomonas aeruginosa 
28‡ 9 SSL Cystic fibrosis 
(F508del/F508del) 
Pseudomonas aeruginosa 
Aspergillus fumigatus 
23‡ 10 SSL Cystic fibrosis 
(F508del/F508del) 
Pseudomonas aeruginosa 
Stenotrophomonas 
maltophilia 
 
Table 14. Clinical details of the patients undergoing lung transplantation used for 
high performance liquid chromatography-mass spectrometry 
*Age in years at time of transplant (completed years only). †SSL: bilateral single 
sequential lung transplant, HL: heart-lung transplant. ‡Patient also used for 
immunohistochemistry (Table 13). §See Table 16 and Table 17. 
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7.5.11. Generation of calibration curves for ceramides C16:0, C18:0, C20:0 and 
C22:0 
 
Calibration curves were constructed from triplicate readings of a mixture of standards of 
the 4 ceramides at 5, 0.5, 0.05 and 0.005 pmoles. Table 15 shows the calibration data 
for each of the specific ceramides. Figures 16 to 19 show the calibration curves for 
ceramides C16:0, C18:0, C20:0 and C22:0 respectively. 
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Concentration 
(pmoles) Peak area under curves 
 C16:0 C18:0 C20:0 C22:0 
5 321454794 338757912 386878421 461716911 
5 309895960 394520533 394408476 394636261 
5 337470071 391280778 378286076 385015360 
0.5 50499758 56725146 80340968 81024680 
0.5 53036558 68302685 81008837 77468080 
0.5 59397105 76549954 75690065 75153958 
0.05 5169044 5194721 8324085 7497218 
0.05 5453865 7215912 8551650 8618399 
0.05 6695481 8077005 7970736 8654490 
0.005 256436 324888 464547 279308 
0.005 378237 448890 510001 414620 
0.005 463414 516844 535174 440815 
 
Table 15. Calibration data for high performance liquid chromatography-mass 
spectrometry ceramide standards 
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Figure 69. Calibration plot for ceramide C16:0 standard 
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Figure 70. Calibration plot for ceramide C18:0 standard 
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Figure 71. Calibration plot for ceramide C20:0 standard 
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Figure 72. Calibration plot for ceramide C22:0 standard 
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7.5.12. Analysis of homogenates of explanted cystic fibrosis and pulmonary 
hypertension lungs 
 
7.5.13. Amount of ceramide per mass of wet tissue 
 
Figure 73 to Figure 76 show the amounts of C16:0, C18:0, C20:0 and C22:0 
respectively measured in each lung per mass of wet tissue. The median levels were 
significantly increased in the CF lungs compared to PH for C16:0 (10.01 and 2.92 
pmoles/mg, P=0.0216), C18:0 (1.09 and 0.31 pmoles/mg, P=0.0367) and C20:0 (0.70 
and 0.17 pmoles/mg, P=0.0216) ceramides. The difference was not significant for 
C22:0 (2.90 and 1.82pmoles/mg, P=0.1437). 
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Figure 73. Amount of C16:0 ceramide per mass of wet tissue in the parenchyma of 
explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis. 
Mann-whitney test.
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Figure 74. Amount of C18:0 ceramide per mass of wet tissue in the parenchyma of 
explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis  
Mann-whitney test.
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Figure 75. Amount of C20:0 ceramide per mass of wet tissue in the parenchyma of 
explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
Mann-whitney test. 
PH CF
0.0
0.5
1.0
1.5
2.0
P = 0.0216 
C2
0:
0 
ce
ra
m
id
e (
pm
ol
es
/m
g)
 219 
 
 
 
 
Figure 76. Amount of C22:0 ceramide per mass of wet tissue in the parenchyma of 
explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis. 
Mann-whitney test. 
 
 
 
	  
PH CF
0
1
2
3
4
5
6
7
P = 0.1437
C2
2:
0 
ce
ra
m
id
e (
pm
ol
es
/m
g)
 220 
 
7.5.14. Amount of ceramide per micromole of phosphate 
 
I performed a further analysis using the concentration of phosphate in the lung 
homogenate as the denominator. The phosphate levels were quantified using the PiBlue 
assay described in Chapter 4. The standard curve for the assay is shown in Figure 77. 
The concentrations of phosphate in each homogenate are presented in Table 16. The 
data for the individual patients is displayed for ceramides C16:0, C18:0, C20:0 and 
C22:0 in Figure 78 to Figure 81 respectively. Despite trends towards increased levels in 
CF compared to PH with each ceramide species none of these differences were 
statistically significant (Figure 78 to Figure 81). 
 221 
 
 
 
Figure 77. Phosphate assay standard curve 
Each symbol represents the mean of triplicate measurements 
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Patient number Phosphate* 
(µM) 
1 7.59 
2 11.98 
3 6.86 
4 9.52 
5 8.27 
6 9.00 
7 5.90 
8 4.97 
9 38.93 
10 6.20 
 
Table 16. Phosphate concentration for each lung homogenate 
*mean of triplicate measurements
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Figure 78. Amount of C16:0 ceramide per micromole of phosphate in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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Figure 79. Amount of C18:0 ceramide per micromole of phosphate in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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Figure 80. Amount of C20:0 ceramide per micromole of phosphate in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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Figure 81. Amount of C22:0 ceramide per micromole of phosphate in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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7.5.15. Amount of ceramide per microgram of protein 
 
I performed a further analysis using the concentration of protein in the lung homogenate 
as the denominator. The protein levels were quantified spectroscopically using a 
Bradford protein assay as described in Chapter 4. The standard curve for the assay is 
shown in Figure 82. The concentrations of protein in each homogenate are presented in 
Table 17. The data for ceramides C16:0, C18:0, C20:0 and C22:0 per microgram of 
protein in each patient are displayed in Figure 83 to Figure 86 respectively. Despite 
trends towards increased levels in CF compared to PH with each ceramide species none 
this was only statistically significant in the case of C18:0.    
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Figure 82. Protein assay standard curve 
Each symbol represents the mean of triplicate assays. 
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Patient number Protein* 
(µg/mL) 
1 6.46 
2 10.49 
3 11.45 
4 29.16 
5 13.87 
6 12.86 
7 9.48 
8 13.28 
9 12.86 
10 10.21 
 
Table 17. Protein concentration for each lung homogenate 
*mean of triplicate measurements
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Figure 83. Amount of C16:0 ceramide per microgram of protein in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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Figure 84. Amount of C18:0 ceramide per microgram of protein in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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Figure 85. Amount of C20:0 ceramide per microgram of protein in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
PH CF
0.0
0.5
1.0
1.5
P = 0.0556
C2
0:
0 
ce
ra
m
id
e (
pm
ol
es
/µ
g 
pr
ot
ein
)
 233 
 
 
	  
	  
Figure 86. Amount of C22:0 ceramide per microgram of protein in the 
parenchyma of explanted cystic fibrosis and pulmonary hypertension lungs 
Each symbol represents an individual patient and is the mean of three independent 
measurements. The median of each group is represented by a horizontal bar. 
Abbreviations: PH pulmonary hypertension, CF cystic fibrosis 
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7.6. Discussion 
 
The data presented in this chapter provides the first quantitative immunohistochemical 
evidence to support the hypothesis that ceramide accumulates in the lower airway 
epithelial cells of people with CF, agreeing with previous descriptive data. (Teichgraber 
et al., 2008) It was of some interest that I found increased ceramide staining in 
emphysematous lungs compared to PH and unused lung donors, although this was at 
lower levels than in the people with CF. This is in keeping with previous work that has 
identified ceramide as a mediator in the development of emphysema, thought to act by 
inducing oxidative stress and apoptosis of alveolar endothelial and epithelial cells. 
(Petrache et al., 2005, Uhlig and Gulbins, 2008, Petrache et al., 2008) 
 
The precise role of epithelial ceramide accumulation in the pathogenesis of CF lung 
disease is yet to be fully elucidated. The work performed by Teichgräber et al. (2008) in 
mice suggests that ceramide accumulation occurs in a constitutive, age-dependent 
fashion in the airway epithelial cells of CFTR-deficient animals and promotes pro-
inflammatory cytokine release, apoptosis, DNA deposition in the airway and 
susceptibility to P. aeruginosa infection. It has previously been elegantly demonstrated 
that ceramide-enriched membrane platforms are central to epithelial defence against P. 
aeruginosa. (Grassme et al., 2003, Nieuwenhuis et al., 2002) Physiological levels of 
ceramide appear to be essential for the homeostasis of cells and inflammatory responses 
and therefore it is plausible that too little ceramide may be equally as deleterious to 
epithelial physiology as a situation where ceramide accumulation occurs. (Guilbault et 
al., 2008a) 
 
A proposed mechanism for ceramide accumulation is that defective CFTR leads to 
inappropriate alkalinisation of intracellular vesicles, in particular pre-lysosomes and 
lysosomes, resulting in an increase in acid sphingomyelase and reduction in acid 
ceramidase activity and subsequent ceramide accumulation. (Teichgraber et al., 2008) 
However, the role of CFTR in the acidification of lysosomes has been hotly debated 
recently with apparently contradictory results published by different investigators. 
(Haggie and Verkman, 2009a, Haggie and Verkman, 2009b, Di et al., 2006, Teichgraber 
et al., 2008, Poschet et al., 2002, Noe et al., 2009)  
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I found that staining for ceramide was not significantly increased in the lower airway 
epithelium in CF compared to end-stage emphysema using the Sigma monoclonal 
antibody. This may make a defective CFTR-specific mechanism for the accumulation of 
ceramide as a sole explanation, less likely. I would however emphasise that low 
numbers were used in this study and that it was not designed to investigate mechanisms 
of ceramide dysregulation. 
 
I found a positive association between the number of cells staining for the neutrophil 
products neutrophil elastase and myeloperoxidase in the airway and epithelial ceramide 
staining across all patients. This suggests a potential link between epithelial ceramide 
levels and neutrophilic inflammation in humans similar to that proposed in mice. 
(Teichgraber et al., 2008) In the lungs of CFTR-deficient mice Teichgräber et al. found 
a constitutive increase in the expression of IL-1 and keratinocyte-derived chemokine 
(KC), the mouse homolog of human IL-8. (Teichgraber et al., 2008) Inhibition of acid 
sphingomyelinase activity normalised levels of IL-1 and KC suggesting that cytokine 
upregulation is linked to ceramide accumulation.  It is known that children with CF who 
have P. aeruginosa infecting their lower airway have higher levels of IL-8, neutrophils 
and neutrophil elastase in bronchoalveloar lavage fluid compared to children free of 
lower respiratory tract P. aeruginosa infection. (Sagel et al., 2009) 
 
In contrast to my results and those of Teichgräber et al., Guilbault et al. found low 
plasma levels of ceramide in people with CF compared to healthy volunteers and 
similarly low levels in the plasma and organs of CFTR-deficient mice that could be 
corrected by treatment with fenretinide. (Guilbault et al., 2008b, Guilbault et al., 2008a, 
Teichgraber et al., 2008) Specifically, Guilbault et al. found decreased levels of several 
ceramide sphingolipid species in the plasma of people with CF, namely C14:0, C20:1, 
C22:0, C22:1, C24:0 and dihydroxy ceramide. (Guilbault et al., 2008a) One explanation 
proposed by the Gulbins group for the apparently discrepant results in mice is that 
CFTR-deficient strains that require high fat feeds, such as Peptamen®, develop 
artificially high cholesterol levels that subsequently reduce acid sphingomyelinase 
activity. (Becker et al., 2010b, Pier, 2008, Teichgraber et al., 2008) However, Guilbault 
et al. did not find low levels of ceramide in the plasma or lungs of CFTR-deficient mice 
after prolonged ingestion of Peptamen®. (Guilbault et al., 2008b) 
 
 236 
The prospective focus for my study was to evaluate levels of ceramide specifically in 
the lower airway epithelium of people with CF. As outlined in the introduction of this 
chapter, I did this because it is the site of the major pathology in CF lung disease. 
(Hamutcu et al., 2002) By using immunohistochemistry coupled with image analysis, 
quantification of ceramide was possible along with architectural resolution to the 
specific tissue compartment of interest, in human patients with CF. Correlations with 
neutrophil numbers, also determined by immunohistochemistry were also possible, 
which is potentially important given the salient importance of neutrophilic inflammation 
to the disease. (Downey et al., 2009) To strengthen my approach, 2 antibodies were 
used in the study.  
 
To confirm my findings and to allow quantification of specific ceramide species, 
namely C16:0, C18:0, C20:0 and C22:0, I used the independent technique of HPLC-MS 
on lung tissue from people with CF. Clearly analysis of whole lung homogenates using 
HPLC-MS does not allow the localisation to specific tissue compartments of interest in 
the lung, however.  A number of other ceramide species, for example C24:0 and C24:1, 
are known to be biologically important and abundant. (Haus et al., 2009) It may be that 
specific species are of particular importance to disease, as highlighted by the work of 
Guilbault et al. in the plasma of people with CF and by Hamai et al. in immortalised 
epithelial cell lines that express defective CFTR. (Guilbault et al., 2008a, Hamai et al., 
2009) The HPLC-MS method used in this study was not designed or optimised to 
characterise all species of ceramide, and I was therefore unable to measure the 
abundance of all potentially relevant ceramides in the lungs of people with advanced CF 
lung disease. This underlines a need for further translational studies in this area of 
research.  
 
A major strength of my work is that it involved human tissue, dissected directly from 
the complex milieu present in the CF lung. (Brodlie et al., 2010f) The correlation of 
findings in cellular or animal work to the actual human disease has been stated as vital. 
(Doring et al., 2007) Given the discrepant results regarding ceramide obtained in 
different models and compartments of CF disease, I feel that the additional human 
airway data provided by this study is a useful contribution to the current debate, offering 
a translational perspective to compliment the available science.  
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The number of individuals included in this study was modest. This unfortunately 
precludes analysis relating to CFTR genotype. Lung transplantation is an intervention 
for end-stage disease and therefore the span of ages was also insufficient to address the 
important question of whether or not ceramide accumulates in an age-dependent manner 
in people with CF, as has been described in CFTR-deficient mice. (Teichgraber et al., 
2008)  
 
At a basic level I was able to examine the level of ceramide staining in people with CF, 
PH and emphysema with consideration of the presence or absence of colonisation with 
P. aeruginosa. The finding that ceramide staining was increased in those colonised with 
P. aeruginosa concurs with the work of Teichgräber et al. in mice and suggests a 
putative link between epithelial ceramide accumulation and P. aeruginosa infection. 
(Teichgraber et al., 2008) Importantly however, P. aeruginosa colonisation is frequent 
in people with end-stage CF lung disease and indeed was universal in my study cohort. 
There was also a high prevalence of colonisation with P. aeruginosa in people with 
emphysema in this study. This is likely to reflect the severity of disease present in those 
who come forward for lung transplantation. (Murphy et al., 2008c) A larger sample size 
would be required to thoroughly evaluate possible inter-relationships between specific 
microbial infections and epithelial ceramide accumulation. Appropriately designed 
animal or cellular studies may also be of value in this area. Yu et al. have recently 
shown that in S9 immortalised human airway epithelial cells and the lungs of wild type 
mice there is a significant increase in acid sphingomyelinase and total ceramide levels 6 
hours after infection with P. aeruginosa. (Yu et al., 2009) This increase did not occur in 
the CF bronchial epithelial cell line IB3-1 or the lungs of CFTR knock out mice. (Yu et 
al., 2009) 
 
At a translational level my findings add weight to the suggestion that the accumulation 
of ceramide is a potential target for pharmacotherapy. Amitriptyline, along with a 
number of other agents, degrades acid sphingomyelinase, thereby reducing ceramide 
production, and has been shown to almost normalise ceramide levels and susceptibility 
to P. aeruginosa infection in CFTR-deficient mice. (Becker et al., 2010b, Teichgraber et 
al., 2008) The efficacy of amitriptyline in humans with CF is yet to be objectively 
evaluated however, along with potential safety issues relating to side effects and 
possible negative consequences for epithelial defence to infection if ceramide 
production is over-inhibited. (Becker et al., 2010b, Pier, 2008) This emphasises the need 
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for a multi-disciplinary approach to further study, and the importance of appropriate 
translational studies in patients. 
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8. Chapter 8. Reticular basement membrane thickness in advanced 
cystic fibrosis lung disease 
 
 
Elements of the work described in this chapter have been previously reported in the 
form of a presentation at a medical and scientific meeting. (Brodlie et al., 2009e) 
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8.1. Abstract 
 
Background: Cystic fibrosis lung disease is characterised by airflow obstruction, 
neutrophilic inflammation and chronic endobronchial infection. Apparent thickening of 
the sub-epithelial reticular basement membrane due to collagen matrix deposition is a 
characteristic feature of airway remodelling seen in people with asthma. Airway 
remodelling has also been implicated in the pathogenesis of cystic fibrosis lung disease 
and basement membrane thickening has been reported in endobronchial biopsies from 
children with cystic fibrosis. Changes in airway dimension have been described in 
explanted cystic fibrosis lungs but basement membrane thickness has not been 
thoroughly investigated in end-stage disease with divergent findings in limited studies 
to date. The primary objective of this study was to quantify RBM thickness in the 
airways of people with CF requiring lung transplantation. In the context of asthma, 
eosinophilic inflammation has been implicated in the pathogenesis of airway 
remodelling via the maintenance and progression of aberrant airway tissue injury and 
repair. I therefore also investigated any relationship between number of airway mucosa 
eosinophils and basement membrane thickness. Finally, it has been suggested that 
basement membrane thickness may increase with age and I therefore investigated any 
correlation between basement membrane thickness and age at time of transplant. 
Methods: Blocks of intermediate-large airway were dissected from the explanted lungs 
of 16 people with cystic fibrosis, median age 28 years [14.7 - 57.7], and fixed in 10% 
formalin and embedded in paraffin before 5µm sections were stained with haematoxylin 
and eosin. Basement membrane thickness was evaluated objectively by measuring the 
distance between two demarcating lines in 5 high-power fields using image analysis 
software. Comparison was made with basement membrane thickness measured in an 
earlier study of 22 healthy subjects and previously published normal measurements.  
Results: Median basement membrane thickness in the cystic fibrosis airways was 
9.58µm [range 7.15 - 13.56]. This compares to 7.7µm [5.2 - 9.6] in healthy subjects in 
the earlier study by Ward et al. (2002) (P=0.0008). Other published normal 
measurements for basement membrane thickness in formalin fixed tissue range from 2.9 
to 6.7µm. There was no apparent relationship between basement membrane thickness 
and number of mucosal eosinophils or age at time of transplant. 
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Conclusion: Reticular basement membrane thickness is significantly increased in 
advanced cystic fibrosis lung disease. This agrees with results in children and provides 
evidence of airway remodelling in advanced disease. In this dataset basement membrane 
thickness appears to be independent of the number of mucosal eosinophils and age. 
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8.2. Introduction 
 
As outlined earlier in this thesis, lung disease accounts for over 95% of morbidity and 
mortality in people with CF. (O'Sullivan and Freedman, 2009) CF lung disease is 
characterised by airflow obstruction, neutrophilic inflammation and chronic 
endobronchial infection. (Davies et al., 2007) Children with CF are born with airways 
of essentially normal structure however. (Konstan and Berger, 1997)    
 
Airway remodelling, in the form of architectural changes in the airway wall, is well 
recognised in people with asthma and chronic obstructive pulmonary disease (COPD). 
(Jeffery, 2001, Davies, 2009) One specific feature of airway remodelling seen in adults 
and children with asthma is apparent thickening of the sub-epithelial reticular basement 
membrane (RBM) due to collagen matrix deposition. (Ward et al., 2002, Payne et al., 
2003) It has also been postulated that airway remodelling may be implicated in the 
pathogenesis of CF lung disease and RBM thickening has been reported in 
endobronchial biopsies from children with CF. (Hilliard et al., 2007)  Clinical evidence 
of structural airway remodelling at an early stage in CF lung disease includes the 
observation that airway function is demonstrably abnormal in infants newly diagnosed 
clinically with CF. (Ranganathan et al., 2001)  Furthermore, their lung function does not 
improve despite intensive treatment, and the airway obstruction would appear to be 
‘fixed’. (Ranganathan et al., 2004)     
 
However, in an earlier study Durieu et al. examined RBM thickness in a mixture of 
endobronchial and lobectomy specimens from a total of 9 children and adults with a 
spectrum of severity of CF lung disease. (Durieu et al., 1998) Durieu et al. assessed the 
basal lamina thickness of the basement membrane qualitatively using immunostaining 
for murine laminin in fresh frozen sections and transmission electron microscopy. In 
contrast to the findings of Hilliard et al., they found the RBM to be thinned in the CF 
specimens compared to 3 healthy, non-smoking volunteers. (Hilliard et al., 2007, 
Durieu et al., 1998) A dense, fibrous, acellular sub-epithelial deposit was observed 
however. (Durieu et al., 1998) Wojnarowski et al. found the RBM to be thickened in 
association with a metaplastic epithelium in endobronchial biopsies taken from children 
during an acute exacerbation of CF. (Wojnarowski et al., 1999)  In this study the 
biopsies were fixed in paraformaldehyde and embedded in paraffin prior to 
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haematoxylin and eosin staining of 2µm sections. Biopsies from clinically stable 
children with CF were found to contain an intact respiratory epithelium with normal 
RBM appearances. (Wojnarowski et al., 1999) Changes in airway dimension have been 
described in explanted CF lungs but RBM thickness has not been specifically 
investigated in end-stage disease to the best of my knowledge. (Tiddens et al., 2000) 
 
Eosinophilic inflammation has been implicated in the pathogenesis of airway 
remodelling in asthma via the maintenance and progression of aberrant airway tissue 
injury and repair. (Holgate and Polosa, 2008) The biological activity of eosinophils is 
largely mediated by the release of stored granules containing potent cytotoxic proteins 
such as eosinophilic cationic protein, eosinophil peroxidase and major basic protein. 
(Stone et al., 2010) In addition, eosinophils produce oxygen radicals, lipid mediators 
and a wide range of pro-inflmmatory cytokines and chemokines. (Hamid and Tulic, 
2009) A number of cytokines produced by eosinophils are associated with remodelling 
and fibrosis, most notably TGF-β but also IL-6, IL-11, IL-13, IL-17 and IL-25. (Hamid 
and Tulic, 2009, Minshall et al., 1997)  Interestingly, Hilliard et al. found a positive 
correlation between RBM thickness and total TGF-β1 concentration in bronchoalveolar 
lavage fluid in chidren with CF. (Hilliard et al., 2007) 
 
In summary, there are contradictory reports in the literature regarding RBM thickness in 
CF lung disease and no descriptions of RBM thickness in end-stage disease. 
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8.3. Aims 
 
The objectives of the work described in this chapter were to 
 
1. Quantify RBM thickness in the lower airways of people with advanced CF lung 
disease requiring transplantation 
2. Investigate any relationship between RBM thickness and number of mucosal 
eosinophils 
3. Investigate any relationship between RBM thickness and age at time of lung 
transplantation 
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8.4. Hypothesis 
 
I hypothesised that RBM thickness is increased in advanced CF lung disease and that 
this is linked to mucosal eosinophils and age at time of lung transplantation. 
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8.5. Results 
 
8.5.1. Reticular basement membrane thickness in advanced cystic fibrosis lung 
disease 
 
Clinical details of the patients with CF that I quantified RBM thickness in are provided 
in Table 18. Measurements were performed on 5µm sections stained with haematoxylin 
and eosin taken from formalin-fixed, paraffin-embeeded blocks as described in Chapter 
2. Figure 87 displays an example of how I quantified RBM thickness by measuring the 
distance between two demarcating lines in each high-power section using Image 
ProPlus software (MediaCybernetics).  
 
Comparison was made with data from a group of healthy volunteers enrolled in a 
previous study. (Ward et al., 2002) In this study endobronchial biopsies were fixed in 
ice-cold acetone and embedded in glycol methacrylate. RBM thickness was then 
quantified using the same image analysis technique that I employed in 2µm sections 
immunostained for collagen type I.   
 
The median RBM thickness was significantly increased in the CF group (9.58µm) 
compared to healthy volunteers (7.7µm, P=0.0002) in the previous study. (Ward et al., 
2002) Figure 88 shows the mean RBM thickness for each individual in the study along 
with other reported ranges for RBM thickness in healthy volunteers in formalin-fixed 
haematoxylin and eosin stained tissue, namely 2.9-6.7µm. (Lundgren et al., 1988, 
Wilson and Li, 1997) 
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Age* CFTR 
Variant$ 
Sputum microbiology 
14 Unknown Pseudomonas aeruginosa 
Candida parapsilosis 
26 p.Phe508del 
p.Phe508del 
P. aeruginosa  
Scediosporium aspiospermum 
23 p.Phe508del 
p.Phe508del 
P. aeruginosa Stenotrophomonas 
maltophilia 
25 Unknown P. aeruginosa 
28 p.Phe508del 
p.Phe508del 
P. aeruginosa  
Aspergillus fumigatus 
57 p.Arg117His   
p.Arg553X 
P. aeruginosa 
32 Unknown P. aeruginosa  
Burkholderia vietnamiensis 
23 Unknown Scedosporium sp.  
Alcaligines sp. 
Staphylococcus aureus 
39 p.Phe508del 
p.Phe508del 
P. aeruginosa 
27 p.Phe508del 
p.Phe508del 
P. aeruginosa 
40 Unknown P. aeruginosa 
46 Unknown P. aeruginosa 
22 p.Phe508del 
p.Phe508del 
P. aeruginosa 
20 p.Phe508del 
p.Phe508del 
P. aeruginosa 
29 p.Phe508del  
c.317+10kbC>T 
P. aeruginosa, 
S. maltophilia 
28 Unknown P. aeruginosa  
Methicillin-Resistant S. aureus 
 
Abbreviations: *Age at time of transplantation (years). $Cystic fibrosis transmembrane 
conductance regulator genotype (where known).  
Table 18. Clinical details of people with cystic fibrosis used to measure reticular 
basement membrane thickness 
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Figure 87. Example of measurement of reticular basemement membrane thickness 
in a haematoxylin and eosin stained section of lower airway from a person 
with advanced cystic fibrosis lung disease 
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Figure 88. Reticular basement membrane thickness in healthy volunteers and 
people with advanced cystic fibrosis lung disease 
Each symbol represents an individual patient (mean of 5 measurements).  
Horizontal bars indicate medians. 
Abbreviations: CF, cystic fibrosis, *Data from Ward et al. (2002), endobronchial 
biopsies fixed in ice-cold acetone, embedded in glycol methacrylate. RBM thickness 
quantified using image analysis in 2µm sections immunostained for collagen type I. 
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8.5.2. Number of mucosal eosinophils and lower airway reticular basement 
membrane thickness in people with advanced cystic fibrosis lung disease 
 
As outlined in the introduction of this chapter, eosinophilic inflammation has been 
implicated in the pathogenesis of airway remodelling in asthma via the maintenance and 
progression of aberrant airway tissue injury and repair. 
 
I therefore quantified the number of mucosal eosinophils in a sub-group of 12 of the 
people with CF that I measured RBM thickness in. I did this by using the tinctorial stain 
Sirius red (Figure 89) and counting the number of mucosal eosinophils per mm of 
basmement membrane in 5 high-power fields in each patient. (Carvalho et al., 2003) 
The number of eosinophils plotted against RBM thickness is shown in Figure 90. There 
is no clear relationship between RBM thickness and number of eosinophils in this 
dataset. However there is a suggestion of a negative correlation from the limited number 
of data points in Figure 90 if one considers the patient with the highest number of 
eosinophils as an outlier (R2=0.274, P>0.05).   
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Figure 89. Example of Sirius red staining in the lower airway mucosa of a person 
with advanced cystic fibrosis lung disease 
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Figure 90. Scatter plot of reticular basement membrane thickness 
against number of lower airway mucosal eosinophils in people with advanced 
cystic fibrosis lung disease 
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8.5.3. Age and reticular basement membrane thickness in advanced cystic fibrosis 
lung disease 
 
It has been suggested that RBM thickness changes with age although there is no 
definitive longitudinal or cross-sectional study published in the literature to confirm 
this. (Liesker et al., 2009) I therefore plotted the RBM thickness results for the people 
with advanced CF lung disease versus age at time of transplant (Figure 91). There is no 
apparent relationship in this dataset. 
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Figure 91. Scatter plot of reticular basement membrane thickness against age at 
transplant 
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8.6. Discussion 
 
The finding of increased RBM thickness in advanced CF lung disease provides 
evidence of structural airway remodelling. My results agree with those published by 
Hilliard et al. in children and are opposite to the findings of Durieu et al. in a mixture of 
adults and children. (Hilliard et al., 2007, Durieu et al., 1998) The data presented in this 
chapter represents the largest sample size in the published literature regarding RBM 
thickness in advanced CF lung disease. 
 
A number of sources of variation are important when considering the measurement of 
RBM thickness. Tissue acquisition (biopsy, explant or post mortem), processing, 
preservation (paraffin wax or plastic resin embedding or snap-freezing) and 
visualisation (tinctorial or immunostaining, light or electron microscopy) methods all 
impact on measurements of RBM thickness and other indices of airway remodelling. 
(Bergeron et al., 2007, Jeffery et al., 2003, Liesker et al., 2009, Wilson and Li, 1997) 
Comparisons between different publications should therefore be made with caution and 
inconsistencies may even exist between control and disease tissue in some studies. The 
fact that the CF tissue used in this study was fixed in formalin and embedded in paraffin 
means that my measurements are likely to be an underestimate compared to those made 
with the acetone and glycol methacrylate technique for the healthy volunteer samples in 
the previous study by Ward et al. (2002). 
 
I found no apparent relationship in my relatively limited dataset between age and RBM 
thickness in end-stage CF lung disease (Figure 91). Similarly, Payne et al. found no 
association between RBM thickness and duration of symptoms in a cohort of children 
with severe asthma. (Payne et al., 2003) One potential explanation is that once 
established in an inflammatory airway milieu, RBM thickness reaches a maximal level 
in individuals.  Suitably powered longitudinal studies involving repeat biopsies of 
children and young adults with CF at different time points would be required to answer 
this question. Such studies would however present ethical and practical issues. As 
mentioned earlier there is also a paucity of good quality data in the literature regarding 
the natural history of RBM thickness in healthy individuals. 
 
At an anecdotal level Wojnarowski et al. describe RBM thickening in endobronchial 
biopsies from children with CF during an acute exacerbation but not in other clinically 
 256 
stable children. (Wojnarowski et al., 1999) This finding would argue against a fixed 
maximal RBM thickness state, at least in early CF lung disease, because presumably the 
stable children had previously experienced acute exacerbations. The situation in 
advanced CF lung disease, where the spiral of inflammation and infection is profound 
and may be almost permanent, is likely to be different however. 
 
In the context of asthma, the precise clinical significance of RBM thickening has been 
debated in the literature. In theoretical models increased RBM thickness has been 
shown to lead to a greater propensity for luminal collapse and obstruction. (Wiggs et al., 
1997) However, it is possible that associated features of airway remodelling such as 
airway smooth muscle hypertrophy are of greater importance. (Bush, 2008) RBM 
thickening has been shown to correlate with several other parameters of airway 
remodelling however. (James et al., 2002) Equally the involvement of eosinophilic 
inflammation as a primary event in airway remodelling in asthma has been challenged 
by indirect evidence from pre-school children, where wheezing is largely viral-induced, 
that corticosteroids are ineffective, the inflammation is principally neutrophilic and 
airway structural remodelling still occurs. (Panickar et al., 2009, Bush, 2008, Saglani et 
al., 2007) Eosinophilic inflammation and remodelling may be best regarded as parallel 
processes but the progression of each is independent. (Bush, 2008) The relationship 
between RBM thickness and numbers of inflammatory cells other than eosinophils in 
the airway mucosa, most notably neutrophils in the context of CF, is an important area 
for future research. (Downey et al., 2009) 
 
In summary the data presented in this chapter provides evidence to support the 
hypothesis that RBM thickness is raised in advanced CF lung disease. To investigate 
RBM thickness more thoroughly in advanced CF lung disease it would be necessary to 
confirm findings in a larger cohort with contemporaneous, age-matched controls and to 
use alternative techniques such as immunostaining for collagen sub-types and/or 
electron microsocopy. More generally, the phenomenon of airway remodelling and its 
pathogenesis in CF lung disease is a relatively neglected area that warrants further 
translational research and may yield novel therapeutic strategies. (Dupuit et al., 1995)  
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9. Chapter 9. Discussion and future work 
 
 
9.1. Introduction 
 
Clinically CF lung disease is characterised by retention of mucopurulent secretions and 
chronic endobronchial infection with specific organisms including P. aeruginosa. 
(O'Sullivan and Freedman, 2009) Histologically the airway pathology is dominated by 
intense neutrophilic inflammation. (Downey et al., 2009) This results in progressive 
bronchiectasis, airway obstruction and ultimately respiratory failure. (Davies et al., 
2007) Lung transplantation is the only life-preserving intervention available for 
advanced CF lung disease. (Meachery et al., 2008)  
 
It is known that CF results from variants in the gene that encodes for the CFTR protein. 
CFTR is a complex and multifaceted protein that along with its principal function as an 
epithelial chloride channel amongst other properties also regulates sodium transport. 
(Sheppard and Welsh, 1999) The precise mechanisms involved in the translation of 
defective CFTR function in to the ‘clinical syndrome’ of CF are yet to be fully 
elucidated however and occupy thousands of researchers worldwide. (Wine, 2010) 
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9.2. Background and summary of results 
 
9.2.1. Development of a method to culture primary bronchial epithelial cells from 
the lungs of people with cystic fibrosis removed at the time of transplantation 
 
Valid experimental models are vital to advance research in to the pathogenesis of CF 
lung disease and identify novel therapeutic targets. Despite a huge amount of work and 
effort recapitulation of the CF lung disease phenotype in murine models has proved 
impossible to date. (Scholte et al., 2004) Preliminary results of the recently developed 
porcine model describe an extreme gastrointestinal and lung phenotype with severe 
morbidity, frequent early mortality and significantly overall reduced survival. (Stoltz et 
al., 2010) In terms of cellular approaches airway epithelial cells may be cultured in 
vitro, differentiated to form a ciliated multi-layered epithelium and co-cultured with 
other cell types or pathogens of interest. Immortalised cell lines frequently exhibit 
phenotypic instability and may not truly replicate the behaviour of cells in vivo 
however. Primary cells used at a low passage level are more likely to provide a superior 
model but are typically a scarce, expensive and time-consuming resource. 
 
Through the work described in this thesis I have established a programme to culture 
PBECs from explanted CF lungs at the largest lung transplant centre in the UK. This 
involved developing a culture method that included tailoring of patient-specific anti-
microbials that yielded a favourable success rate of around two-thirds. The PBECs were 
characterised in terms of morphology, cytokeratin immunohistochemistry, 
electrophysiology and cytokine production. Prolonged culture was possible at ALI with 
generation of a raised TER and mucus production, but not true ciliogenesis. Importantly 
low passage cells were cryopreserved and successfully reanimated for submerged 
culture. 
 
The routine culture of PBECs from explanted CF lungs represents an important resource 
for CF research that has not previously been realised outside of a small number of large 
North American centres. The number of cells obtained is substantially greater than that 
from alternative methods such as bronchial or nasal brushings and clearly does not 
involve any additional invasive procedures for the donor. In addition, the procurement 
of fixed and snap-frozen tissue and airway lavage from explanted lungs is another 
 259 
valuable resource that allowed much of the other work described in this thesis to be 
performed. The importance of this work has been recognised by invitations to speak at 
the European CF Society Basic Science Conference and the EuroCare CF ‘Workshop 
on Epithelial Cells from Lung: Production, Cultivation and Characterization’ in 2008 
and led to the publication of a peer-reviewed paper. (Brodlie et al., 2008a) (Brodlie et 
al., 2010e) 
 
9.2.2. The role of interleukin-17 in cystic fibrosis lung disease 
 
IL-17 is known to be pivotally involved in the accumulation and associated activity of 
neutrophils in the bronchoalveolar space and is important in pulmonary host defense. 
(Linden et al., 2005, Aujla et al., 2007) This is achieved indirectly via the local release 
of neutrophil-mobilising factors, including CXC chemokines, from cells resident in the 
lung. (Linden et al., 2005) IL-17 also increases the expression of the mucin genes 
MUC5AC and MUC5B by bronchial epithelial cells in vitro. (Chen et al., 2003) IL-17 
is therefore linked to neutrophilic inflammation and mucus excess, which are two of the 
key features of CF lung disease.  
 
A great deal of work in the literature has focussed on TH-17 lymphocytes, a recently 
described novel CD4+ TH subset, as the principal source of IL-17 in biological systems. 
This is clearly of huge interest and relevance because IL-17 in this context represents a 
strategic link between acquired and innate immunity. (Glader et al., 2010) However, γδ 
T cells and natural killer T cells have also recently been identified as producing IL-17. 
(Michel et al., 2007, Roark et al., 2008) In addition cells from the myeloid lineage have 
also been shown to produce IL-17, including mast cells in human rheumatoid arthritis 
synovium and neutrophils in human alcoholic liver disease and rodent models of 
lipopolysaccharide-induced airway inflammation, renal iscahemia-reperfusion injury 
and p-ANCA positive vasculitis. (Hueber et al., 2010, Lemmers et al., 2009, Ferretti et 
al., 2003, Li et al., 2010, Hoshino et al., 2008) 
 
In the work described in this thesis I have shown using immunohistochemistry that 
expression of IL-17 is raised in the lower airway epithelium of people with advanced 
CF lung disease compared to those with PH. Furthermore, levels of IL-17 were raised in 
airway lavage fluid from explanted CF lungs compared to bronchoscopic BAL from 
 260 
healthy volunteers. Another important finding was that IL-17 was consistently 
immunolocalised to mucosal neutrophils that stained positively for the transcription 
factor RORγ. This is the first description of neutrophils as a potential source of IL-17 in 
the human airway. In proof-of-principle experiments I went on to show that stimulation 
of PBECs from people with CF with IL-17 led to an increase in production of the pro-
neutrophilic cytokines IL-8, IL-6 and GMCSF. IL-6 is known to be critical in the 
differentiation of TH-17 cells and along with the suggestion that neutrophils themselves 
are a potential source of IL-17 in the airway a novel paradigm emerges of a positive 
feedback loop of neutrophilic inflammation. Figure 92 illustrates the potential positive 
feedback loop of neutrophilic inflammation involving IL-17 in a CF airway. 
 
 
 
Figure 92. Illustrative diagram of potential positive feedback loop of neutrophilic 
inflammation involving interleukin-17 in cystic fibrosis airway 
Abbreviations: Ep. Epithelium, IL. Interleukin, DC dendritic cell, N neutrophil,  
Pa Pseudonas aeruginosa. 
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9.2.3. Ceramide and cystic fibrosis lung disease 
 
The sphingolipid ceramide is a ubiquitous component of cell membranes. In addition 
ceramide-enriched membrane domains are important in interactions with pathogens and 
intracellularly sphingolipids are key second messengers in several signalling cascades, 
most notably with regard to cell fate. (Uhlig and Gulbins, 2008) 
 
Teichgraber et al. (2008) recently reported that CFTR-deficient mice accumulate 
ceramide in airway epithelial cells and that this led to chronic inflammation, death of 
epithelial cells and deposition of DNA in the airways and susceptibility to P. 
aeruginosa infection. Importantly all of these features could be reversed by systemic, 
and in a later paper nebulised, treatment with the acid sphingomyelinase inhibitor 
amitriptyline. (Becker et al., 2010b, Teichgraber et al., 2008) Accumulation of ceramide 
was demonstrated qualitatively in nasal epithelial cells from people with CF and in a 
limited number of lower airway sections. (Teichgraber et al., 2008) 
 
In direct contrast researchers from Canada have reported low levels of ceramide in the 
organs and plasma of a different CFTR-deficient mouse that could be corrected by 
treatment with fenretinide. (Guilbault et al., 2008a) The same group also found reduced 
levels of ceramide in the plasma of people with CF. (Guilbault et al., 2008b) 
 
Proposed explanations for this divergence in the literature include variations between 
strains of CFTR-deficient mice, the effects of high-fat animal feeds and different 
techniques used to measure ceramide. (Pier, 2008) A definitive explanation is yet to be 
established. Ceramide truly represents a family of around 50 molecularly distinct 
species. (Novgorodov and Gudz, 2009) There is evidence that the relative levels of 
individual ceramide species is important in cellular homeostasis and this is likely to be 
true in the context of ceramide in CF. (Wooten-Blanks et al., 2007, Brodlie et al., 
2010b) In this context, different measurement techniques will clearly impact on the 
interpretation of results. It is certain however that further translational studies are 
warranted and in particular relating to the lower airway in humans with CF. 
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In the work described in this thesis I have demonstrated that ceramide is increased in the 
lower airway epithelium of people with advanced CF lung disease. This was shown in 
comparison to PH and unused lung donors using immunohistochemistry with two 
different ceramide antibodies. Across all disease groups, staining for ceramide was 
increased in people colonised with P. aeruginosa and was correlated with the neutrophil 
markers neutrophil elastase and myeloperoxidase. Furthermore, levels of the ceramide 
species C16:0, C18:0 and C20:0, but not C22:0, were increased in lung homogenates of 
CF lungs compared to PH measured using the independent technique of HPLC-MS. 
These findings provide further evidence to support the ‘ceramide accumulation 
hypothesis’ suggested by the Gulbins group and add weight to the argument that 
ceramide may represent a potential therapeutic target in CF lung disease.  
 
9.2.4. Reticular basement membrane thickness in cystic fibrosis lung disease 
 
Thickening of the sub-epithelial RBM is a recognised feature of airway wall 
remodelling in asthma. (Ward et al., 2002, Payne et al., 2003) Eosinophilic 
inflammation has been implicated in its pathogenesis via the maintenance and 
progression of aberrant airway tissue injury and repair. (Holgate and Polosa, 2008) 
Airway remodelling has also been implicated in the pathogenesis of CF lung disease 
and RBM thickening has been described in endobronchial biopsies from children with 
CF. (Hilliard et al., 2007) Other researchers, in studies involving only small numbers of 
patients, have described a thinned RBM in children and adults with CF or thickening 
only in association with an infective exacerbation. (Durieu et al., 1998, Wojnarowski et 
al., 1999) Tissue sampling, fixation, staining and measurement techniques are all likely 
to impact on the results of such studies. (Jeffery et al., 2003) To the best of my 
knowledge RBM thickness has not been investigated in advanced CF lung disease. 
 
In the work described in this thesis I have shown that RBM thickness is increased in 
advanced CF lung disease compared to measurements in endobronchial biopsies from 
healthy volunteers. There was no apparent correlation between number of mucosal 
eosinophils or age at time of transplantation and RBM thickness in this dataset.  
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9.2.5. Experimental controls 
 
As has been outlined in this thesis a non-suppurative disease comparator (pulmonary 
hypertension) was used for the IL-17 work and in the case of the ceramide chapter 
sections from unused lung donors (previously healthy and objectively free of significant 
lung fibrosis or inflammation) were also used. These control groups were chosen largely 
due to logistical considerations and the availability of tissue for research use in our 
transplant centre. The ideal control group for many of the experiments would have been 
tissue and samples from healthy volunteers however there are obvious limitations in the 
availability of such tissue and constraints with in the scope of a PhD project. 
 264 
 
9.3. Potential future work 
 
9.3.1. Development of a method to culture primary bronchial epithelial cells from 
the lungs of people with cystic fibrosis removed at the time of transplantation 
 
PBECs harvested from explanted CF lungs are by definition only representative of 
advanced CF lung disease. As a paediatrician I am acutely aware of the spectrum of 
severity and progressive nature of CF lung disease and therefore primary cellular 
models that reflect less advanced stages of disease are also vitally important. This may 
be achieved by opportunistic brushing of the lower airway at the time of flexible 
bronchoscopy or other general anaesthetic for a clinical indication. (McNamara et al., 
2008) An alternative approach is to sample nasal epithelial cells from the upper airway, 
which is clearly a more accessible method with the potential for repeated sampling. A 
related and important question however is: how representative of the lower airway are 
nasal epithelial cells and indeed are cells from different anatomical locations in the 
lower airway comparable? In the context of advanced CF lung disease the resource of 
explanted lungs represents a potentially useful tool to investigate these questions. A 
greater understanding of disease processes at the early stages of CF lung disease would 
allow the development of interventions with the potential to maintain lung function in 
the normal range. 
 
There is also potential to use pieces of fresh intact large airway from explanted CF 
lungs to perform electrophysiology experiments in mini-Ussing chambers or real-time 
cilia or mucus studies. (Derichs, 2009, N'Dow et al., 2005) 
 
Some of the greatest challenges in the continuation of the culturing of PBECs from 
explanted CF lungs will arguably relate to logistics and infrastructure. To date the 
programme has relied on a permanent on-call commitment from myself and funding for 
this form of core resource is often difficult to obtain outside of North America. 
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9.3.2. The role of interleukin-17 in cystic fibrosis lung disease 
 
There are a number of potential future avenues for research leading from this work. In 
relation to CF lung disease specifically, larger scale BAL and tissue-based studies are 
warranted across the spectrum of severity of disease. Of interest it has been reported 
that in children with earlier stages of CF lung disease the inflammatory infiltrate of the 
endobronchial mucosa is dominated by lymphocytes with neutrophils only 
predominating in the airway lumen. (Tan et al., 2009) This is in contrast to my findings 
in advanced CF lung disease of intense neutrophilic inflammation of the airway mucosa, 
for example in Figure 60. Using dual staining CD4+ IL-17+ presumed TH-17 cells have 
also been demonstrated in the airway mucosa of endobronchial biopsies from children 
with CF and non-CF bronchiectasis. (Tan et al., 2009) It is plausible therefore that TH-
17 cells may be more important in the pathogenesis of the early stages of CF lung 
disease than in advanced disease, although this is pure conjecture. 
 
The suggestion from my work that neutrophils themselves may be a source of IL-17 is 
potentially very significant but requires further investigation. Taken with the evidence 
that I found that IL-17 leads to the increased production of pro-neutrophilic mediators 
from CF PBECs the possibility of a novel vicious cycle of inflammation emerges in 
advanced CF lung disease. This could also be of relevance to other neutrophilic lung 
pathologies such as non-CF bronchiectasis, asthma or bronchiolitis. 
 
At a more fundamental level ex vivo experiments using isolated neutrophils are required 
to investigate IL-17 transcription and translation. Investigation of relevant factors 
involved in the production of IL-17 by neutrophils should also be performed. The most 
accessible source of neutrophils for such work would be those isolated from peripheral 
blood, however activated neutrophils from the lung compartment are likely to be harder 
to obtain but physiologically more relevant. (Sabroe et al., 2004, Zemans et al., 2009) 
  
I believe that a much greater understanding of IL-17 receptor biology and signalling 
pathways is required before serious consideration is made of the potential for 
antagonism. (Gaffen, 2009) However, at least at a superficial level, IL-17 is an 
attractive therapeutic target given the major role of neutrophilic inflammation in the 
pathogenesis of CF lung disease. As with any immunomodulatory strategy a balance 
would have to be struck between the benefits of reducing the harmful effects of 
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neutrophilic inflammation versus potential harm from compromising innate defenses 
against infection. (Sabroe and Whyte, 2007) A stark parallel is provided if one considers 
children with autosomal dominant hyper-immunoglobulin E syndrome (HIES). Children 
with HIES have very high levels of IgE and reduced neutrophil chemotaxis resulting in 
amongst other features, problems with S. aureus infection of the skin and lungs. 
(Grimbacher et al., 1999) The molecular basis of HIES has recently been shown to 
involve mutations in STAT3 and defective IL-17 signalling. (Holland et al., 2007) 
 
9.3.3. Ceramide and cystic fibrosis lung disease 
 
The potential role of ceramide in the pathogenesis of CF lung disease remains topical 
but highly controversial. The genuine complexities of studying lipids in biological 
systems have made this field a particularly difficult one. (Becker et al., 2010c) In my 
opinion a larger scale study is required to provide a definitive answer about levels of 
individual ceramide species in the human CF lower airway epithelium. This could 
potentially be achieved using a modern imaging modality such as matrix-assisted laser 
desorption and ionization mass spectrometry. (Fuchs et al., 2010) 
 
The hypothesis put forward by Teichgraber et al. involving impaired acidification of 
intracellular vesicles in the presence of defective CFTR to explain the accumulation of 
ceramide has been challenged. (Teichgraber et al., 2008, Haggie and Verkman, 2009b) 
One potential explanation for the divergent findings however relates to different 
methods used to measure vesicular pH. (Becker et al., 2010a) A method that involves 
the endocytosis of a pH-sensitive marker will clearly only measure the pH of 
endocytotic vesicles and it is suggested that CFTR may not be involved in the 
regulation of this subset of vesicles. Clearly a great deal of careful in vivo laboratory 
work is required in this complex area to resolve this issue in the future. 
 
From a clinical perspective the most attractive aspect of this area of work is the 
potential to antagonise the accumulation of ceramide with acid sphingomylinase 
inhibitors. The Gulbins group have demonstrated that acid sphingomyelinase inhibitors, 
including amitriptyline, amlodipine and fluoxetine, delivered via nebuliser can 
normalise ceramide levels, pulmonary inflammation and susceptibility to P. aeruginosa 
in CFTR-deficient mice. (Becker et al., 2010b) Clinical evidence of the use of 
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amitriptyline in people with CF is largely anecdotal aside from a single n=4 placebo-
controlled, double-blinded crossover trial and linked n=19 14 day phase II trial. (Becker 
et al., 2010b, Riethmuller et al., 2009) In this study amitriptyline was well tolerated 
orally and its use was associated with a modest improvement in lung function. 
(Riethmuller et al., 2009) Clearly further trials are indicated with particular caution 
indicated with regard to potential toxic effects of tricyclic antidepressants and any 
deleterious impact on epithelial physiology and host defense of overinhibition of 
ceramide biosynthesis given its key homeostatic role. (Pier, 2008, Brodlie et al., 2010b) 
 
9.3.4. Reticular basement membrane thickness in cystic fibrosis lung disease 
 
The topic of airway remodelling in CF lung disease has received relatively little 
attention in the literature to date. This is despite histological evidence of structural 
airway remodelling in children with CF and demonstrably abnormal airway function in 
infants newly diagnosed clinically with CF. (Ranganathan et al., 2001, Hilliard et al., 
2007) This abnormal lung function does not improve despite intensive treatment, and 
the airway obstruction would therefore appear to be ‘fixed’. (Ranganathan et al., 2004)      
 
In contrast, aberrant epithelial wound repair and airway remodelling in other lung 
diseases, such as asthma, pulmonary fibrosis and obliterative bronchiolitis, has been the 
topic of intense study in recent years. (Gardner et al., 2010) Interestingly 
polymorphisms in TGF-β1 have been shown to be modifier genes for CF lung disease. 
(Collaco and Cutting, 2008) Increased concentrations of TGF-β1 have been detected in 
BAL from children with CF and levels found to correlate with neutrophil markers, 
reduced lung function, RBM thickness and disease activity. (Harris et al., 2009, Hilliard 
et al., 2007) Little is known about the potential mechanisms behind these observational 
findings and further research in this general area is clearly warranted. The potential role 
of TGF-β1 driven epithelial-mesenchymal transition in CF lung disease has also not 
been investigated. (Ward et al., 2005, Borthwick et al., 2009) Markers of epithelial 
remodelling have been linked to the relative expression and cellular distribution of 
CFTR in nasal polyps from wild type and p.Phe508del homozygous individuals 
suggesting that airway remodelling may play a role in the regulation of CFTR 
expression. (Dupuit et al., 1995) 
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9.3.5. Summary 
 
The work described in this thesis has led to the establishment of an ex vivo PBEC 
culture model to study CF lung disease. Using primary lung tissue and the PBEC model 
I have provided insights in to the possible roles of IL-17, ceramide and airway 
remodelling in the pathogenesis of CF lung disease, thus contributing to the scientific 
literature and suggesting potential therapeutic targets and areas for future translational 
research.   
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9.4. Reflection 
  
Over the course of this PhD I have gained experience in many of the key core skills and 
techniques used in translational respiratory research.  
 
These have included:  
• processing and standardising of BAL  
• sampling and fixation of lung tissue and associated sectioning, tinctorial staining 
and immunohistochemistry 
• image analysis techniques for semi-quantitative 
histology/immunohistochemistry 
• primary airway epithelial cell culture and associated laboratory techniques 
• ELISA and associated techniques 
• principles of HPLC-MS 
• principles of electrophysiology 
• compliance with the Human Tissue Act 
• involvement in a randomised-control trial 
• ethics application procedure 
• informed consent, good clinical practice training 
• setting-up of collaborations 
• writing of grant applications and scientific papers 
• MRC fellowship interview 
• oral and poster presentation at local, national and international meetings 
• review of scientific papers 
• organisation and self-discipline required for a successful research project 
  
I have been fortunate to have received excellent supervision and to have enjoyed access 
to and involvement in an active translational respiratory research programme in 
Newcastle. This has included my involvement in a number of other areas of research in 
addition to the work formally presented in this thesis. This has included the consenting 
and organisation of samples from lung transplant patients undergoing surveillance 
bronchoscopies, consenting and procurement of explanted lungs for a tissue bank, 
mitochondrial studies of paediatric cardiac tissue and investigation of aspiration as a 
source of lung injury in CF. Over the course of my PhD I have written several 
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clinically-based case reports and an editorial, in keeping with my planned career path as 
a paediatric respiratory clinician. This experience has established a firm platform from 
which I hope to build an academic clinical career and in the short-term to pursue some 
of the research areas outlined in section 9.3. 
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